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Poly(ADP-ribose)polymerase 1 (PARP-1) is a highly abundant multi-domain chromatin-
associated enzyme found in all higher eukaryotic cell nuclei. It is the founding member of 
the PARP family of enzymes that modify themselves and other proteins by adding 
negatively charged poly(ADP-ribose) chains derived from NAD+. PARP-1 is a key sensor 
of DNA strand breaks and becomes automodified in response to DNA damage. PARP-1 
activation occurs following recognition of single or double strand breaks by PARP-1’s N-
terminal zinc finger domains. A multi-domain allosteric activation pathway leads to 
conformational changes in the HD subdomain of the catalytic domain that promote increased 
catalytic activity and lead to PARP-1 automodification and recruitment of DNA damage 
response proteins.   
Small molecule inhibitors of PARP-1 catalytic domain activity are also the first 
compounds to be discovered which target tumour cells with deficiencies in homologous 
recombination via a synthetically lethal approach. PARP-1 inhibitors cause cytotoxicity by 
preventing PARP-1 from being released from sites of DNA damage, but the mechanistic 
basis of the wide differences in effectiveness between different compounds has yet to be 
definitively established.  Therefore, the aims of the work described in this thesis are to 
further elucidate the changes that occur in the HD subdomain during catalytic domain 
activation, and to help establish how binding of different PARP inhibitors to the catalytic 
domain leads to the formation of trapped PARP-1 lesions. 
The differences in chemical shift perturbations and relaxation parameters between 
the 360-residue wild-type catalytic domain and three constitutively partially active HD 
subdomain mutants were studied using NMR spectroscopy, and the wild-type PARP-1 
catalytic domain was titrated with four different PARP inhibitors with varying levels of 
potency in order to compare the chemical shift perturbations, relaxation parameters and 
solvent exchange properties of the complexes.  
Mutation of residues from key a-helices of the HD subdomain appeared to show that 
the arrangement of a-helices in the HD subdomain is important for maintenance of PARP-
1 autoregulatory function. Additionally, the strength of HD subdomain contacts appears to 
be correlated with inhibitor binding affinity. Furthermore, binding of the PARP inhibitor 
EB-47 causes destabilisation of the same HD subdomain a-helices as does PARP-1 
activation. Although further work is required to characterise the binding of EB-47 to full-
length PARP-1, this finding suggests that EB-47 may promote formation of trapped PARP-
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Poly(ADP-ribose) polymerase 1 (PARP-1) is a highly abundant chromatin-associated 
enzyme found in all higher eukaryotic cell nuclei. It is the founding member of the PARP 
family of enzymes; these modify a range of target proteins via the posttranslational 
modification of poly ADP-ribosylation, in which negatively charged poly ADP-ribose 
(PAR) chains derived from NAD+ are added (D'Amours et al., 1999). 
PARP-1 plays a key role in the DNA damage response in higher eukaryotic cells. It 
is not involved directly in the chemical reactions of DNA strand break repair, but instead 
acts as a key initial sensor, particularly for DNA single-strand breaks that are the most 
common form of DNA damage.  Upon becoming activated by such damage, PARP-1 
responds by adding long, negatively-charged, branched chains of PAR to itself and other 
proteins. These long, branched chains effectively act as a signal to the repair machinery by 
providing a scaffold for recruitment of factors essential for multiple DNA repair pathways 
(Caldecott, 2007). PARP-1 is also the target of the first commercially available drugs to 
exploit the genetic principle of synthetic lethality, in which the combined loss of function of 
two genes or proteins promotes cell death, but the loss of a single one does not. Thus, 
tumours resulting from germline mutations in BRCA1 and BRCA2 genes that lack a 
functional homologous recombination pathway are sensitive to inhibition of PARP-1 
catalytic activity using small molecules, whereas healthy cells are not (Bryant et al., 2005; 
Farmer et al., 2005). 
In this introduction, the structure and metabolism of poly ADP-ribose will be 
discussed, as well as its predominant cellular functions including its role in the DNA damage 
response. The structural and biochemical information published to date relating to the 
function of the PARP family of proteins which carry out poly and mono-ADP-ribosylation 
will be outlined, with a focus on the structure and function of the catalytic domain and other 
domains of the protein PARP-1, the predominant generator of poly(ADP-ribose) in higher 
eukaryotic cells. Finally, the clinical utility, importance and putative mechanism of the 







1.1 Poly ADP-Ribose and the PARP family 
 
1.1.1 Poly ADP-ribose 
Poly ADP-ribose (PAR) was first discovered by the group of Paul Mandel, who observed 
that addition of the NAD+ precursor nicotinamide mononucleotide (NMN) to a nuclear 
fraction isolated from hen liver resulted in the enzymatic production of a polymer containing 
adenine that was resistant to digestion by both DNAse and RNAse (Chambon et al., 1963). 
While initially misidentified as polyA, the polymer was later identified as PAR  and NAD+ 
was later identified as the substrate of PARP-1 (Chambon et al., 1966).     
Poly ADP-ribose is formed by the polymerisation of the ADP ribose moiety of 
NAD+ (Chambon et al, 1966). Its structure is well characterised (Figure 1.1), with ADP-
ribose monomers linked by a(1®2) ribose-ribose O-glycosidic bonds (Miwa et al., 1981). 
Chain lengths are heterogenous and polymers also branch every 40 to 50 residues both in 
vitro and in vivo via the formation of additional a(1®2) ribose-ribose linkages (Hayashi et 
al., 1983; Alvarez-Gonzalez and Jacobson, 1987).  
Figure 1.1 Chemical structure of poly ADP-ribose (PAR). PAR is a post translational modification 
that is covalently attached to side chains of certain residue types in acceptor proteins via formation of O-
glycosidic linkages (shown here in blue). Polyenzyme members of the PARP family (see section 1.1.3) elongate 
PAR chains by catalysing the formation of a(1®2) glycosidic bonds (highlighted in orange) between ribose A 
of one unit of ADP ribose and ribose B of another. Branching occurs at a less frequent rate via formation of 
a(1®2) glycosidic bonds between ribose B moieties of two units of ADP ribose. PAR synthesis proceeds from 





1.1.2 Mono ADP-ribose 
Post-translational modification of proteins via the addition of a single ADP-ribose moiety to 
side chains of amino acid residues also occurs, and proteins that catalyse only this reaction 
are considered to be mono (ADP-ribosyl) transferases (MARTs), also sometimes called 
monoenzymes (Gupte et al., 2017). The first MARTs to be discovered were bacterial toxins, 
including from diphtheria, cholera and pertussis (Krueger and Barbieri, 1995). However, it 
has been established that MARTs perform widespread functions across many organisms, 
including in higher eukaryotes where the majority of members of the PARP family are 
considered to be MARTs (see further discussion in Section 1.1.4).    
 
1.1.3 Production of ADP ribose by PARP-1 
Poly ADP-ribosylation of acceptor proteins, using NAD as a substrate, is catalysed by poly 
ADP-ribose polymerases (PARPs), also sometimes referred to as polyenzymes (Gupte et al., 
2017). Despite the polyenzyme PARP proteins’ ability to catalyse formation of long PAR 
chains, the catalytic mechanism of ADP ribose formation from NAD is identical in PARPs 
and mono ADP ribosyl transferases (MARTs), with the three-dimensional structure of 
chicken PARP-1 catalytic domain revealing a high degree of structural homology and shared 
evolutionary history with bacterial toxins that have mono ADP-ribosyl transferase activity 
(Ruf et al., 1996). In all cases NAD+ is recognised by a characteristic motif β-α-loop-β-α, a 
fold now designated as a “PARP signature” and used to identify and classify members of the 
PARP family and PARP paralogues (Amé, 2004). This motif includes the NAD+ binding 
site, a 50-residue block of amino acids (residues 859-908 in PARP-1), which is the location 
for binding of a nicotinamide analogue in the published crystal structure of PARP-1 catalytic 
domain from chicken (Ruf et al., 1996), and which is highly conserved across PARP 
sequences in vertebrates (de Murcia and Ménissier de Murcia, 1994). Formation of PAR 
chains requires three distinct steps, and PARP-1 catalytic domain is able to perform all three: 
1. Initiation: Formation of an ADP-ribose unit from NAD+ and attachment of this unit 
to the sidechain of an amino acid via an O or N glycosidic linkage (a step also carried 
out by MARTs) 
2. Elongation: Addition of one ADP-ribose unit to a growing chain by formation of a 
a(1®2) O glycosidic bond from ribose A of one unit to ribose B of another unit, 
using the 2'-hydroxyl group from the ribose A at the chain terminus as an acceptor. 
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3. Branching: Formation of a a(1®2) O glycosidic bond between ribose B on two 
separate units of ADP-ribose. Each of these ADP ribose units can be elongated from 
the 2'-hydroxyl group from the ribose A moiety as described in step 2. 
It has been proposed that both elongation and branching are permitted by PARP-1 because 
the active site is accessible to PAR chains in two different orientations, which facilitate 
formation of linear and branched linkages respectively (Ruf et al., 1998). The conserved 
PARP fold contains histidine and tyrosine residues that bind and orient NAD+ in the required 
arrangement for formation of PAR, while a key glutamate residue is responsible for 
mediating transfer of ADP-ribose to the acceptor residue and is also considered to be 
essential for elongation, as its mutation abolishes poly ADP-ribosylation in favour of mono 
ADP-ribosylation (Ruf et al., 1998).  
Only the side chains of certain amino acid types in PARP-1 and other targets of ADP-
ribosylation are ADP-ribosylated and evidence strongly suggests that there is no sequence-
specific targeting of residues in acceptor proteins of ADP-ribosylation, with ADP 
ribosylation patterns in PARP-1 itself and target proteins simply based on amino acid type 
and proximity to the catalytic centre of the ADP-ribosylating protein. The g-COOH group 
of glutamic acid was the first acceptor of ADP-ribosylation to be identified (Riquelme et al., 
1979; Burzio et al., 1979), with the -COOH group of aspartic acid also proposed later 
(Suzuki et al., 1985). Subsequent studies have reported ADP ribosylation of side chains from 
arginine, asparagine and lysine residues (Laing et al., 2011; Manning et al., 1984; Altmeyer 
et al., 2009). More recently, evidence has emerged to show that serine residues of histones 
Figure 1.2 Structure of PARP-1 catalytic domain (pdb 1a26). The autoregulatory HD subdomain 
domain is shown in cyan. The C-terminal ART domain (teal) contains the “PARP signature” fold (pink).  
Side chains of residues H862, Y907 and E988 comprising the H-Y-E motif required for poly-ADP-





are ADP-ribosylated in response to DNA damage (Leidecker et al., 2016; Palazzo et al., 
2018). It has also been reported  that ADP-ribosylation of histone serine residues is 
dependent on interaction of histone PARylation factor 1 (HPF1) with PARP-1 or PARP-2 
and that PARP-1 also automodifies its own serine residues when it becomes activated in the 
presence of HPF1 (Bonfiglio et al., 2017). 
 
1.1.4 The PARP family 
The entire PARP family contains 17 members, all of which share a conserved catalytic 
domain containing the PARP signature that was first discovered in PARP-1 (Gibson and 
Kraus, 2012). However, the members of the PARP family vary widely in their enzymatic 
activity, the presence or absence of N-terminal domains, subcellular localisations and 
cellular function. In addition, only four members of the PARP family (PARP-1, PARP-2, 
and tankyrases PARP-5a and PARP-5b) have been shown experimentally to exhibit poly 
ADP- ribosylation activity. All other members of the PARP family have been identified as 
MARTs, with the exception of PARP-9 and PARP-13 that appear to be catalytically inactive 
(Vyas et al., 2014). Differences in the ability of members of the PARP family to perform 
mono- or poly-ADP ribosylation can be explained by variations in the three residue H-Y-E 
motif found in the PARP-1 catalytic domain. In all MART members of the PARP family, 
the key glutamate residue has been replaced with isoleucine, leucine or tyrosine, leading to 
loss of polymerase activity (Gupte et al., 2017). PARP-3 and PARP-4 share the classical H-
Y-E motif with the polyenzyme members of the family; however, they only display 
monoenzymatic activity due to their structurally distinct donor (“D”) loops (position 880 to 
900 in PARP-1 catalytic domain), indicating that the H-Y-E motif is necessary but not in 
itself sufficient to confer polyenzyme activity (Vyas et al., 2014). PARP-9 and PARP-13 
lack the conserved histidine residue of this motif, which could disrupt NAD+ binding and 
account for their catalytic inactivity (Vyas et al., 2014).   
PARP-1 is distinguished from other members of the PARP family (including PARP-
2 and PARP-3, the other DNA damage response PARPs) by its N-terminal domain structure 
(Barkauskaite et al., 2015) (see Figure 1.2). Human PARP-1 is a 113 kDa protein of 1014 
residues and contains six independently folded domains connected by flexible linkers. N 
terminal F1 and F2 zinc-finger domains are responsible for initial binding to sites of DNA 
damage, leading to activation of the C terminal CAT domain, which itself contains two 
subdomains; the ADP-ribosyl transferase (ART) subdomain where the signature PARP fold 
is found and a regulatory helical domain (HD). In between these regions, a third zinc finger 
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domain (F3) structurally unrelated to the F1 and F2 domains, a BRCT domain containing 
acceptor sites for autoPARylation and a WGR domain (named after its Trp-Gly-Arg motif 
conserved within the PARP family) are found. PARP-2 and PARP-3 share a WGR domain 
and catalytic domain with PARP-1, complete with the HD regulatory subdomain, but have 
only short, disordered N-terminal regions in contrast to PARP-1’s four N-terminal 
subdomains. In contrast to PARP-1, which can sense many forms of damaged DNA, DNA 
single-strand breaks must be 5' phosphorylated to activate PARP-2 or PARP-3 (Langelier et 
al., 2014).  
 
1.1.5 Cellular functions of PARP-1 and PAR metabolism 
As mentioned earlier, in higher eukaryotes PARP-1 is the key sensor of single-strand breaks, 
the most common form of DNA damage that occurs in vivo, and acute activation of PARP-
1 is one of the earliest responses to this form of stress in eukaryotic cells. The main target of 
PAR chain addition by PARP-1 is PARP-1 itself, and, following DNA-damage dependent 
activation, addition of highly negatively-charged branched PAR chains to PARP-1 acts as a 
signal for recruitment of DNA repair complexes such as XRCC1 (Caldecott, 2007). 
Although PARP-1 itself does not participate in the covalent chemistry of DNA repair and 
must be released from the site of DNA damage in order for repair to proceed, it has been 
shown that activation of PARP-1 following binding to DNA single-strand breaks (SSBs) 
plays an important role in DNA repair processes including base excision repair (BER), 
homologous recombination (HR), non-homologous end-joining (NHEJ), nucleotide excision 
repair (NER) and single-strand break repair (SSBR) (Caldecott, 2007; De Vos et al., 2012). 
In addition to recognising single-strand breaks (SSBs), PARP-1 has been shown to recognise 
other less common forms of DNA damage, including double-strand breaks (DSBs), 
cruciforms and hairpins, and has also been implicated in detection and re-initiation of stalled 
replication forks (Bryant et al., 2009; Lonskaya et al., 2005; Potaman et al., 2005). The 
release of activated PARP-1 from sites of DNA damage is likely to occur at least in part as 
a result of electrostatic repulsion between DNA and the negatively-charged PAR chains 
resulting from automodification (Satoh and Lindahl, 1992) (Mortusewicz et al., 2007). 
As well as its role in DNA damage sensing and repair, post-translational modification 
via poly ADP-ribosylation (both of PARP-1 itself and other proteins such as histones) has 
been shown to play a role in regulation of cellular processes such as chromatin remodelling, 
gene expression, histone chaperoning and even cell fate decisions, as hyperactivation of 




distinct from both apoptosis and necrosis referred to as “parthanatos”, a portmanteau of PAR 
and Thanatos, the ancient Greek personification of death (Galluzzi et al., 2012). In 
parthanatos, high quantities of PAR produced by PARP-1 in response to high levels of DNA 
distal ADP-ribose group of the PAR chain during PAR elongation
reactions (Karlberg et al., 2013; Steffen et al., 2013; Vyas et al.,
2014). While these binding sites are highly conserved, the com-
parison of the PARP family ART domains has revealed some
structural and sequence alterations in the acceptor as well as
the donor sites reviewed in detail in Steffen et al. (2013). These
differences, as described below, may play a role in determining
whether PARPs act as mono(ADP-ribosyl) transferases (MARTs)
or bona fide PARPs.
The PARP donor site is highly conserved across PARPs and is
consistently composed of a nicotinamide-binding pocket, a
phosphate binding site (PH site), and an adenine-ribose binding
site (AD site) (Steffen et al., 2013). The nicotinamide binding
pocket of PARPs als contains a donor lo p, which differs in
length and observed conformations across PARPs, and a
conserved His-Tyr-Glu (H-Y-E) triad, which is also called the
ART signature sequence (Figure 3) (Steffen et al., 2013). While
the exact function of the donor loop is still unclear, the role for
the conserved ART signature sequence in defining PARP activity
is more understood. In particular, substitutions of the His residue
in the ART sequence interfere with the binding of NAD+, and such
substitutions are observed for the catalytically inactive PARP
family members, namely PARP9 and PARP13 (Aguiar et al.,
2005; Steffen et al., 2013; Vyas et al., 2014).
Poly(ADP-Ribose) Synthesis. At least two studies report that
in vitro a number of PARPs act as mono(ADP-ribosyl) transfer-
ases (MARTs) (Kleine et al., 2008; Vyas et al., 2014). However,
there have been everal c nflicting reports on the matter, and
Figure 2. Domain Architecture of Human PARPs
PARP1–16 with alternative names listed on the side domain structures. ARTD, ADP-ribosyl transferase diphtheria type; vPARP, vault PARP; TNKS, Tankyrase;
TIPARP, TCDD inducible PARP; BAL, B cell aggressive lymphoma; ZC3HDC1, zinc finger CCCH-type domain containing 1; ZC3HAV1, zinc finger CCCH-type
antiviral 1; ZAP, zinc finger antiviral protein. Structural information availability of specific domains is indicated by PDB code under the specific domains. The
number of amino acids composing the protein is indicated on the right. The following domain names were used: ZnF, zinc finger; BRCT, BRCA1C-terminal; WGR,
conserved Trp-Gly-Argmotif domain; HD, helical domain; ART, ADP-ribosyl transferase; VIT, vault protein inter-alpha-trypsin; vWFA, vonWillebrand type A; ANK,
ankyrin; SAM, sterile alpha motif; CCCH ZnF, CCCH type zinc finger; WWE, three conserved residues W-W-E motif domain; Macro, macrodomain; RRM, RNA
recognition motif; UIM, ubiquitin interaction motif; TM, transmembrane motif.
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Figure 1.3 Domain structures of proteins of the PARP family. The names and domain structures of 
t e 17 members of the PARP family, including alternative names. All members of th  PA  f mily have an 
ART domain containing the PARP signature fold. espite this, only PARP-1, PARP-2, and tankyrases PARP-
5a and PARP-5b have been shown to exhibit poly-ADP ribosylation activity, with all other members now 
considered to be mono ADP-ribosyl transferases (MARTs) (Vyas et al., 2014). In PARP-1, PARP-2 and PARP-
3, the ART is a subdomain of the catalytic domain and is prec ed by an HD regulatory subdomain. Where 
structures of domains from the PARP family have been previously solved, a PDB code is listed underneath the 
domain. The number of amino acids in each protein is shown on the right-hand side of the figure. Abbreviations: 
ARTD, ADP-ribosyl transferase diphtheria type; vPARP, vault PARP; TNKS, Tankyrase; TIPARP, TCDD 
inducible PARP; BAL, B cell aggressive lymphoma; ZC3HDC1, zinc finger CCCH-type domain containing 1; 
ZC3HAV1, zinc finger CCCH-type antiviral 1; ZAP, zinc finger antiviral protein. Abbreviations of domain 
names: ZnF, zinc finger (PARP-1 zinc finger domains are referred to using simply F [for finger] elsewhere in 
this thesis); BRCT, BRCA1 C-terminal; WGR, conserved Trp-Gly-Arg motif domain; HD, helical domain; 
ART, ADP-ribosyl transferase domain; VIT, vault protein inter-alpha-trypsin; vWFA, von Willebrand type ; 
ANK, ankyrin; SAM, sterile alpha motif; CCCH ZnF, CCCH type zinc finger; WWE, three conserved residues 
W-W-E motif domain; Macro, macrodomain; RRM, RNA recognition motif; UIM, ubiquitin interaction motif; 
TM, transmembrane motif. Reproduc d from Barkauskaite et al., 2015. 
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damage migrate from the nucleus to the cytosol, triggering release and transport to the 
nucleus of the mitochondrial protein Apoptosis Inducing Factor, and eventually chromatin 
condensation and cleavage of genomic DNA into large fragments by endonucleases 
(Fouquerel and Sobol, 2014). Although parthanatos is a functionally distinct process from 
apoptosis and PARP-1 does not participate in the apoptosis pathway, PARP-1 interdomain 
linkers are cleaved by caspases, abrogating PARP-1 activity and producing signature 
fragments (notably PARP-1 1-214) which are considered to be biomarkers for induction of 
apoptosis (Chaitanya et al., 2010). As a result of its role in parthanatos and ability to rapidly 
deplete cellular reserves of NAD+ upon hyperactivation, PARP-1 activity must be tightly 
regulated, and turnover of PAR in the cell is rapid (Gupte et al., 2017). 
In addition to poly and mono-PARP enzymes which act as “writers” of ADPr, 
“erasers” of ADPr which catalyse the removal of PAR chains or mono-ADP ribose from 
proteins also exist. These include ADP-ribosyl hydrolase 3 (ARH3) and PAR glycohydrolase 
(PARG), which catalyse cleavage of the ribose-ribose bonds in PAR but leave a single ADP-
ribose moiety bound to the acceptor amino acid (Oka et al., 2006; Slade et al., 2011), and 
TARG, MacroD1 and MacroD2 which can catalyse the complete removal of ADPr by 
hydrolysing the ester bond between ADP-ribose and glutamic or aspartic acid side chains 
(Jankevicius et al., 2013; Rosenthal et al., 2013; Sharifi et al., 2013). Removal of ADPr by 
the NUDIX family of hydrolases results in the formation of a phosphoribose moiety attached 
to the acceptor side chain (Daniels et al., 2015).  
 
1.1.6 PARP-1 DNA damage sensing and activation 
NMR spectroscopy and X-ray crystallography have revealed the structural and 
mechanistic basis of the function of all PARP-1 domains in response to detection of DNA 
single strand and double strand breaks, with the exception of BRCT which does not appear 
to directly participate in the activation of PARP-1 following binding to the site of DNA 
damage (Altmeyer et al., 2009).  
While SSBs are the most common form of DNA damage found in the cell, to date no 
crystal structures of PARP-1 in complex with an SSB have been obtained, presumably due 
Figure 1.4 PARP-1 domain structure, domain nomenclature and colour scheme as used throughout 
this thesis. 
 
F1 F2 F3 WGR
Catalytic Domain
BRCTN CHD ART




to the inherent flexibility of the DNA around the intact strand that likely interferes with the 
formation of crystals.  Previous work in the Neuhaus group (by Sebastian Eustermann), used 
a gapped DNA dumbbell as a model of an SSB and studied its interaction with PARP-1 F1F2 
by NMR in combination with other biophysical techniques (EMSA, centrifugation and 
fluorescence).  This revealed that recognition of SSBs is achieved by F1F2 acting as a 
monomer and in a single orientation, while parallel studies with the separated F1 and F2 
domains showed that it is F2 that provides most of the affinity for DNA binding. Addition 
Figure 1.5 The structural basis of F1 and F2 binding to DSBs and SSBs. (A), (B). Crystal structures 
of F1 (A, green) and F2 (B, purple) domains bound to DNA blunt ends. (C) Hybrid X-ray and NMR structure of 
F1F2 bound to a model of an SSB (gapped dumbbell DNA ligand with a 5'-phosphorylated single nucleotide 
gap). The ensemble of all 78 acceptable structures derived from the structure determination process are shown.      
pdb 3ODA pdb 3ODC A 
C 
Figure 1.6. Formation of interdomain contacts upon binding to a DNA duplex or SSB. (A) Cartoon 
representation of PARP-1 F1, F3, WGR and CAT domains assembled at each end of a DNA duplex (pdb 4DQY). 
Each domain can be identified via the colour scheme in the domain structure. (B) Superposition of the common 






of a nicked DNA dumbbell ligand instead of a gapped DNA dumbbell resulted in only minor 
differences in chemical shift perturbations (CSPs) in spectra of F1F2, indicating that PARP-
1 recognises both forms of SSB in a highly similar manner (Eustermann et al., 2011).  
Work in the Neuhaus group to obtain a solution NMR structure of F1F2 bound to an 
SSB dumbbell ligand continued, but in the event crystal structures of separate F1 and F2 
domains bound to blunt ends of DNA duplexes (pdb 3ODA and pdb 3ODC; see Figures 1.4A 
and 1.4B) were published soon afterwards by the group of John Pascal (then at Thomas 
Jefferson University Philadelphia, now moved to Université de Montréal, Canada). These 
showed strong similarities with unpublished structural features of SSB binding by F1F2 
observed by NMR in the Neuhaus group. Notably, in the crystal structures of both F1 and F2 
on DNA blunt ends, the domains engaged the exposed nucleotide bases of DNA through a 
“base stacking loop” (to use the nomenclature introduced by Pascal), used a “phosphate 
backbone grip” comprising a set of suitably positioned basic sidechains to recognise the 
phosphate backbone of the DNA, and inserted an arginine side chain into the minor groove 
of the DNA in a non-base specific manner (Langelier et al., 2011).  In combination, these 
interactions resulted in the positioning of each finger domain over the minor groove and 3' 
terminus of the DNA stem to which they bound.   
Given that the existing NMR data (intermolecular NOEs and chemical shift 
perturbations upon DNA binding) were fully consistent with this same binding mode being 
adopted by both F1 and F2 in the complex of F1F2 with the gapped dumbbell DNA, the 
Neuhaus group devised a protocol for calculating a structure for this complex based on a 
combination of constraints derived from NMR experiments (F1-F2 and intermolecular NOEs 
as well as amide group RDCs) and similarity to the crystal structures (non-crystallographic 
symmetry constraints to adapted template copies of pdb 3ODA, for F1, and pdb 3ODC, for 
F2).  The resulting hybrid NMR/X-ray structure is shown in Figure 1.4C). Very shortly after 
this structure for the complex of F1F2 with the gapped dumbbell was derived in the Neuhaus 
group, the Pascal group published a crystal structure (pdb 4DQY, Fig 1.5A) of the F1, F3, 
and WGR-CAT domains (as three separate protein chains) in complex with a DNA duplex, 
which showed that these domains assemble onto a DNA blunt end and thereby form a 
network of interdomain contacts (Langelier et al., 2012).  They suggested that these contacts 
were involved in transmission of the DNA-damage-dependent activation signal to the 





However, this crystal structure lacks the F2 domain of PARP-1, as well as the second 
stem of DNA that would be present for a complex with an SSB.  It was therefore of great 
interest to superpose the F1F2 SSB complex structure with pdb 4DQY, using those parts of 
the structure that were common to both, i.e. the F1 domain and its associated DNA stem.  
This superposition (Figure 1.5B) strongly suggested that a similar domain arrangement 
might occur for a complex with an SSB, as well as showing how the F2 domain might 
participate in such a case.  Given the complementary nature of the work in the two groups, 
the Neuhaus and Pascal groups initiated a collaboration at this point, and chemical shift 
perturbation and 15N relaxation experiments were carried out by the Neuhaus group on 
complexes containing F1, F2, F3 and WGR domains (Eustermann et al., 2015).  Overall, this 
work provided a number of insights into DNA damage binding and subsequent activation of 
PARP-1 (see Figure 1.6), summarised below: 
• F1F2 binds to an SSB as a monomer and in a single orientation. F2 binds first due to 
its greater affinity. F1 then also binds, thereby forming a small, DNA-damage 
dependent interface between F1 and F2. This model of binding explains non-
sequence specific PARP-1 DNA damage sensing activity by showing how F1F2 
binding forces damaged DNA into a conformation that undamaged DNA cannot 
reach, with the DNA stems on each side of the damage site bent and twisted apart to 
expose both 5' and 3' ends to F1 and F2 respectively. 
• F3 interacts with F1 and the DNA (this also occurs following binding of F1 to a DSB 
site) and thereby forms a composite interface to receive the WGR domain. Upon 
titration of WGR to an F1F2F3 complex, existing CSPs between other interfaces 
were reinforced, supporting the idea that formation of these interfaces is co-operative 
and stepwise. 
• WGR binds to F1, F3 and the DNA, which creates a further composite interface on 
WGR and F3 for the catalytic domain to bind, which leads to activation.   
Importantly, no direct contact between F1F2 or DNA and the catalytic domain occurs and 
only binding of F1F2 as a monomer in the orientation described above allows subsequent 
co-operative stepwise assembly of PARP-1 domains in this manner, as binding in the 
opposite orientation would not allow subsequent interaction of F1 with F3. 
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In contrast with the steps involved in allosteric transmission of the activation signal 
to the catalytic domain, less high-resolution structural or dynamic information is available 
concerning the events taking place in the catalytic domain itself during activation. Although 
the Pascal group was able to obtain a crystal structure which included PARP-1 catalytic 
domain and showed that the catalytic domain was somewhat destabilised and structurally 
distorted upon DNA binding (Langelier et al., 2012), their subsequent study of activated full-
length PARP-1 using hydrogen/deuterium exchange-mass spectrometry (HXMS) 
unexpectedly revealed more profound effects, in that some parts of the catalytic domain’s 
HD subdomain undergo significantly faster exchange of amide protons with solvent once 
DNA damage recognition has occurred. This suggests that at least some degree of secondary 
structure perturbation occurs, possibly in the form of local partial unfolding (Dawicki-
McKenna et al., 2015). In conjunction with mutational and crystallographic studies carried 
out in in the same paper, this suggests that the HD subdomain is autoinhibitory in nature and 
Figure 1.7 Allosteric activation mechanism of PARP-1 by DNA single-strand breaks. In the absence of 
damaged DNA, PARP-1 domains behave independently and are connected by disordered linkers.  Recognition of 
an SSB by F1 and F2 initiates stepwise multidomain folding, leading to formation of an interface composed of 
surfaces on F3 and WGR for the catalytic domain to bind. Residues forming part of interfaces between domains 
are coloured red or orange. DEVD indicates the location of a caspase cleavage site between F2 and F3. Reproduced 





performs its regulatory function by blocking productive binding of NAD+ to the ART 
domain in the absence of damaged DNA, and that HD unfolding upon PARP-1 activation 
relieves this autoinhibition. However, the intrinsic resolution of HXMS is limited to the level 
of fragment peptides, and even if a fully activated state was crystallised, the full extent and 
detailed nature of HD unfolding is unlikely to be captured at atomic resolution in a crystal 
structure.  
 
1.2 Inhibition of PARP-1 using small molecules 
 
1.2.1 Synthetically lethality of PARP-1 inhibition 
PARP-1’s role in DNA repair has made it a target for the first cancer therapies based on the 
principle of “synthetic lethality”, in which the combined loss of function of two genes, 
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Figure 1. PARP-1 DNADamageDetection Leads toMajor Decreases in HX in DNA-Binding Domains, and aDramatic Increase in HX in the HD
(A) PARP-1 domain architecture.
(B) Combined model of the crystal structure of the PARP-1 (F1, F3, WGR–CAT)/DNA complex, and the NMR structure of F1–F2 in complex with an SSB
(Eustermann et al., 2015).
(C) Color key for the binning of HX differences. Percent difference is calculated by subtracting the percent deuteration of PARP-1 in complexwith DNA from that of
PARP-1 alone.
(legend continued on next page)
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(A) PARP-1 domain architecture.
(B) Combined model of the crystal structure of the PARP-1 (F1, F3, WGR–CAT)/DNA complex, and the NMR structure of F1–F2 in complex with an SSB
(Eustermann et al., 2015).
(C) Color key for the binning of HX differences. Percent difference is calcula ed by subtracting the percent deuteration of PARP-1 in complexwith DNA from that of
PARP-1 alone.
(legend continued on next page)
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Figure 1.8 Changes in rates of solvent exchange in full-length PARP-1 following detection of DNA 
damage after 100 seconds. Slower rates of hydrogen exchange (HX) shown in blue are observed in fragment 
peptides at sites of interdomain contacts following activation. Faster rates of HX shown in red are observed in 
fragments from the active site location (ASL) and the HD subdomain of the catalytic domain. The extent of 
hydrogen exchange in the affected regions of the HD subdomain after 100 seconds is not consistent with 
maintenance of stable helices during catalytic domain activation and is more consistent with significant partial 
melting of the helical regions. Consensus behaviour of each region of the sequence was determined according to 
rates of exchange in peptide fragments. Individual fragments from the experiment and their differences in HX are 
shown below the domain structure, sequence numbering, secondary structure and consensus behaviour. 
Abbreviations of structural elements:  bg, backbone grip; bsl, base stacking loop; (i), F1–F3 interface; (ii), F3–
WGR–HD interface; (iii), GR–HD interface. Reproduced from Dawicki-McKenna et al., 2015.   




proteins or pathways results in cell death, but the loss of one of them does not (Ashworth et 
al., 2011). PARP-1-/- mouse knockouts are embryonically viable and fertile, but are 
demonstrably deficient in repair of SSBs (Conde, 2001; de Murcia et al., 1997). However, 
PARP-1 knockout in these mice does not lead to an associated increase in accumulations of 
mutations or tumours, due to a resulting increase in error-free repair of DNA double strand 
breaks by the homologous recombination pathway (de Murcia et al., 1997). However, in 
tumour cells containing mutations in the tumour-suppressing BRCA1 or BRCA2 genes 
associated with familial breast cancer (in which repair via homologous recombination is 
defective) it was subsequently discovered that inhibition of PARP-1 enzymatic activity by 
small-molecule PARP inhibitors, in conjunction with addition of alkylating agents or 
radiation, leads to a highly selective collapse in genome integrity in comparison with healthy 
cells (Bryant et al., 2005; Farmer et al., 2005). It was suspected that in the absence of PARP-
1, unrepaired single-strand breaks collapse replication forks into double strand breaks, 
triggering repair via homologous recombination, and that selective toxicity in the mutant 
BRCA cells resulted from the accumulation of unrepaired double-strand breaks that would 
normally be repaired by homologous recombination. These findings represented the first 
demonstration of the synthetic lethality of PARP-1 inhibition in vivo.  
Intriguingly, it was later shown by the group of Yves Pommier that the cytotoxicity 
of alkylating agents towards the tumour cells was more strongly enhanced by addition of 
PARP inhibitors than it was by siRNA-mediated knockdown of PARP-1 (Murai et al., 2012). 
This demonstrated that it is not simply the absence of signalling via ADP-ribosylation and 
lack of repair of single strand breaks by PARP-1 that causes cytotoxicity, but that the 
behaviour of PARP-1 itself is modified upon binding to small-molecule inhibitors in a 
manner which results in an increase in genomic instability in the absence of functional HR 
machinery. They showed that the cytotoxicity of PARP inhibitors in vivo arises from 
trapping of PARP-1 or PARP-2 enzymes at the sites of DNA damage; since inhibited PARP 
fails to be released from the DNA, it remains in place forming a bulky, toxic lesion that 
eventually collapses to form a double strand break. They also found that PARP inhibitors 
varied in their ability to form these trapped PARP lesions. They proposed that this could be 
due to prevention of automodification (thought to be required for release) upon binding of 
PARP inhibitors to the catalytic domain, but they also hypothesised that a component of the 
effect might arise because binding of inhibitors to the NAD+ acceptor site of the PARP 
signature fold could enhance the binding affinity of PARP-1 to DNA via a reverse allosteric 




detection of DNA damage could be strengthened. Inhibitors could vary in their ability to 
promote this reverse-allosteric mechanism depending on factors such as their steric bulk and 
the precise mode of catalytic domain binding, although the detailed nature of such proposed 
differences remained unclear.  The compounds veliparib, olaparib (the first PARP inhibitor 
to be approved by the FDA as a targeted therapy for breast and ovarian cancer in people with 
hereditary BRCA1 or BRCA2 mutations under the name Lynparza) and niraparib were 
initially tested by the Pommier group, with veliparib exhibiting negligible trapping activity 
and olaparib and niraparib exhibiting greater and equivalent trapping and cytotoxicity in vivo 
(Murai et al., 2012). Another PARP inhibitor with significantly higher potency for trapping, 
talazoparib, was later discovered (Shen et al., 2013). Talazoparib remains the most active 
PARP inhibitor (as defined by cytotoxicity and trapping potency) discovered to date. It has 
been estimated that talazoparib is approximately 100-fold more effective at forming trapped 
PARP-1 DNA complexes than olaparib (Murai et al., 2014). The chemical structures, in vivo 
cytotoxicity, and results of published biochemical and kinetic assays for these PARP 
inhibitors are summarised later in this thesis in Section 5.1.   
 
1.2.2 Structures of PARP inhibitors in complex with PARP-1    
The majority of PARP inhibitors discovered so far, including those described above, mimic 
the binding mode of the nicotinamide moiety of NAD+ to the ART subdomain of the PARP-
1 catalytic domain, containing groups that form hydrogen bonds with key residues in the 
conserved NAD+ binding pocket (Steffen et al., 2013). Many crystal structures of the PARP 
inhibitors veliparib, olaparib and talazoparib have been published in complex with PARP 
catalytic domains from across the polyenzyme PARP family, but to date the only inhibitor 
to have been solved in complex with the entire PARP-1 catalytic domain is talazoparib 
(Aoyagi-Scharber et al., 2014). The structure of olaparib in complex with PARP-1 ART 
subdomain (i.e. catalytic domain ∆HD) has been solved by the Pascal group (Dawicki-
McKenna et al., 2015) and structures of veliparib in complex with PARP-2 catalytic domain 
(Karlberg et al., 2010) and PARP-5b (Tankyrase 2) ART subdomain (Qiu et al., 2014), but 
not with PARP-1 CAT domain, have been deposited in the Protein Data Bank (PDB). 
Consequently, meaningful comparison of structural differences in binding of these 
compounds to PARP-1 and their relation to trapping ability or other mechanisms of potency 
up to this point has been challenging. The structure of talazoparib in complex with PARP-1 
catalytic domain (Aoyagi-Scharber et al., 2014) revealed that as well as forming contacts 
with the nicotinamide binding pocket via hydrogen bonds and p-stacking interactions, 
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binding occurs at the D-loop in the outer edges of this pocket in the ART subdomain, and to 
the aF helix of the HD subdomain, a portion of which was identified by the Pascal group as 
becoming destabilised upon catalytic domain activation (Dawicki-McKenna et al., 2015) 
(see Figure 1.7). Comparison of binding at these sites with olaparib and veliparib is hindered 
by the lack of any published structure of PARP-1 in complex with olaparib including the 
HD subdomain, and the fact that key residues in both the D-loop and aF helix implicated in 
talazoparib binding differ between PARP-1 and PARP-2 (Aoyagi-Scharber et al., 2014). 
Additionally, all structural information relating to the binding and mechanism of these 
compounds to date has been derived from crystal structures, and whilst no major structural 
rearrangements have been observed, no exploration of potential changes in solvent exposure 
or dynamics distant from the binding site upon drug binding have been carried out via 
methods such as NMR spectroscopy. 
 
1.2.3 Proposed mechanisms of PARP inhibition by small molecules 
 The reasons that trapping occurs in vivo, and the question of whether and how it can 
be reconstituted and studied in vitro remain to be fully resolved. It has been shown that 
veliparib, olaparib, niraparib and talazoparib all potentiate the cytotoxicity of alkylating 
agents to varying extents, indicating that all four compounds are capable of PARP-1 trapping 
(Hopkins et al., 2015). Differences in trapping ability were observed in vivo and were 
correlated with strength of catalytic inhibition, but in a non-linear fashion. Although 
talazoparib was 10-fold more potent than veliparib with respect to catalytic inhibition, it was 
10,000 times more potent with respect to trapping activity. However, as part of the same 
study, no strengthening of PARP-1 binding to DNA upon addition of inhibitors, or vice 
versa, was observed in vitro in biochemical assays or kinetic studies in the absence of NAD+. 
The presence of NAD+ in vitro prevented PARP-1 incubated with inhibitors from being 
released, but in a linear IC50 dependent manner, suggesting that there was no reverse 
allosteric component to trapping for these compounds in their assay, and that variations in 
trapping ability are due purely to efficacy of catalytic inhibition. It remains unclear why the 
difference in talazoparib’s trapping potency in cells and mouse models is so great compared 
to the difference in IC50 between the compounds, or why talazoparib was the only compound 
tested which could potentiate the effect of alkylating agents in vivo at concentrations below 




 Nonetheless there is evidence to suggest that some compounds do promote trapping 
via reverse allostery. Notably, the Pascal group showed using HXMS that binding of the 
non-hydrolyzable NAD+ analogue benzamide adenine dinucleotide (BAD) to the catalytic 
domain in the presence of damaged DNA caused a decrease in HX at interdomain interfaces 
and sites of DNA binding, and that this was consistent with BAD/NAD+ binding to already 
activated PARP-1 shifting the HD further towards an unfolded conformation and then 
stabilising it (Langelier et al., 2018). Hypothetically, persistence of activated ADP-
ribosylated PARP-1 on DNA strand breaks following NAD+ binding in vivo may contribute 
to more efficient downstream SSB repair. In contrast to the clinical PARP inhibitors above, 
the larger molecule BAD (molecular weight 662.442 g/mol) does not bind to the catalytic 
domain of inactivated full-length PARP-1, but rather binds only to PARP-1 ∆HD or to 
PARP-1 in the presence of DNA damage, indicating that the HD domain in its fully folded 
state imposes a complete steric block on NAD+ binding and does not simply disfavour 
productive catalysis as was previously thought to be possible. However, PARP inhibitors 
bind to the catalytic domain with extremely high affinity that is much higher than for BAD, 
typically with nanomolar dissociation constants in comparison to the estimated KD of 50 µM 
for BAD. Nonetheless, one PARP inhibitor with a chemical structure that has a high 
similarity to NAD+ is EB-47 (Jagtap et al., 2004).  John Pascal informed us that his group 
was unable to obtain a crystal structure of EB-47 in complex with PARP-1 catalytic domain, 
and we jointly speculated that this could be because binding of EB-47 may destabilise the 
HD subdomain (unpublished personal communication).  The chemical structures of NAD+, 
BAD and EB-47 are shown later in this thesis in Section 5.1, Figure 5.1. To date, only crystal 
structures of EB-47 in complex with PARP-2 ∆HD catalytic domain and tankyrase 2 (PARP-
5b), which has no HD subdomain, have been published (Dawicki-McKenna et al., 2015; 
Haikarainen et al., 2013), demonstrating that EB-47 binds to the NAD+ binding pocket of 
the PARP ART fold but providing no insight into the effect of EB-47 binding on the HD 
subdomain of PARP-1 catalytic domain.  Therefore, the potential structural basis of any 
mechanistic differences between clinically approved PARP inhibitors and compounds such 
as EB-47 remains to be fully explored.    
 
1.3 Project aims 
Therefore, at the start of the work described in this thesis, we wished to address the following 
key questions. Firstly, we aimed to further characterise the changes described by the group 
of John Pascal (Dawicki-McKenna et al., 2015) that take place in the HD subdomain of the 
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catalytic domain following DNA damage detection by PARP-1 using NMR spectroscopy. 
How exactly does the secondary structure of these helical regions change upon activation 
and is there further evidence that this deprotection occurs as a result of partial loss of 
structure or even partial melting, as hypothesised by the Pascal group? Can the underlying 
causes of these dynamic changes be probed in solution at the level of individual residues (as 
opposed to peptide fragments) or at timescales faster than those investigated using HXMS 
(i.e. <10 seconds)? 
 Secondly, how might binding of the PARP inhibitors described above to PARP-1 
catalytic domain lead to “trapping” of PARP-1 at sites of DNA damage, and what is the 
structural basis of the differences in potency between PARP inhibitors? As binding of these 
compounds to PARP-1 active sites has provided relatively few insights into these questions, 
determining whether any dynamic or conformational changes take place in the HD 
subdomain in these complexes will be key to answering this question. With the exception of 
talazoparib, to date no structures of complexes with these compounds have been solved by 
X-ray crystallography that include the PARP-1 HD subdomain, and even in the case of 
talazoparib there may be important dynamic changes in the HD subdomain that are not 
observed in the crystal structure (in a manner similar to the difference between the structure 
of the activated catalytic domain in pdb 4DQY and the HXMS data described above). 
Furthermore, if binding by any of the compounds described above to the catalytic domain 
leads to tightening of interdomain and DNA-binding interfaces in the rest of the full-length 
PARP-1 protein via a reverse allosteric mechanism, this is highly likely to be mediated 
through the HD subdomain, as formation of these interfaces following DNA binding leads 
to conformational changes in the HD subdomain.  
 With these questions in mind, Chapter 3 describes the work that was necessary to 
complete the sequential resonance assignment of backbone amides in the 360 residue, 40 
kDa wild-type catalytic domain fragment, as well as three mutants of the catalytic domain 
and the wild-type catalytic domain in complex with four different PARP inhibitors. Chapter 
4 describes work characterising the differences between the wild-type catalytic domain and 
these three catalytic domain mutants using NMR spectroscopy, all of which exhibit a 
constitutive partial DNA-independent increase in activity and are used as a model of PARP-
1 activation in the isolated catalytic domain fragment. Chapter 5 describes experiments to 
characterise, compare and contrast the binding of the PARP inhibitors veliparib, olaparib, 








Materials and methods  
 
2.1 Molecular cloning 
All sequences from human PARP-1 used in this work originated from a plasmid (pQE-T7) 
containing the DNA sequence coding for the human PARP-1 protein, codon-optimised for 
bacterial expression (Qiagen). 
 Initially, the codon-optimised PARP-1 catalytic domain fragment 660-1014 was 
cloned by Laura Easton into a modified pET28a vector which contained a DNA sequence 
encoding the Bacillus stearothermophilus dihydrolipoamide acetyltransferase lipoyl domain 
(referred to as lipoyl domain) as an N-terminal fusion tag. The lipoyl domain itself also 
included an N-terminal His6 tag. To facilitate cleavage of this fusion tag, when the PARP-1 
catalytic domain fragment was subcloned into this vector, a DNA sequence encoding a 
recognition sequence (ENLYFQG) for Tobacco Etch Virus protease (TEVpro) was inserted 
each time a new fragment was cloned. However, in the fragment 660-1014 this left only two 
residues between the protease cleavage site and the beginning of the structured catalytic 
domain at residue 662, which sterically inhibited cleavage of the N-terminal fusion tag by 
TEV protease. To resolve this problem, three further versions of this vector were cloned to 
include additional residues from the CAT-WGR linker to increase the number of residues 
from the WGR-CAT linker and facilitate improved cleavage by TEV protease (see Table 
2.1). 
In each case, the DNA sequence of the desired length of PARP-1 catalytic domain 
fragment was amplified by PCR using Pfu Turbo DNA Polymerase (Agilent) according to 
the manufacturer’s instructions and the sequence for the TEV protease recognition motif 
was added using the forward PCR primer. Following the PCR reaction, the amplified 
product was purified using a QIAquick PCR Purification Kit (Qiagen). The purified product 
and pET28a-lip vector were then digested with the restriction enzymes Nde1 and Xho1 
(New England Biolabs), and digestion products were purified using agarose gel 
electrophoresis and a gel extraction kit from Qiagen. The digested vector was then 
dephosphorylated using alkaline phosphatase (Roche). The digested insert and vector were 
ligated together during an overnight incubation at 16°C with T4 DNA ligase (New England 
Biolabs) and the ligated product was transformed into chemically competent DH5a cells. 
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To achieve this, 10 µL of ligated plasmid vector was added to 50 µL DH5a cells in a round-
bottomed 14 mL Polypropylene Falcon tube, gently mixed and left on ice for 30 minutes; 
the cells and vector were then heat shocked at 42°C for 45 seconds and allowed to recover 
on ice for 2 minutes before 450 µL SOB medium was added and cells were grown at 37°C 
in an incubator with shaking. Cells were plated on TYE agar plates containing kanamycin 
(Formedium, working concentration of 50 µg/mL) and incubated overnight at 37°C. 
Colonies were sequenced to confirm the presence of the chosen insert in the vector.  
Although the TEV protease recognition motif was initially formed using the 
canonical residue G660 from the PARP-1 WGR-CAT linker, fragments containing a longer 
section of the CAT-WGR linker that did not begin with a canonical glycine residue from the 
PARP-1 sequence resulted in a non-canonical glycine at the N-terminus of the catalytic 
domain fragment following cleavage by TEV protease, as TEV protease cleaves its substrate 
between the Q and G residues of the recognition sequence. Proteins CAT2 V762 (G-PARP-
1656-1014), CAT3 V762 (G-PARP-1652-1014) and CAT4 V762 (PARP-1646-1014) were expressed in 
rich media and cleavage with TEV protease was equally efficient for all three extended 
linker lengths. 
Additionally, since the codon-optimised gene that had originally been obtained from 
Qiagen corresponded to protein that differed by a single amino-acid from that used in the 
Pascal group (both are naturally occurring isoforms of PARP-1), in order to be consistent 
with their work we replaced valine 762 with alanine in the HD subdomain of all catalytic 
domain fragments. This change was introduced by cloning via PCR with Pfu Turbo DNA 
Polymerase using a site-directed mutagenesis approach based on Strategene’s Quikchange 
II methodology. Following the mutagenesis reactions, parent DNA templates were digested 
using Dpn1 endonuclease (New England Biolabs). Reactions were subsequently 
transformed into DH5a cells and clones from TYE agar plates containing kanamycin were 
sequenced to confirm that the desired mutagenesis had taken place. All vectors cloned with 
this mutation are summarised in Table 2.1. CAT2, which contained the V762A mutation 
and the shortest of the extended linkers (G-PARP-1656-1014) was considered to be the optimal 
fragment to use for studies of wild-type PARP-1 catalytic domain. Attempts to carry out 
mutagenesis of CAT4 V762 to alanine were repeatedly unsuccessful and were abandoned 
once CAT2 was found to be optimal. As used from this point onwards in this thesis, the 
abbreviation “CAT” implies that position 762 is alanine; on those occasions that it is 
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necessary to refer explicitly to fragments or constructs carrying valine at position 762, these 
will be referred to as CAT V762. 
 
Name Number Protein Vector 
Fusion proteins, 
purification tags, protease 
cleavage sites 
PARP-1 FL 216 PARP-11-1014 pQE-T7 His6 
CAT V762 217 PARP-1660-1014 V762 pET28a-lip His6, lipoyl, TEV protease 
CAT  218 PARP-1660-1014 V762A pET28a-lip His6, lipoyl, TEV protease 
CAT2 V762 224 G-PARP-1656-1014 pET28a-lip His6, lipoyl, TEV protease 
CAT3 V762 225 G-PARP-1652-1014 pET28a-lip His6, lipoyl, TEV protease 
CAT4 V762 226 PARP-1646-1014 pET28a-lip His6, lipoyl, TEV protease 
CAT2  227 
G-PARP-1656-1014 
V762A 
pET28a-lip His6, lipoyl, TEV protease 
CAT3  228 
G-PARP-1652-1014 
V762A 
pET28a-lip His6, lipoyl, TEV protease 
CAT mutant L713F 230 
G-PARP-1656-1014 
V762A L713F 
pET28a-lip His6, lipoyl, TEV protease 
CAT2 mutant L765F 231 
G-PARP-1656-1014 
V762A L765F 
pET28a-lip His6, lipoyl, TEV protease 
CAT2 mutant L765A 232 
G-PARP-1656-1014 
V762A L765F 
pET28a-lip His6, lipoyl, TEV protease 
TEVpro N/A 
(TEV protease 
“SuperTEV” from Mark 
Allen with N-terminal 
lipoyl domain) 
pRET3a His6, lipoyl 
CAT2 E988A N/A 
G-PARP-1656-1014 
V762A E988A 
pET28a-lip His6, lipoyl, TEV protease 
Constitutively partially active CAT mutants L713F, L765F and L765A were also 
cloned using the Quikchange II methodology. Reactions were performed with KOD Hot 
Start DNA Polymerase (Novagen) and overhanging primers for site-directed mutagenesis 
were designed by Chris Tate using the program Optimus Primer (Brown et al., 2010). All 
corresponding fragments of PARP-1 catalytic domain (including any artefacts from 
molecular cloning) are summarised in Table 2.1. From this point onwards, reference to wild-
type catalytic domain refers to the protein fragment CAT2, post cleavage of N-terminal His6-
lipoyl fusion protein. 
Table 2.1 Summary of protein constructs used in this thesis. All fusion proteins, purification tags 
and protease cleavage sites were located at the N-terminus.    
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The plasmid used for bacterial expression of His6-Lipoyl-TEV protease was a gift 
from Mark Allen and based on a pRET3a plasmid which confers ampicillin resistance. 
 
2.2 Protein expression and purification using E. coli 
All PARP-1 proteins were expressed in the Escherichia coli strain BL21 (DE3). 
 
2.2.1 Expression of unlabelled PARP-1 catalytic domain 
The plasmid CAT2 encoding wild-type PARP-1 catalytic domain was transformed into 
BL21 (DE3) cells using the protocol described above and plated on TYE agar plates 
containing kanamycin (Formedium, working concentration of 50 µg/mL). Plates were 
incubated overnight at 37°C. A single colony was picked from the plate and used to inoculate 
50 mL LB medium supplemented with kanamycin, which was subsequently grown 
overnight at 37°C with shaking at 200 rpm. Starter cultures were used to inoculate LB 
medium supplemented with kanamycin, at a ratio of 1:40. For expression of unlabelled 
protein, 500 mL of expression medium was used per 2L flask to ensure adequate aeration of 
cells during growth and expression of recombinant protein. Following inoculation, 
expression cultures were grown at 37°C with shaking at 200 rpm until OD600 was between 
0.8 and 1.0. Protein expression was then induced by addition of 1 M isopropyl ß-D-1-
thiogalactopyranoside stock (IPTG, Melford) to give a final concentration of 2 mM and cells 
were incubated overnight (minimum of 16 hours) at 30°C with shaking at 200 rpm. Cells 
were pelleted by centrifugation at 4000 rcf for 20 minutes at 4°C in 1L polycarbonate 
Beckman bottles in a JLA 8.1000 rotor and pellets were resuspended in ice-cold PBS before 
a second centrifugation step was carried out in 50 mL Falcon tubes as described above. The 
supernatant was discarded and pellets were frozen at -20°C.   
 
2.2.2 Expression of unlabelled PARP-1 catalytic domain mutants 
Catalytic domain mutants were expressed and purified based on an approached outlined for 
production and purification of full-length human PARP-1 from E. coli (Langelier et al., 
2017). Following transformation with plasmids encoding catalytic domain mutants or full-
length PARP-1, cells were plated on TYE agar plates containing kanamycin and 10 mM 
benzamide (Sigma-Aldrich). To prepare TYE agar with kanamycin and benzamide, 
autoclaved TYE agar was kept at 50°C in a water bath, kanamycin was added and benzamide 
powder was dissolved to give a final concentration of 10 mM.  Expression of unlabelled 
catalytic domain mutant proteins then followed a similar procedure to expression of wild-
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type catalytic domain, but with all media supplemented with 10 mM benzamide. Expression 
was induced by addition of IPTG to give a final concentration of 0.5 mM and expression 
cultures were grown overnight at 20°C with shaking at 200 rpm. Cells were harvested as 
described for wild-type PARP-1 catalytic domain. 
 
2.2.3 Expression of isotope-labelled catalytic domain and mutants 
Expression of uniformly-labelled 15N and/or 13C isotopically labelled proteins (without 
deuteration) was carried out in M9 minimal media (composition in Table 2.2) supplemented 
with 15NH4Cl and/or 13C6-glucose instead of their natural abundance equivalents. BL21 
(DE3) cells transformed with plasmid encoding wild-type or mutant catalytic domain were 
plated and starter cultures inoculated as described for unlabelled expression. Starter cultures 
were then pelleted by centrifugation (4000 rcf, 20 mins at 4°C), supernatant discarded and 
pellets washed gently with ice-cold phosphate-buffered saline (PBS) and re-suspended into 
minimal media which was used to inoculate 500 mL minimal media per 2L flask. As with 
expression of unlabelled protein, starter culture media and minimal media for expression of 
isotope-labelled catalytic domain mutants contained 10 mM benzamide. Cells were grown 
at 37°C with shaking at 200 rpm until OD600 was between 0.8 and 1.0 and expression and 
harvesting was carried out for each protein as described for its unlabelled counterpart. 
 Expression of perdeuterated wild-type and mutant catalytic domains in conjunction 
with uniform 15N and 13C labelling was based on the approach described in (Marley et al., 
2001) in which a high cell mass is cultivated in unlabelled rich media before E. coli cells are 
re-suspended into a smaller volume of isotopically enriched minimal media and recombinant 
protein expression is induced.  Starter cultures were inoculated as described for unlabelled 
protein expression and used to inoculate 4x desired expression culture volume of LB 
medium containing kanamycin. Cells were grown at 37°C with shaking at 200 rpm until 
OD600 reached 0.6. Cells were then pelleted via centrifugation at 4000 rcf for 20 minutes at 
4°C and pellets were gently washed with ice-cold PBS and resuspended in M9 minimal 
media containing 2H2O (Sigma-Aldrich), 15NH4Cl and 13C6,2H7-glucose. Cells were 
incubated for 45 minutes at 37°C with shaking at 200 rpm and a further 45 minutes at the 
desired expression temperature (37°C for wild type catalytic domain and 20°C for catalytic  
domain mutants). Expression of recombinant protein was induced by adding IPTG to a final 
concentration of 2 mM. 
 





Selective amino acid labelling of wild-type and mutant PARP-1 catalytic domains 
was also carried out using this approach in H2O-based M9 minimal media containing 
14NH4Cl and 12C6-glucose. For selective 15N labelling of lysine and arginine residues, M9 
minimal media was supplemented with 0.1 g/L L-Lysine-α-15N dihydrochloride, 
(Cambridge Isotope Laboratories), or L-Arginine-15N4 hydrochloride (Sigma-Aldrich) 
respectively. For selective 15N labelling of leucine and isoleucine residues as well as joint 
selective 15N labelling of glycine and serine residues, expression media was supplemented 
with 0.1g/L of all non-target proteinogenic amino acids respectively (all from Sigma-
Aldrich) and 15 minutes prior to induction 0.1g/L L-Leucine-15N, L-Isoleucine-15N or 
Glycine-15N respectively (all from Cambridge Isotope Laboratories) and 0.5 g/L of non-
target unlabelled amino acids (including serine for joint glycine-serine labelling) were added 
to the media. 
 
2.2.4 Purification of human PARP-1 catalytic domain and mutants 
Wild-type and mutant PARP-1 catalytic domains were purified via the following steps: Ni-
affinity purification, cleavage of His6-tagged lipoyl domain using TEV protease, removal of 
TEV protease, cleavage product and uncleaved protein via a second Ni-affinity step and a 
final gel filtration step. 
 Cell pellets were resuspended in 35 mL Buffer A+. Cell pellets harvested from 
culture volumes of 4L or below were lysed by sonication (microprobe, 70% amplitude, 3s 
Minimal Media 
Reagent Concentration 
Na2HPO4 50 mM 
KH2PO4 25 mM 
NaCl 10 mM 
Thiamine 40 mg/L 
MgSO4 4 mM 
CaCl2 0.2 mM 
Trace Elements 1x 
Vitamin Mix 1x 
NH4Cl 1g/L 
Glucose 4g/L 





















Table 2.2 Recipes used for the production of M9 minimal media, required for the expression of 
isotope-labelled proteins in E. coli. 
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on and 7s off at 4°C for 6 minutes total on-time). For pellets from culture volumes of greater 
than 4L, cells were re-suspended in 200 mL lysis buffer and cells were lysed by three passes 
through a cell disruptor (Constant) at 25 kpsi. Total cell lysate was cleared via centrifugation 
(27,000 rcf, 45 min, 4°C) and supernatant was incubated with 5 mL 50% Ni-NTA agarose 
resin (Qiagen) re-suspended in the chosen lysis buffer (following 2x wash steps in Millipore 
water) for 1.5 hours on a roller at 4°C. Resin was loaded onto a glass chromatography 
column (Bio-Rad) and flow-through was discharged by gravity and collected. The resin was 
washed with 2x 50 mL Wash Buffer and 50 mL High Salt Wash Buffer. Three elution steps 
in Elution Buffer were performed: a 10 mL step, a 5 mL step and a 5 mL step with a five-
minute incubation period to make a total elution volume of 20 mL. Elution fractions were 
pooled and 2 mg His-tagged TEV protease was added to the sample. The mixture was then 
dialysed overnight in 1L HepA+ buffer in a dialysis membrane with a 3500 molecular 
weight cut-off (Snakeskin, Thermo Scientific). 
 Following dialysis, SDS-PAGE was carried out to verify completed cleavage of N-
terminal His6-lipoyl domain and the mixture was incubated with 2 mL 50% NiNTA re-
suspended in HepA+ (following 2x wash steps in Millipore water) on a roller at 4°C for one 
hour to bind uncleaved protein, TEV protease and His6-lipoyl domain (the last of these being 
the unwanted product of the cleavage by TEV protease). The mixture was passed through a 
Bio-Rad Poly-Prep column via centrifugation in a 50 mL Falcon tube and the flow-through 
containing cleaved PARP-1 catalytic domain was collected. The resin was then washed with 
3 mL HepA+. The flow-through and wash were checked using SDS-PAGE to ensure that 
uncleaved protein, TEV protease and His6-lipoyl domain had been removed, then pooled 
and concentrated in a Vivaspin 20 with a 10000 molecular weight cut-off (Sartorius 
Stedium) before purification via gel filtration. The sample was loaded onto a HiLoad 26/60 
Superdex 75 or 200 gel filtration column (GE Healthcare) equilibrated with GF150+ gel 
filtration buffer and run at 2 ml/min with 4 mL fractions collected immediately following 
the void volume. Collected fractions were analysed using SDS-PAGE and fractions 
containing pure CAT domain were pooled. The concentration of pooled fractions was 
measured via A280 on a Nanodrop 2000 (Thermo Scientific). Pooled fractions were 
concentrated in a Vivaspin 20 as described above. Samples prepared for NMR spectroscopy 
were exchanged into CAT NMR Buffer by 5 repeated 10 x concentrations and dilutions in 
a Vivaspin 2 with a 10,000 molecular weight cut-off (Sartorius Stedium). For samples 
prepared for applications other than NMR, 20% glycerol was added and the samples were 
snap frozen in 2 mL Eppendorf tubes using dry ice and stored at -80°C.  




50 mM Na-HEPES pH 8.0, 0.5 M NaCl, 0.5 mM TCEP, 1 mM PMSF, 
Roche EDTA-free Complete protease inhibitor tablets (1 tablet per 2L 
culture) 
Wash Buffer 50 mM Na-HEPES pH 8.0, 0.5 M NaCl, 0.5 mM TCEP, 1 mM PMSF 
High Salt Wash Buffer 50 mM Na-HEPES pH 8.0, 1 M NaCl, 0.5 mM TCEP, 1 mM PMSF 
Elution Buffer 50 mM Na-HEPES pH 8.0, 0.5 M NaCl, 0.3 M imidazole, 0.5 mM TCEP, 1 mM PMSF 
Hep A+ Buffer 
50 mM Na-HEPES pH 8.0, 0.2 M NaCl, 0.5 mM TCEP, 5% glycerol, Roche 
EDTA-free Complete protease inhibitor tablets (1 tablet per litre dialysis 
buffer) 
GF150+ 50 mM Na-HEPES pH 8.0, 0.15 M NaCl, 0.5 mM TCEP 
Low Salt Wash Buffer 50 mM Na-HEPES pH 8.0, 0.5 M NaCl, 10 mM imidazole, 0.5 mM TCEP, 1 mM PMSF 
TEV Buffer A 50 mM Tris-HCl pH 8.0, 0.3 M NaCl, 2 mM b-mercaptoethanol, 1 mM PMSF 
TEV Elution Buffer 50 mM Tris-HCl pH 8.0, 0.3 M NaCl, 0.1 M imidazole, 2 mM b-mercaptoethanol, 1 mM PMSF 
2x TEV Dialysis Buffer 50 mM Tris-HCl pH 7.5, 5 mM DTT 
 
2.2.5 Expression and purification of TEV protease 
Cells from E. coli strain C41 (DE3) were transformed with the plasmid containing the DNA 
sequence of His6-lipoyl TEV protease, plated on TYE agar plates containing ampicillin 
(Formedium, 100 µg/mL) and grown overnight in an incubator set to 37°C. Plates were 
scraped directly into 3L 2xTY medium supplemented with ampicillin (1 plate per 1L 
medium in a 2L flask) and cultures were grown at 37°C until OD600 reached 0.5. The 
temperature was lowered to 22°C and expression was induced via addition of 0.5 mM IPTG. 
Cells were harvested 4-6 hours after expression, as described for PARP-1 catalytic domain 
fragments. 
Cell pellets were re-suspended in TEV Buffer A, then cells were lysed and lysate 
clarified as described for PARP-1 catalytic domain. The supernatant was incubated for 1 
hour on a roller at 4°C with 10 mL 50% Ni-NTA pre-washed with Millipore water and 
equilibrated in TEV Buffer A. Resin was loaded onto a glass chromatography column (Bio-
Rad) and flow-through was discharged by gravity and collected. TEV protease was eluted 
via 3 x 15 mL washes with TEV Elution Buffer with a five-minute incubation before 
Table 2.3 Summary of all buffers used in protein purifications. Abbreviations: HEPES: (4-(2-
hydroxyethyl)-1-piperazineethanesulfonic acid) Tris: Tris(hydroxymethyl)aminomethane  TCEP: Tris(2-
carboxyethyl)phosphine hydrochloride PMSF: Phenylmethylsulfonyl fluoride. DTT:  Dithiothreitol. EDTA:  
Ethylenediaminetetraacetic acid.  
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collection of each fraction. Eluates were pooled and dialysed into 2x TEV Dialysis buffer 
overnight and concentrated to 4 mg/mL before addition of 50% glycerol, snap freezing and 
storage at -20°C.   
 
2.3 NMR spectroscopy 
NMR data was acquired at the MRC-LMB MRS facility on Bruker Avance III HD 800, 
Avance III 600 or Avance I 600 spectrometers. Some data was also acquired at the MRC 
Biomolecular NMR centre at the Francis Crick Institute, London on a Bruker Avance III 
HD 950. All spectrometers used were equipped with triple resonance (15N/13C/1H) 
cryoprobes. Unless otherwise specified, all NMR experiments performed using wild type 
PARP-1 catalytic domain fragment or mutants were performed at 25°C in NMR Buffer 
containing 50 mM Tris-d11-HCl pH 7.0 (at 25°C), 50 mM NaCl, 2 mM DTT d-10, 0.02% 
NaN3 and 95:5 H2O:D2O in 5 mm NMR tubes (Norell). 
 
2.3.1 Triple-resonance backbone experiments  
TROSY-based HNCA, HN(CO)CA, HNCACB and HN(CO)CACB triple-resonance 
backbone experiments (Salzmann et al., 1998; Eletsky et al., 2001) were performed by Ji-
Chun Yang on wild-type catalytic domain and catalytic domain mutant L713F using non-
uniform sampling (NUS). For TROSY-based HNCA and HNCACB experiments, between 
25% and 30% of data was collected under the NUS scheme, and for TROSY-based 
HNCOCA and HNCOCACB experiments, the data collection percentage was 20%. For 
wild-type catalytic domain, experiments were carried out on perdeuterated 15N 13C labelled 
wild-type catalytic domain (200 µM) in NMR Buffer at 30°C. For L713F mutant, 
experiments were carried out on both perdeuterated 15N 13C labelled (200 µM) and non-
deuterated 15N 13C domain in NMR Buffer at 25°C. Data was processed using the 
programmes MddNMR (Orekhov et al., 2011) and NMRPIPE (Delaglio et al., 1995). 
Analysis of data, including sequential assignment of wild-type catalytic domain and 
catalytic domain L713F, was performed using the programme CcpNMR Analysis 2.4 
(Vranken et al., 2005). 
 
2.3.2 15N NOESY-HSQC experiments 
15N NOESY-HSQC experiments (Sklenáŕ et al., 1993) with a mixing time of 70 ms were 
recorded from 400 µM samples of 15N-labelled samples of wild-type PARP-1 catalytic 
domain, L713F, L765F and L765A catalytic domain mutants, and samples of wild-type 
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PARP-1 catalytic domain in complex with a 1:1.5 ratio of veliparib (300 µM catalytic 
domain), olaparib (400 µM), talazoparib (500 µM) and EB-47 (400 µM). All samples were 
made in NMR Buffer and catalytic domain samples were titrated with 50 mM stock solutions 
of PARP inhibitors in 100% DMSO-d6 to a final ratio of 1:1.5 to ensure that the inhibitor 
was present in excess. Data for all samples was collected at 25°C on a Bruker Avance III 
HD 800 spectrometer, with the exception of the catalytic domain mutant L765F, for which 
data was collected on a Bruker Avance III HD 950 at the MRC Biomolecular NMR centre 
at the Francis Crick Institute, London. Both spectrometers were equipped with triple-
resonance cryoprobes (15N/13C/1H). Data analysis, including sequential assignment of 
catalytic domain mutants L713F, L765F, L765A and wild-type catalytic domain in complex 
with the PARP inhibitors veliparib, olaparib, talazoparib and EB-47, was performed using 
the programme CcpNMR Analysis 2.4 (Vranken et al., 2005). 
 
2.3.3 Chemical shift perturbation 
Analyses of backbone amide chemical shift perturbations (CSPs) relative to wild-type 
catalytic domain were performed for 15N-labelled catalytic domain mutants and 15N-labelled 
wild-type catalytic domain following titration with PARP inhibitors. In all cases, 15N and 
1H chemical shifts of backbone amides from [15N-1H]-TROSY spectra were recorded and 
the chemical shift perturbation ∆d (measured in ppm) was calculated using the formula Dd 
= ((Dd(1H))2+(Dd(15N)/5)2)1/2 (Williamson, 2013).  The scaling of the 15N shifts by a factor 
of 1/5 was used to compensate approximately for the different chemical shift ranges for the 
1H and 15N chemical shifts; the same scaling factor was used for all amino acids and analyses 
of CSPs described in this dissertation. All CSP analyses described in this dissertation used 
amide chemical shifts from [15N-1H]-TROSY spectra acquired on a Bruker Avance III HD 
800 spectrometer under the conditions described at the beginning of this section. 
 Chemical shift perturbation analyses of 15N wild-type PARP-1 catalytic domain and 
15N PARP-1 catalytic domain mutants were achieved by comparing the amide chemical 
shifts assigned to each residue measured from [15N-1H]-TROSY spectra of wild-type and 
mutant domains.  
 Chemical shift perturbation analyses of 15N-labelled wild-type PARP-1 catalytic 
domain upon binding to selected PARP inhibitors was achieved by titrating the catalytic 
domain to a 1:1.5 protein:inhibitor ratio (to ensure complete saturation) with veliparib, 
olaparib, talazoparib (all from Selleck) or EB-47 (Sigma-Aldrich) solubilised in deuterated 
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dimethyl sulfoxide (DMSO-d6, Aldrich), and comparing the amide chemical shifts from 
[15N-1H]-TROSY spectra. Titrations were performed with an appropriate concentration of 
inhibitor to ensure that the final concentration of DMSO-d6 did not exceed 5%, and a control 
titration was carried out to confirm that addition of DMSO-d6 alone did not cause any CSPs. 
 Chemical shift perturbations from catalytic domain mutants and inhibitor titrations 
were mapped onto the structure of wild-type catalytic domain and complexes of the catalytic 
domain and inhibitors for display in Pymol using a combination of in-house scripts written 
by members of the Neuhaus group.  First, CSP values exported directly from CCPN analysis 
were globally normalised to values between zero and one (using a shell script written by 
David Neuhaus), with the largest chemical shift perturbation found across all mutant and 
inhibitor complexes being set to one. This allowed for later simultaneous visual comparison 
between the mapping results across all datasets.  For each dataset in turn, these scaled CSP 
values were then used as input to a python script (written by Christoph Brockmann) that 
converted them into RBG colour settings corresponding to a colour ramp running between 
two pre-defined colours. In this work, a CSP of zero corresponded to grey (RGB 0.6,0.6, 
0.6) and a CSP of one corresponded to yellow (RGB 1.0, 1.0, 0.0).  The output of this python 
script is a Pymol-command script (.pml file) that, when run in a Pymol session where the 
relevant structure has been pre-loaded, sets the colour for each residue to the RGB values 
calculated according to the defined colour ramp.  For CSPs from catalytic domain mutants 
and wild-type catalytic domain in complex with EB-47, for which no solved crystal 
structures exist, globally scaled CSP values were mapped onto the crystal structure of wild-
type PARP-1 catalytic domain (pdb 4DQY). For CSPs from wild-type PARP-1 catalytic 
domain in complex with talazoparib, globally scaled CSP values were mapped onto pdb 
4PJT, a published crystal structure of talazoparib bound to the catalytic domain Aoyagi-
Scharber et al., 2014). We gratefully acknowledge Marianne Schimpl at AstraZeneca who 
very kindly supplied us with the co-ordinates of unpublished crystal structures of PARP-1 
catalytic domain in complex with veliparib or olaparib, which were used to display the 
mapping results for CSPs from wild-type PARP-1 catalytic domain in complex with these 
compounds. 
 
2.3.4 15N relaxation analysis 
Backbone 15N longitudinal relaxation time (T1), spin-locked transverse relaxation time (T1r) 
and 15N{1H} steady state NOEs were determined for 15N-labelled samples of wild-type 
Materials and methods 
 32 
PARP-1 catalytic domain, L713F, L765F and L765A catalytic domain mutants, and samples 
of wild-type PARP-1 catalytic domain in complex with veliparib, olaparib, talazoparib and 
EB-47, using TROSY-based pulse sequences described by Lakomek et al. (2012). The spin 
lock field strength for all T1r experiments was 1.56kHz and all T1r measurements were 
corrected for the off-resonance tilted field using the equations described in Lakomek et al. 
(2012). All samples were made in NMR Buffer at a concentration of 400 µM and catalytic 
domain samples were titrated with 50 mM stock solutions of PARP inhibitors in 100% 
DMSO-d6 to a final ratio of 1:1.5 to ensure that the inhibitor was present in excess. Data 
was collected at 25°C on a Bruker Avance III HD 800 spectrometer equipped with a triple-
resonance cryoprobe (15N/13C/1H). T1 data was recorded for all samples using delays of 0, 
120, 120, 280, 480, 800, 1200, 1200, 2000, 3200, 4800 and 6800 ms and T1r data was 
recorded for all samples using delays of 0.15, 2, 4, 4, 7, 12, 20, 34, 50 and 100 ms. Relaxation 
times were derived in Sparky using non-linear least square fitting of peak heights at different 
delays. In order to determine 15N{1H} steady state NOEs, CcpNMR Analysis 2.4 (Vranken 
et al., 2005) was used to calculate the peak intensity ratios in pairs of spectra recorded with 
and without 1H saturation. A saturation time of seven seconds was used for steady state NOE 
experiments. For T1r  values, error bars were plotted according to the data fitting error in 
Sparky. For heteronuclear NOE, error bars were plotted according to standard deviation 
determined on the basis of background noise levels as described in Farrow et al. (1994).  tc 
values for backbone amides in all samples described above were calculated from T1 and T1r 






− 7, where 𝜐1 is the 15N resonance frequency in 
Hz (Rossi et al., 2010).  
 
2.3.5 CLEANEX experiments 
Experiments were recorded for 400 µM 15N-labelled samples of free wild-type PARP-1 
catalytic domain and PARP-1 catalytic domain in complex with veliparib, olaparib, 
talazoparib and EB-47 using a phase-modulated CLEANEX pulse sequence (Hwang et al., 
1998) with a mixing time of 150 ms.  Data was collected at 25°C on a Bruker Avance III 
HD 800 spectrometer equipped with a triple-resonance cryoprobe (15N/13C/1H). Peak heights 
were normalised according to the difference between the average peak heights of N-terminal 
residues 657,658 and 660 relative to a 400 µM 15N TROSY reference sample to give a 
measure of CLEANEX Relative Intensity.   
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2.3.6 2H2O exchange experiments 
Solvent exposure of backbone amides over a timeframe of 48 hours was compared in 15N-
labelled wild-type catalytic domain and 15N-labelled wild-type catalytic domain in complex 
with PARP inhibitors. 500 µL, 100 µM samples of 15N-labelled wild-type catalytic domain 
in H2O-based NMR Buffer were snap frozen in dry ice and lyophilised overnight (>16 hours) 
in a 2 mL Eppendorf tube. Pellets were re-suspended in 2H2O, samples were transferred to 
5 mm NMR tubes and a repeating series of 16 [15N-1H]-TROSY experiments was 
immediately started with the aim of measuring the height of backbone amide peaks at 
repeating intervals over a period of 48 hours. For complexes of catalytic domain with PARP 
inhibitors, PARP inhibitor solubilised in 100% d6-DMSO was added immediately after re-
suspension of the pellet in 2H2O to give a final concentration of 150 µM (a 1:1.5 ratio to 
ensure complete saturation, as described above). Data was collected at 25°C on a Bruker 
Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (15N/13C/1H). 
The heights of peaks from TROSY spectra were measured in CCPN analysis 2.4 (Vranken 
et al., 2005. A measure of relative residual intensity for every sample at 6-hour, 15-hour and 
42-hour time points was calculated by scaling peak heights between TROSY spectra in order 
to normalise variations in concentration (according to the 1D proton spectra of the samples) 
and number of scans. Data from 2H2O and CLEANEX experiments was mapped onto the 
structure of wild-type catalytic domain and structures of the catalytic domain in complex 
with the relevant inhibitors for display in Pymol using a script written by David Neuhaus 
that coloured residues light blue (6 hours), blue (15 hours) or dark blue (42 hours) according 
to the latest time point for which signals were observed or red where signals were recorded 
from CLEANEX experiments. For residues where no signals were observed from 2H2O and 
CLEANEX experiments, residues were coloured white.    
 
2.4 Thermal stability measurements 
The thermal stability of wild-type PARP-1 catalytic domain and the catalytic domain 
mutants L713F, L765F and L765A was assessed by nano differential scanning fluorimetry 
(nanoDSF) using a Prometheus NT.48 instrument manufactured by NanoTemper. 500 µM 
samples of wild-type and mutant catalytic domain samples in a Tris-based buffer (50 mM 
Tris pH 7.0, 50 mM NaCl, 2 mM DTT) were loaded into capillaries, heated by the 
Prometheus NT.48 (30% excitation, 15-75°C, increasing at a rate of 2°C per minute) and 
scattering was recorded as a measure of protein denaturation. Scattering and Tonset values 
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3.1 Sequential assignment and difficulties of assigning large proteins 
Interpretation of data acquired from isotopically labelled proteins using NMR, whether in 
the form of chemical shift perturbations or dynamic experiments, is contingent upon 
resonance assignment. Following acquisition of 2D HSQC or TROSY spectra for a target 
protein, or relaxation or solvent-exchange data-based experiments, it is necessary to identify 
which two-dimensional cross peak corresponds to each backbone amide in the sequence of 
the protein. Only once this has been achieved can changes in chemical shifts, relaxation 
times, rates of solvent exchange or results from any other two-dimensional experiments be 
linked to a particular residue in the protein, allowing biological interpretation of the results 
at the level of individual residues.  
Assignment of backbone amides using a sequential assignment approach requires 
acquisition of a set of three-dimensional triple-resonance spectra, each of which contain a 
1H, a 15N and a 13C dimension. These experiments transfer magnetisation between directly 
bonded nuclei, which have large scalar (through-bond) couplings, and can therefore 
correlate the chemical shifts of each NH group with the chemical shifts of the Ca or Cb 
atoms in either the same residue (referred to as i) and the preceding residue (i-1), or the 
preceding residue only.  This allows the Ca, Cb and NH of the preceding residue to be 
identified and a chain of NH chemical shifts that are progressively linked to be built up. In 
principle, assignment of the residues in the entire sequence can be inferred from the Ca and 
Cb chemical shifts of every residue in the chain, as these chemical shifts are highly 
characteristic according to the amino acid type. Ambiguity between amino acid types with 
similar Ca and Cb chemical shifts can be resolved using less ambiguous chemical shifts 
from other residues in the sequence such as alanine, glycine, serine or threonine, with the 
aim being to complete the assignment of the chain as a whole.  
 As the molecular weight of a protein increases, resonance assignment becomes 
progressively more difficult. For proteins of increasing size, tumbling rates in solution are 
progressively slower, shortening the relaxation time of the NMR signal and reducing 
sensitivity of the experiments. Interpretation of the spectra also becomes more challenging 
as an increase in the number of NMR-visible nuclei in the protein results in greater 
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complexity of the spectra and leads to more overlap of peaks, in both 2D and in 3D 
experiments.  
 With this in mind, a range of strategies have been developed to aid the assignment 
of challenging proteins. These can take the form of isotopic labelling strategies, new NMR 
experiments or a combination of the two, and may aim to either improve the quality of the 
data collected, reduce spectral congestion or overlap in the recorded spectra, or both.  
 Most significantly, for NMR spectroscopy of proteins greater than 25 kDa in size, 
the data quality of triple-resonance spectra for assignment of backbone amides is greatly 
enhanced by deuteration of the target protein, in which spin-½ 1H nuclei (protons) are 
substituted for nuclei of the heavier stable hydrogen isotope deuterium (2H) that contain a 
proton and a neutron and have a spin quantum number of 1. Deuterium nuclei are not visible 
in proton NMR, but due to their smaller dipole moment, their presence in place of hydrogen 
in high molecular weight proteins very greatly reduces the contributions of proton-proton 
dipolar interactions and scalar couplings to the linewidths of remaining protons of interest 
in the sample (Grzesiek et al., 1993; Kay and Gardner, 1997). The results of this 
improvement in sensitivity are even more pronounced when deuteration is combined with 
the use of NMR experiments based on the TROSY (transverse relaxation optimised 
spectroscopy) effect, which selects for long-lived signal components (Tugarinov et al., 
2006).  
 Deuteration of non-labile sites in a protein sample can be achieved by expression of 
a protein by E. coli in partially deuterated M9 minimal media that includes deuterium oxide 
(D2O) instead of H2O. In minimal media, deuteration can be easily combined with 15N and 
13C labelling to produce triple-labelled samples for optimal acquisition of data from triple-
resonance backbone experiments. Subsequent incubation of the protein in H2O (e.g. during 
purification using H2O-based buffers) exchanges deuterons with protons at labile sites, the 
positions (including backbone amides) where protons or deuterons can be easily exchanged 
with those from the solvent, ensuring that signals from these nuclei in these chemical groups 
can be detected during NMR experiments.  
 Labelling of individual amino acid types with 15N and/or 13C nuclei can also be 
carried out reliably for many residue types in E. coli in vivo. Acquisition of HSQC spectra 
from samples containing different selectively labelled 15N residue types can reveal the 
residue types of individual crosspeaks when overlaid with a uniformly labelled HSQC or 
TROSY spectrum of the uniformly labelled protein (see Section 3.3). However, 
combinatorial amino acid type-selective labelling, in which samples are prepared containing 
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both 15N and 13C nuclei in selected pairs of residue types, can provide information on 
sequential connections as well as information about residue type alone. These strategies 
typically rely on sample preparation via cell free protein production, which permits 
straightforward incorporation of isotopically labelled amino acids into the protein of interest 
due to the absence of enzymes that can promote metabolic scrambling (Hoffman et al., 
2018). However, as demonstrated by Butterwick and MacKinnon (2010), assignments for 
residues that could not be completed by analysing conventional triple-resonance spectra 
were obtained from only three samples produced in vivo, containing a combination of six 
labelled amino acid types containing 15N, 13C or both. 
 Signals from specific groups of residue types can also be selected from uniformly 
15N labelled samples using carefully selected triple resonance experiments. These 
experiments initially select XH2 or XH3 side chain groups (where X can be either 15N or 13C) 
via a step based on the MUSIC (multiplicity selective in phase coherence transfer) coherence 
transfer scheme, and can provide further specificity in combination with selective pulses and 
tuned delays, enabling visualisation of two dimensional spectra containing only 1H-15N 
correlations from groups of residue types such as valine, isoleucine and alanine, leucine and 
alanine, aspartic acid, asparagine and glycine and even serine residues alone (Schubert et 
al., 2001).       
 Standard triple resonance backbone experiments such as HNCA provide both intra-
residue and sequential correlation peaks. In order to reduce complexity and spectral overlap 
intra-residue experiments in which only H, N and Ca nuclei of the same residue are 
correlated can be collected instead, with the aim of reducing the number of peaks in the 
spectrum, enhancing resolution of the spectra and reducing ambiguity by avoiding overlap 
with peaks from other experiments such as HN(CO)CA. An HN(CO)CA experiment can be 
performed separately in order to obtain sequential correlation peaks (Brutscher, 2002). In 
contrast, a strategy to obtain sequential assignments from a single HNCA spectrum has 
recently been developed (Robson et al., 2018). In this approach, a sample is prepared in E. 
coli with a combination of 2-13C and 3-13C pyruvate as the sole carbon source, with the aim 
of producing protein samples in which Ca, but not Cb,  nuclei are 13C labelled, suppressing 
the coupling between these nuclei and permitting significantly enhanced resolution for i and 
i-1 Ca resonances.    
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3.2 Deuteration of PARP-1 wild-type catalytic domain 
 At 40 kDa in size and 360 residues in length, we considered that deuteration in 
conjunction with use of these experiments would be required for comprehensive sequential 
assignment of the PARP-1 catalytic domain using triple-resonance backbone experiments. 
Early in the project, expression trials and NMR experiments established that PARP-1 
catalytic domain could be expressed and purified from E. coli strain BL21 (DE3) grown in 
rich media (LB medium) and that [15N-1H] HSQC and TROSY spectra could be acquired at 
30°C from pure highly concentrated 15N-labelled catalytic domain expressed in E. coli 
grown in H2O-based M9 minimal medium (data not shown). Expression of recombinant 
protein from E. coli in deuterated media often results in lower yields than from H2O-based 
media and therefore requires careful optimisation of expression parameters.  Following these 
experiments, a small-scale trial of catalytic domain expression at different temperatures 
(18°C, 22°C, 25°C, 30°C and 37°C) and over different time periods (harvest of cells either 
Figure 3.1. NMR spectrum of perdeuterated 13C 15N labelled wild-type catalytic domain. [15N-1H] 
TROSY spectrum of PARP-1 catalytic domain (656-1014). 200 µM in H2O, 50 mM Tris d-11 pH 7.0, 50 mM 
NaCl, 2 mM DTT d-10, 5% D2O. The spectrum was acquired at 30°C using a Bruker Avance III HD 800 
spectrometer equipped with a triple resonance (15N/13C/1H) cryoprobe. Assignments were completed and 
copied to the spectrum of 15N labelled (non-deuterated) catalytic domain (see Figure 3.4), which was used as 
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4 hours post-induction or overnight) was carried out in BL21 (DE3) in D2O-based M9 
minimal media made according to the recipe described in Chapter 2, and containing 14NH4Cl 
and 12C6-glucose. Based on the approach described in Marley et al (2001), cells were initially 
grown in rich media, pelleted and re-suspended in a four-fold smaller volume of deuterated 
minimal media as described in Chapter 2. Due to the resulting density of the cultures, 
expression was induced in all cultures with 2 mM final concentration of IPTG.  Yield of 
recombinant deuterated catalytic domain was negligible at temperatures below 30°C and 
highest overnight at 37°C (data not shown). On that basis, PARP-1 catalytic domain was 
then expressed in BL21 (DE3) overnight at 37°C from 250 mL D2O-based M9 minimal 
media enriched with 15NH4Cl and 13C6-glucose. A [15N-1H] TROSY spectrum (see Figure 
3.1) was then recorded from the resulting sample (concentration ~200 µM). As with TROSY 
spectra recorded from non-deuterated catalytic domain, the partially deuterated catalytic 
domain was highly stable at 30°C and contained a number of well dispersed peaks 
approximately corresponding to the number of non-proline residues in the protein (343). 
Perdeuterated protein samples can require denaturation and refolding in H2O-based buffers 
in order to ensure that solvent exchange occurs for all backbone amides, including those 
buried inside the protein fold with limited solvent exposure. However, this step was not 
required in the case of the catalytic domain. Work then proceeded with the acquisition of 
Figure 3.2 Backbone assignment of wild-type PARP-1 catalytic domain. TROSY versions of the triple 
resonance backbone experiments HNCA, HN(CO)CA, HNCACB and HN(CO)CACB were acquired at 30°C 
from a perdeuterated 13C 15N labelled wild-type catalytic domain sample (200 µM, 50mM Tris-d11-HCl pH 
7.0, 50mM NaCl, 2mM DTT d-10, 5% D2O) using Bruker Avance III HD 800 or Avance III 600 spectrometers 
equipped with triple resonance (15N/13C/1H) cryoprobes. The selected strips show the assignment for the short 
section E680-F677. Superimposed HNCACB (blue) and HNCACOCB (teal) spectra, and superimposed 
HNCA (black) and HNCOCA spectra (red) reveal the connections between adjacent residues in the sequence. 
The assigned reference [15N- 1H] TROSY spectrum is shown in Figure 3.4.  
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suites of 3D triple-resonance spectra (TROSY-HNCA, TROSY-HN(CO)CA, TROSY-
HNCACB and HN(CO)CACB) at 30°C as described in Section 2.3.1 in order to carry out 
resonance assignment of backbone amides. Using the parameters described in that section, 
non-uniform sampling (NUS) was employed to improve the quality of the spectra. Using 
these spectra, assignment of the backbone amide signals from the TROSY spectrum was 
performed in the programme CCPN Analysis 2.4 (Vranken et al, 2005) using the sequential 
approach described above in Figure 3.2. 
 
3.3 Selective 15N labelling of backbone amides for individual residue types  
Although the typical Ca and Cb chemical shifts recorded from triple-resonance backbone 
experiments are well characterised for each residue type, the possible chemical shifts of 
many residue types overlap with only some residue types exhibiting unique Ca and/or Cb 
chemical shifts. This ambiguity can be partially resolved by selectively labelling the 
backbone amide moieties of individual residue types, revealing which of the amide signals 
from the uniformly 15N-labelled domain are from that residue. For sequential assignment of 
larger proteins, 2D spectra from selectively labelled backbone amides can aid significantly 
in resolving ambiguities encountered during the assignment process by identifying the 
residue type of otherwise ambiguous or overlapping signals, as well as providing a number 
of starting points for chains of sequential assignments. Therefore, we attempted to selectively 
15N label backbone amides of a number of individual residue types during the assignment 
process. 
 
3.3.1 Selective 15N labelling of lysine, arginine, leucine and isoleucine 
residues 
 The feasibility of successfully selectively labelling backbone amide moieties varies 
by residue type, as selective 15N labelling is achieved by supplementation of otherwise 
unlabelled M9 minimal media with the desired 15N-labelled L-amino acid and atoms from 
some amino acid molecules may be metabolised into others by E. coli. For example, 
glutamate is a precursor for production of arginine, glutamine and proline, and glutamate 
and glutamine are inter-convertible by transaminases (Takeuchi et al., 2007) so 
supplementation of media with isotopically-labelled glutamate is likely to result in 
scrambling to these residue types, though this can be partially mitigated by the use of 
measures such as the use of auxotrophic strains or the addition of enzyme inhibitors. 
Additionally, selective labelling of backbone amides of residue types such as alanine, which 
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can be unambiguously distinguished from all or most others from triple-resonance spectra 
alone, is of limited utility for the purpose of resonance assignment. Therefore, the first amino 
acid types to be selectively labelled in the wild-type catalytic domain were lysine and 
arginine, which were labelled by supplementing unlabelled M9 minimal media with L-
Lysine-α-15N dihydrochloride, (Cambridge Isotope Laboratories), or L-Arginine-15N4 
hydrochloride (Sigma-Aldrich) respectively as described in Chapter 2. Lysine was chosen 
due to the high proportion of lysine residues in the sequence (33 out of 360, representing 
9.2% of all residues) and because its average Ca and Cb shifts of 56.98 ppm and 32.76 ppm 
respectively (all values taken from Biological Magnetic Resonance Data Bank, Ulrich et al., 
2008) both overlap considerably with Ca and Cb shifts of other residues such as methionine 
(56.15 ppm and 32.93 ppm), phenylalanine (58.13 ppm and 39.92 ppm) and tyrosine (58.18 
ppm and 39.26 ppm). Additionally, according to Chae (2000), backbone amides of lysine 
residues could be selectively labelled by addition of 15N L-lysine alone and no additional 
steps, with only minor metabolic scrambling of isotope-labelled material. The 11 arginine 
residues make up a smaller proportion of the catalytic domain (3.1%), but its average Ca 
and Cb shifts (56.81 ppm and 30.64 ppm) both overlap with residues including histidine 
(56.51 ppm and 30.22 ppm), glutamic acid (57.35 ppm and 29.95 ppm) and glutamine (56.61 
ppm and 29.15 ppm). As with lysine, arginine is an end product in E. coli’s amino acid 
biosynthetic pathway and we hypothesised that mis-incorporation of 15N-labelled arginine 
would therefore also be minimal.  
 In both cases, high quality [15N-1H] HSQC spectra were acquired from wild-type 
catalytic domain in which backbone amides of either lysine or arginine were selectively 15N 
labelled (Figure 3.3). The number of peaks in each case corresponded to the expected 
number of residues of the labelled amino acid type from the wild-type catalytic domain 
sequence and overlays of each spectrum with spectra acquired from uniformly 15N labelled 
catalytic domain revealed that chemical shifts of all peaks corresponded to a subset of peaks 
from the uniformly labelled spectra. Minimal isotopic scrambling occurred, as inferred from 
the very low number of smaller peaks observed and the fact that the numbers of strong peaks 
corresponded to the exact number of lysine and arginine residues expected from the 
sequence. In the case of arginine, minimal media was supplemented with uniformly 15N 
labelled L-arginine which contained 15N at side chain NH moieties in addition to the 
backbone NH. Strong peaks corresponding to side chain NH epsilons were visible in the 
selectively labelled 15N arginine HSQC spectrum due to peak folding; this occurs when 
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peaks whose true frequencies fall outside the selected boundaries of the spectrum in the 
indirect dimension appear folded, or reflected, about one of the edges of the spectrum so 
that they appear at frequencies (and subsequently display chemical shifts) inside the spectral 
width after Fourier transformation. Folded peaks can be distinguished from unfolded 
(backbone) amide signals, as for the latter chemical shifts do not change when the spectral 
width is changed; in the case of spectra of uniformly 15N labelled catalytic domain reported 
here, the greater spectral width of this experiment causes side chain NH epsilon signals to 
fold at chemical shifts outside the boundaries of the spectrum displayed in Figure 3.3. 
 Following the success of 15N selective labelling for lysine and arginine, we sought 
to label more residue types in a similar way. PARP-1 catalytic domain contains 39 leucine 
residues (10.2% of all catalytic domain residues), the most of any residue type. When 
chemical shifts of both Ca (55.69 ppm) and Cb (42.25 ppm) are considered, signals from 
leucine also overlap closely with average chemical shifts of aspartic acid (54.69 ppm and 
40.86 ppm), which itself appears 25 times in the CAT domain sequence, and phenylalanine 
(58.13 ppm and 39.92 ppm), which appears 10 times. In order to selectively 15N label leucine 
residues, a protocol was adapted from the approach described in Tong et al., (2008), which 
is described in detail in Chapter 2. This strategy involves supplementation of unlabelled M9 
minimal media with both L-Leucine-15N and unlabelled L-amino acids of all residue types 
except leucine, with the aim of saturating all biosynthetic pathways of non-leucine amino 
acid synthesis and disfavouring incorporation of 15N atoms from labelled leucine into other 
amino acid types. This approach led to successful 15N selective labelling of all 39 leucine 
residues with minimal isotopic scrambling (Figure 3.3). As this approach is simple, not 
specific to any single residue type, and requires no auxotrophic strains or specific inhibitors 
of E. coli enzymes, we later attempted to selectively 15N label isoleucine residues in this 
manner. Although chemical shifts of isoleucine residues are typically considered to be 
distinctive, with Ca shifts commonly overlapping between isoleucine, valine and proline, 
but Cb shifts of isoleucine easy to distinguish from the other two residue types, 25 isoleucine 
residues (6.9% of the catalytic domain sequence) were present in the protein sequence. Once 
again, all 25 residues of isoleucine were selectively labelled with this approach, with 
minimal isotopic scrambling observed. At this point, backbone amide assignments were 
completed for all lysine, arginine, leucine and isoleucine residues with the help of selective 
15N labelling, representing a full 30% of all 360 residues in the sequence.  
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3.3.2 Selective 15N labelling of glycine and serine residues 
According to results from Chae (2000), serine residues can be inexpensively labelled by 
supplementing otherwise unlabelled M9 minimal media with 15N-Glycine, which leads to 
the expression of jointly 15N glycine and serine labelled protein. 15N labelled glycine is 
considerably cheaper then 15N labelled serine, and Chae also found that in the strain BL21 
(DE3), isotopically labelled serine scrambled to NH groups of glutamine or asparagine side 
chains. We attempted to selectively label serine residues (average Ca chemical shift of 58.74 
ppm, Cb 63.78 ppm) in order to distinguish them from threonine (average Ca chemical shift 
of 62.26 ppm, Cb 69.69 ppm) in severely overlapped regions of the HNCA spectra, which 
also contained some particularly broad signals. Glycine residues can be easily distinguished 
from all other amino acid types, including serine, because glycine lacks a Cb atom, and its 
Ca has a highly distinctive average chemical shift of 45.36. Two samples were prepared 
using slightly different methods, both using the adapted approach from Tong et al (2008) as 
described in Chapter 2. Both samples were supplemented with 15N-Glycine, one with non-
isotopically labelled serine and one without, and with both samples containing all 18 other 
amino acids in unlabelled form. We expected that the first sample would be glycine labelled 
only and that the second sample would contain labelled serine and glycine residues. 
However, HSQC spectra revealed that the first sample exhibited significant isotopic 
scrambling (data not shown), whereas in the second sample (Figure 3.3) only strong peaks 
corresponding to signals from glycine and serine residues were observed. Signals were 
observed for all 30 serine residues in the sequence. In the case of glycine, excluding the N-
terminal residue which has no backbone amide moiety, backbone amide signals were 
observed for all glycines excluding G699, which remained unassigned across all spectra 
acquired from the catalytic domain, or G863, which was assigned in uniformly-labelled 
spectra using data from triple-resonance backbone experiments but exhibited low signal 
strength in a region highly overlapped with signals from other glycine and serine residues.  
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Figure 3.3 Selective 15N labelling of backbone amides in individual residue types. Assigned [15N-1H] HSQC 
spectra of selectively 15N labelled lysine (150 µM), arginine (250 µM), leucine (400 µM), isoleucine (400 µM), 
glycine and serine (400 µM) residues in wild-type PARP-1 catalytic domain, including superposition of [15N-
1H] HSQC spectra of all selectively 15N labelled residue types with [15N-1H] TROSY of PARP-1 catalytic 
domain (all experiments performed in NMR Buffer as described in Figure 3.1). Selectively labelled spectra of 
lysine, arginine, leucine and isoleucine residues were acquired on a Bruker Avance I 600 spectrometer at 30°C. 
HSQC spectra of 15N labelled glycine and serine residues and [15N-1H] TROSY of uniformly 15N labelled PARP-
1 catalytic domain were acquired at 25°C on a Bruker Avance III HD 800 spectrometer. All spectrometers were 
equipped with triple-resonance (15N/13C/1H) cryoprobes.  
 































































































































































































































































































































































































































































































































Figure 3.4 NMR resonance assignment of PARP-1 wild-type catalytic domain. (A) Assigned [15N-1H] 
TROSY spectrum of 15N labelled (non-deuterated) PARP-1 (656-1014), 400 µM in NMR buffer at 25°C. 
Sequential assignments were performed based on triple-resonance backbone data acquired from 13C 15N 2H 
labelled PARP-1 catalytic domain at 30°C and transferred to the TROSY spectrum of 15N labelled PARP 
catalytic domain acquired at 25°C.  This latter spectrum, shown here, was used as a reference for all subsequent 
experiments with catalytic domain mutants and PARP inhibitors. (B) Completion of backbone amide resonance 
assignments by residue type in the reference TROSY spectrum of wild-type PARP-1 catalytic domain. (C) 
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3.4 Completed assignments of wild-type PARP-1 catalytic domain 
Using a sequential assignment approach combined with acquisition of spectra from samples 
with selective 15N labelling of individual residue types, resonances were assigned for over 
96% of backbone amides from the 343 non-proline residues in the wild-type PARP-1 
catalytic domain. Assignments from experiments run on the triple-labelled wild-type 
catalytic domain at 30°C were copied to the TROSY spectrum of 15N labelled PARP-1 
catalytic domain acquired at 25°C, which was used as a control and reference for subsequent 
experiments. Of the 11 non-proline residues that could not be assigned, 2 were residues from 
the N-terminus of the sequence (a non-canonical glycine residue and T656) and 5 were the 
residues 823-827 (sequence: ATTHN), a consecutive sequence of residues found in a single 
loop in the ART subdomain. Additionally, weak signals from NH moieties of residues K667 
and L920 were assigned in spectra from the triple-labelled and selectively labelled samples 
but were not visible in the reference TROSY spectrum.  The assigned reference TROSY 
spectrum, completion of assignment by residue type and the location of residues 823-827 
are all shown in Figure 3.4.  
 
3.5 Assignment of PARP-1 catalytic domain mutants and wild-type 
catalytic domain in complex with PARP inhibitors 
During this project, we aimed to investigate both the structural basis of activation in the 
PARP-1 catalytic domain using constitutively partially active mutants of the PARP-1 
catalytic domain fragment (Chapter 4) and the structural and mechanistic basis of PARP-1 
inhibition by 4 different PARP inhibitors (Chapter 5). Therefore, following the resonance 
assignment of PARP-1 wild-type catalytic domain, it was also necessary to carry out 
assignment of as many backbone amides as possible in the chosen constitutively partially 
active mutants of the catalytic domain, as well the wild-type catalytic domain in complex 
with our chosen PARP inhibitors. Chemical shifts are exquisitely sensitive to the 
environment of individual nuclei, and are affected not only by changes in covalent bonding 
in a protein structure, but also by interactions with binding partners. Therefore, changes such 
as the introduction of a mutation in the HD subdomain or binding of a PARP inhibitor may 
introduce changes in the environment of many backbone amides, which means that the 
transfer of assignments to these spectra from those of the wild-type catalytic domain cannot 
be considered a trivial task, especially in light of the catalytic domain’s number of residues 
and high molecular weight, obstacles which applied equally to the 3 mutant domain and 4 
inhibitor complexes investigated. 
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 In the case of the constitutively partially active HD subdomain mutants L713F, 
L765F and L765A, we initially aimed to complete the resonance assignment by performing 
and analysing the same TROSY-based triple-resonance backbone experiments as carried out 
on the wild-type catalytic domain, in conjunction with perdeuteration, 13C and 15N labelling. 
We anticipated that for the majority of residues, there would be no large differences in Ca 
or Cb chemical shifts, so that for these, as well as for backbone amide signals that only had 
small CSPs, assignments could be made largely by comparison against wild-type signals, 
with the possibility of making sequential assignments using explicit connectivity tracing 
through the triple resonance data in the most difficult cases.   However, this strategy was 
hampered by the lower thermal stability of the mutant catalytic domains in comparison to 
the wild-type domain. Initial attempts to acquire TROSY spectra from 15N-labelled samples 
of L713F at 30°C failed when the sample rapidly precipitated. In order to determine the 
highest temperature that spectra could be safely recorded without destroying the samples, 
thermal unfolding profiles of wild-type PARP-1 catalytic domain and all three mutants were 
generated via nanoDSF (differential scanning fluorimetry) using a Prometheus NT.48 
machine from Nanotemper (Figure 3.5). This revealed that for the catalytic domain mutants, 
onset of melting (Tonset) occurred at lower temperature than for wild-type catalytic domain.  
In wild-type catalytic domain, Tonset occurred at 42.5°C, whereas L713F, L765F and L765A 
mutants, Tonset occurred at 34.8°C, 35.5°C, and 36.7 °C respectively. Although the Tonset 
temperatures obtained from the unfolding profiles were greater than 30°C, which we had 
already tested during acquisition of mutant domain spectra, it was clear that the thermal 
Figure 3.5 Thermal unfolding of wild type catalytic domain and catalytic domain mutants. Scattering 
from wild-type catalytic domain and catalytic domain mutants (all 500 µM in 50 mM Tris pH 7.0, 50 mM 
NaCl, 2 mM DTT)  plotted against temperature. Samples were loaded into capillaries and heated by the 
Prometheus NT.48 (30% excitation, 15-75°C, increasing at a rate of 2°C per minute).   
 























Resonance assignment of PARP-1 catalytic domain 
 48 
stability of the catalytic domain mutants was lower than for the wild-type catalytic domain. 
Therefore, we attempted to acquire spectra from fresh 15N labelled catalytic domain mutant 
samples at 25°C and found that high quality [15N-1H] TROSY spectra could be acquired 
from all mutants at this temperature (see Section 4.3), and that labelled mutant samples 
remained stable when stored at room temperature or 4°C. However, the quality of spectra 
from perdeuterated 13C 15N labelled L713F mutant at 25°C was not sufficient to make 
unambiguous assignments for all of the L713F mutant based on similarity of the signals to 
the wild-type domain. Although data recorded from HNCA and HNCOCA experiments was 
of high quality and signals from NH groups of some residues could be assigned based on 
proximity to wild-type signals in TROSY spectra and similarity of Ca chemical shift 
perturbations alone, the quality of HNCACB and HNCOCACB spectra was low and without 
high quality data from these experiments it was not possible to make unambiguous 
assignments on a sequential basis for difficult cases, such as for signals from residues in 
close proximity to the mutation site, which were highly perturbed by ring currents from the 
substitution of a leucine residue by a phenylalanine.  
 In the case of wild-type catalytic domain in complex with PARP inhibitors, the 
assignment task was complicated by the high binding affinities and slow dissociation rates 
of the inhibitors (summarise in Section 5.1), which bind tightly to the catalytic domain and 
form complexes that are in slow exchange on the NMR timescale. For complexes in fast 
exchange, with weak binding where the off rate of the binding partner is greater than the 
chemical shift difference between free and bound states, a single peak averaging the 
chemical shift of both states will be observed in the spectrum, and multi-point titration of 
binding partners leads to progressively larger chemical shift perturbations which can in 
principle be followed and assigned with no follow-up experiments. However, if the 
complexes exchange between states over a slow exchange timescale, two separate signals 
will be observed in the spectra with different chemical shifts, with their intensities 
corresponding to the size of each population. Assignment of complexes in slow exchange is 
consequently far more challenging, because even with multiple titration points, chemical 
shift perturbations cannot be progressively traced to the end point of the titration by eye, so 
the bound-state signals must be carefully assigned using further experiments. Assignment 
of four PARP inhibitor complexes using a sequential backbone assignment approach would 
have necessitated production of four further perdeuterated 15N 13C labelled samples, with 
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accompanying spectrometer time required to carry out separate sets of HNCA, HNCOCA, 
HNCB and HNCOCB triple-resonance experiments on each complex.   
Consequently, we adopted a different strategy in order to complete the assignment 
of the catalytic domain mutants, which was also later applied to assignment of TROSY 
spectra from complexes of the catalytic domain with PARP inhibitors. Instead of triple-
resonance backbone data, we recorded a three-dimensional 15N NOESY-HSQC experiments 
at 25°C from 15N labelled wild-type catalytic domain, as well as from all of the catalytic 
domain mutants and wild-type catalytic domain samples titrated to saturation with the PARP 
inhibitors veliparib, olaparib, talazoparib and EB-47, as described in Section 2.3.2. The 15N 
NOESY-HSQC experiment exchanges magnetisation between hydrogens using the nuclear 
Overhauser effect (NOE) before transferring the magnetisation to neighbouring 15N and 
back to nearby 1H nuclei for detection. This experiment exploits the NOE to reveal which 
nuclei are in close spatial proximity to one another and is typically used to generate restraints 
for structure calculations using NMR. However, it can also be used to make assignments, as 
when the experiment is visualised for a given amide signal, NOEs from neighbouring 
residues, including for the backbone amide, can be observed (see Figure 3.6). As with data 
from triple-resonance backbone experiments, assignments can be made by analogy to data 
from wild-type protein, and neighbouring residues can be identified, in this case via NOEs. 
This approach requires less time to collect high quality data (4 days for the PARP-1 catalytic 
domain as opposed to approximately 2 weeks to collect all triple-resonance backbone 
experiments) and sample preparation was significantly cheaper as no 13C labelling or 
deuteration was required. Using this approach, assignments were largely completed for all 
mutants and inhibitor complexes (see Table 3.1). The backbone amide assignment of all 
mutants and complexes was completed to a similar level as for the wild-type catalytic 
domain, with the exception of the catalytic domain in complex with EB-47, for which only 
Figure 3.6 (previous page) Backbone assignment of catalytic domain mutants and wild-type catalytic 
domain in complex with PARP inhibitors using 15N NOESY-HSQC. (A) Selected strips from 15N NOESY-
HSQC spectra of wild-type catalytic domain (black) and wild-type catalytic domain titrated with a 1:1.5 ratio 
of talazoparib (red) for the short section of L768-I771. Comparison of strips from free wild-type catalytic 
domain reveals NOE signals from backbone amides of neighbouring residues, enabling identification of the 
corresponding connections and residues in 15N NOESY-HSQC spectra from PARP inhibitor complexes and 
catalytic domain mutants, even where chemical shift perturbations have occurred (see B). (B) Assigned 
backbone amides of the short sequence L768-I771 in [15N 1H] TROSY spectra of wild-type catalytic domain 
(black) and new assignments of backbone amides from the same sequence in in complex with talazoparib 
(red) made using 15N NOESY-HSQC spectra.  15N NOESY-HSQC and [15N 1H] TROSY spectra were 
acquired at 25°C from 15N labelled catalytic domain samples (500 µL volume, 400 µM concentration) using 
a Bruker Avance III HD 800 spectrometer. 6 µL of a 50 mM talazoparib stock solution in 100% DMSO-d6 
was added to make a final concentration of 600 µM at a ratio of 1:1.5 to ensure that the catalytic domain was 
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88% of non-proline residues were assigned. The number of assignments was lower in 
comparison with complexes containing the other inhibitors because no signals were 
observed for some residues that were part of or in close proximity to the loop in the ART 
subdomain (residues 880-900) where the catalytic domain’s active site is located. 
 
3.6 Spectral changes occurring following sample preparation 
During initial acquisition of 2D TROSY spectra from both deuterated and non-deuterated 
15N labelled wild-type and mutant PARP-1 catalytic domains, it was observed that consistent 
and progressive small changes in chemical shifts occurred for a subset of peaks over the first 
1-2 days after the sample had been prepared. After this time period, no further changes 
occurred and chemical shifts of all spectra acquired subsequently were identical. As the end 
point of the changes was consistently reproducible, all assignments and subsequent 
experiments were carried out once these changes had been allowed to progress effectively 
to completion.  Therefore, as wild-type and mutant PARP-1 domains are stable at room 
temperature (22°C), samples were incubated at room temperature for 48 hours following 
purification before NMR experiments were carried out, or before addition of PARP 
inhibitors during PARP inhibitor titrations, in order to ensure that no changes would occur 
during data collection.  
Because the peaks changed their chemical shifts smoothly over time and only a small 
proportion were affected, mostly in vicinity of the NAD+ binding site, we concluded that the 
most plausible original of the effect was weak binding of some small molecule binding 
Sample Assigned Not Assigned Percentage  
Wild-type (WT) 331 12 96.5% 
L713F 323 20 94.2 % 
L765F 326 17 95.0 % 
L765A 328 15 95.6 % 
WT + Veliparib (1:1.5) 328 15 95.6% 
WT + Olaparib (1:1.5) 327 16 95.3% 
WT + Talazoparib (1:1.5) 324 19 94.4% 
WT + EB-47 (1:1.5) 302 41 88.0% 
Table 3.1 Assignments completed for wild-type PARP-1 catalytic domain, catalytic domain mutants and 
complexes of wild-type catalytic domain with 4 PARP inhibitors. All catalytic domains contained 343 non-
proline residues (out of 360 residues in total). All percentages are calculated as percentages of non-proline 
residues.   
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partner that slowly changed its bound concentration over time.  Based also on discussion 
with John Pascal, who had observed density corresponding to an unidentified molecule in 
the active site of catalytic domain crystals (unpublished personal communication), we 
hypothesised that this binding partner was located in the NAD+ binding pocket.   
However, we were not able to identify this compound using either 1H NMR spectra 
of the wild-type catalytic domain, or via time-of-flight mass spectrometry of an inactive 
catalytic domain mutant, E998A, in both cases looking unsuccessfully for changes over time 









Chapter Four  
 
Studies of PARP-1 activation in catalytic domain mutants 
 
The mechanism of DNA damage recognition by the N-terminal zinc finger domains of 
PARP-1 and the subsequent formation of interdomain contacts leading to activation in the 
catalytic domain have been well characterised (Eustermann et al., 2015). Data from HXMS 
experiments in full-length PARP-1 has also provided insight into the activation process in 
the catalytic domain itself, revealing that the HD (helical domain) subdomain of the catalytic 
domain is autoinhibitory and blocks productive NAD+ binding in the absence of DNA 
damage, and that upon DNA binding at the N-terminus of the protein some regions of the 
catalytic domain’s HD subdomain undergo local partial unfolding, promoting substrate 
access to the active site (Dawicki-McKenna et al., 2015). However, the resolution of HXMS 
is limited to the level of fragment peptides and these events could not be studied at the level 
of individual residues or atomic resolution. Using three constitutively partially active 
mutants of the isolated catalytic domain fragment that were hypothesised to mimic the 
effects of DNA binding, the role of different helical regions in the HD was investigated 
using NMR spectroscopy.   
 
4.1 Constitutively partially active catalytic domain mutants  
Multiple catalytic domain mutants with elevated DNA-independent activity have been 
identified, all with mutations in the hydrophobic core of the HD subdomain. These mutants 
have a constitutive level of activity that is greater than wild-type PARP-1’s basal level of 
activity and is independent of DNA-binding and the resulting allosteric activation 
mechanism involving other domains of PARP-1. The HD mutant L713F was the earliest 
mutant of this type to be identified (Miranda et al., 1995) via a random mutagenesis 
approach. L713F is located in the aD helix of the of the HD subdomain (Figure 4.1) and 
initial kinetic studies upon its discovery estimated that the L713F mutation increased 
catalytic domain activity by at least 9-fold. Later biochemical and kinetic analysis by the 
Pascal Group (Langelier et al., 2012) showed that L713F has DNA-independent catalytic 
activity 20-fold greater than the basal level, with no change in affinity for NAD+. They also 
tested a novel mutant L765A, with a mutation site located in the aF helix, which exhibited 
near-identical properties to L713F.  However, the catalytic activity of these mutants was not 
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as great as the estimated 50-fold increase in the catalytic activity of full-length PARP-1 
following binding to sites of DNA damage (Langelier et al., 2014). Nonetheless, subsequent 
study of the effect of the L713F mutation on HX behaviour by the Pascal group showed that 
at the time points 104 and 105 seconds, increases in HX occurred at the same locations of the 
HD subdomain as for full length wild-type PARP-1 following DNA damage binding, 
independent of changes in HX near the mutation site, which occur far earlier (Dawicki-
McKenna et al., 2015). Therefore, the behaviour of this mutant, whilst only displaying a 
partial increase in activation with respect to fully activated wild-type PARP-1 or the fully 
activated DNA-independent mutant PARP-1 ∆HD, appeared to mimic the effect of the full-
length wild-type PARP-1 following binding to DNA damage.  Importantly, given the 
independence of the mutants’ catalytic activity from the activity of the N-terminal domains 
of PARP-1, there is no difference in the effect on catalytic activity between the mutations in 
the context of full-length PARP-1 and the isolated catalytic domain fragment. Consequently, 
as we considered that the size (116 kDa) of full-length PARP-1 would be prohibitive for the 
initial study of catalytic domain activation using NMR spectroscopy, we hypothesised that 
introducing these mutations into the isolated catalytic domain fragment instead would act as 
a model system enabling us to study the mechanistic basis of activation in the PARP-1 
catalytic domain fragment in vitro using NMR spectroscopy. Therefore, we sought to clone, 
B 
Figure 4.1 Constitutively partially active mutants of PARP-1 catalytic domain. (A) PARP-1 
domain structure and colour scheme used throughout this thesis (top) and constructs of the catalytic domain 
used in this chapter (bottom). (B) Structure of PARP-1 catalytic domain (pdb 4DQY). Side chains of L713 
(situated in the aD helix) and L765 (situated in the aF helix) are shown in red. 
 
A 
Studies of PARP-1 activation in catalytic domain mutants 
 
 57 
express and acquire spectra from the catalytic domain mutants L713F, L765A and L765F, 
the last of these being another mutation tested by the Pascal group with similar kinetic 
properties to L713F and L765A (unpublished personal communication with John Pascal). 
These particular mutants were selected because during expression trials carried out by the 
Pascal group, their effect on catalytic domain activity was greater than other single amino-
acid substitutions in the HD subdomain mutations that were tested and expression of 
catalytic domain containing double mutations was significantly worse in E. coli (John 
Pascal, unpublished personal communication). 
 
4.2 Optimisation of catalytic domain mutant expression in E. coli 
In order to study the catalytic domain mutants, it was necessary to express and purify isotope-
labelled proteins from E. coli. As wild-type PARP-1 catalytic domain had been successfully 
cloned and expressed from the modified pETt28a vector described in Section 2.1, primers 
were designed to clone the desired mutants from this same vector using a site-directed 
mutagenesis approach, also described in Section 2.1. However, in initial expression trials 
carried out in E. coli under the expression conditions previously used for wild-type catalytic 
domain, it became clear that the expression of all three mutants in E. coli was poor at all 
temperatures, IPTG concentrations and harvesting time points tested. Furthermore, it was 
not possible to purify the expressed mutant proteins from E. coli because all three mutant 
catalytic domains were persistently found in the insoluble fraction during the centrifugation 
step following cell lysis. As the transformed cells grew well prior to induction of protein 
expression with IPTG, we hypothesised that the greater catalytic activity of the constitutively 
partially active mutants was depleting levels of NAD+ inside the E. coli cells following 
expression, causing the cells either to reject the plasmid or sequester the over-expressed 
recombinant protein in an unfolded state inside inclusion bodies. As a result, we adopted a 
published protocol from the group of John Pascal, which optimises the expression and 
purification of full-length wild-type and mutant constructs of PARP-1, PARP-2 and PARP-
3 from E. coli via the supplementation of expression media with the low affinity PARP 
inhibitor benzamide (Langelier et al., 2017). Benzamide mimics NAD+ (see Figure 4.2A) 
and binds to the active site of PARP family catalytic domains, inhibiting NAD+ binding and 
PARP catalytic activity and consequently automodification of PARP proteins. With an IC50 
(the concentration required for 50% inhibition in vitro) of 22 µM, benzamide is potent 
enough to inhibit 92% of PARP catalytic activity at a concentration of 1 mM (Banasik et al., 
1992), but its binding affinity is also modest enough to allow it to be removed from PARP-
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1 catalytic domains during purification of PARP proteins from E. coli (Langelier et al., 
2017).  
 In order to test the effectiveness of benzamide, TY agar plates and 2x TY liquid 
media containing 10 mM benzamide were prepared as described in Chapter 2. For expression 
of non-codon optimised full-length PARP-1, PARP-2 and PARP-3 in E coli, the Pascal group 
carried out expression overnight at 16°C in Rosetta 2 (DE3) cells in LB media containing 10 
mM benzamide, inducing expression with addition of IPTG to a final concentration of 0.2 
mM. All catalytic domain constructs in our study were codon optimised and we had 
previously expressed wild-type PARP-1 catalytic domain (with N-terminal His6-lipoyl tag) 
at both 37°C and 30°C overnight with a final IPTG concentration of 2 mM. Therefore, in 
order to compare the effect of supplementation with benzamide for wild-type and mutant 
catalytic domains, wild-type catalytic domain and catalytic domain mutants L713F, L765F 
and L765A were expressed overnight in the E. coli strain BL21 (DE3) at either 16°C or 37°C, 
in small-scale 10 mL culture volumes of LB media containing kanamycin, with either no 
benzamide or 10 mM benzamide. Expression in all cultures was induced with a final 
concentration of 0.2 mM IPTG and cells were harvested as described in Chapter 2, 16 hours 
after induction. Cells were then lysed using BugBuster (Novagen) and the soluble and 
insoluble fractions were separated via centrifugation according to the manufacturer’s 
instructions. Aliquots from the total lysate (soluble and insoluble fractions) and supernatant 
(soluble fraction only) were analysed using SDS-PAGE (Figure 4.2B). In this expression 
trial, wild-type catalytic domain was observed in the soluble fraction under all conditions 
(16°C and 37°C, with and without the addition of benzamide). However, catalytic domain 
mutants were observed in the soluble fraction only following expression at 16°C in media 
supplemented with 10 mM benzamide. No catalytic domain mutants were found in the 
soluble fraction following expression at 16°C without benzamide or at 37°C under any 
conditions, although the presence of large bands corresponding to 51 kDa observed in the 
total lysate fractions indicate that the mutants were expressed in E. coli cells at 37°C 
following induction. At 16°C with 10 mM benzamide, large 51 kDa bands were observed in 
both fractions of WT, L713F and L765A lysates, in contrast to wells from the same 
temperature without benzamide, in which only faint bands no larger than background 
proteins were observed. Due to the significant improvement in expression and solubility of 
catalytic domain mutants L713F and L765A at 16°C with addition of 10 mM benzamide, all 
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catalytic domain mutants were subsequently expressed overnight in media containing 10 mM 
benzamide, including in M9 minimal media for later production of isotope-labelled samples. 
The fact that wild-type catalytic domain was observed in the soluble fraction at 37°C with 
and without benzamide, in contrast to the catalytic domain mutants (even with addition of 
benzamide) also suggested that the catalytic domain mutants exhibited lower thermal 
stability than the wild-type catalytic domain. This was subsequently confirmed by 
thermophoresis experiments and melting curves described in Chapter 3 (Section 3.5). 
However, after further optimisation of the expression conditions for the catalytic domain 
mutants (data not shown), it was established that in media including 10 mM benzamide, 
higher yields of soluble target proteins could be acquired with overnight expression at 20°C 
and induction of recombinant protein expression with a final IPTG concentration of 0.5 mM. 
Additionally, in Figure 4.2B, no protein bands are observed in any lysate fractions from 
benzamide cultures for the mutant L765F. However, follow-up tests of L765F expression in 
Figure 4.2 Addition of the low-affinity PARP inhibitor benzamide improves expression and 
solubility of constitutively partially active catalytic domain mutants in E. coli at low temperature. (A) 
Chemical structures of NAD+ and benzamide. Benzamide closely resembles the nicotinamide moiety of NAD+ 
(inside red outline). (B) Aliquots from total lysate (T) and supernatant from total lysate clarified by 
centrifugation (SN) analysed using SDS-PAGE. The presence of a 51 kDa band in T indicates that the domain 
was expressed in E. coli.  The presence of a 51 kDa band in SN indicates that the domain was found in the 
soluble fraction. 
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both rich and minimal media confirmed that L765F can be expressed and purified from E. 
coli under identical conditions to L713F and L765A (data not shown). The lack of bands in 
these wells, including those of endogenous proteins from E. coli, most likely indicates that 
cell lysis of these pellets by the BugBuster reagent was ineffective for these samples. 
 
4.3 Mutation of residues in a-helices of the HD subdomain causes wide-
ranging chemical shift perturbations in the HD and ART subdomains 
 
Following optimisation of catalytic domain mutant expression and purification using 
benzamide, work proceeded with acquisition of high quality 15N-1H TROSY spectra from 
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Figure 4.3 [15N-1H] TROSY spectra of PARP-1 catalytic domain mutants L713F, L765F and 
L765A. All spectra were acquired at 25°C from 400 µM samples of 15N labelled catalytic domain mutants in 
NMR Buffer. Data was collected using a Bruker Avance III HD 800 spectrometer equipped with a triple-
resonance cryoprobe (1H/15N/13C). 
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of conditions for spectral acquisition is described in Section 3.5, and 15N-1H TROSY spectra 
were recorded for wild-type catalytic domain and all three HD mutants at 25°C in NMR 
buffer (Figure 4.3). As with the equivalent spectra of wild-type catalytic domain, the spectra 
of all three mutants were of high quality and well-dispersed with no random-coil shifts, 
indicating that the proteins were well-folded and homogenous. This suggested that no partial 
melting or significant, large-scale change in the secondary structure of any region of the HD 
subdomain had occurred. However, from comparison of spectra from the mutants with 
spectra from wild-type (Figure 4.4) it was also clear that the chemical shifts of many amide 
cross peaks had changed. Chemical shifts are extremely sensitive to changes in the nuclear 
environment and in the 15N-1H TROSY experiment, chemical shifts of all non-proline 


























Figure 4.4 Comparison of [15N-1H] TROSY spectra of wild type PARP-1 catalytic domain and 
catalytic domain mutants L713F, L765F and L765A. All spectra were acquired at 25°C from 400 µM 
samples of 15N labelled wild-type catalytic domain or catalytic domain mutants in NMR buffer. Data was 
collected using a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe 
(1H/15N/13C). 
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individual residues. Although chemical shift perturbations near to the mutation site would 
be expected in the case of amino acid substitutions such as those of the catalytic domain 
mutants, given the expected properties of the constitutively partially active catalytic domain 
mutants, we hypothesised that any change in the regulatory properties of the HD subdomain 
resulting from the amino acid substitutions could have longer-range effects which might be 
detected using CSPs.  The spectra acquired from the mutants were primarily assigned using 
data collected from 15N NOESY-HSQC experiments (Section 3.5), with partial assignment 
of L713F also completed using data from HNCA and HNCOCA spectra. In order to assess 
the effect of each HD mutation on the catalytic domain, we then compared the chemical shift 
perturbations of 15N-1H TROSY spectra from each mutant with respect to spectra from the 
Figure 4.5 Chemical shift perturbations observed in PARP-1 catalytic domain as a result of 
mutations L713F, L765F and L765A. (A), (B) and (C). All chemical shift perturbations observed for 
mutations L713F, L765F and L765A respectively. Scaling of CSP mapping by colour to the catalytic domain 
structure in Figure 4.6 is shown next to each plot. Subdomain and secondary structure boundaries are shown 
below each plot. Chemical shift perturbations below 0.249, the upper limit of CSP scaling by colour, are 
enlarged in (D), (E) and (F).  
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wild-type catalytic domain. Chemical shift perturbations of the backbone amides were 
plotted by residue (Figure 4.5) and subsequently mapped onto the previously solved structure 
of the wild-type catalytic domain as described in Chapter 2 number (Figure 4.6). Because 
such mapping can easily be dominated by the very largest CSP values, which can make the 
many informative but smaller variations that occur for other residues difficult to see, it is 
useful to define an upper threshold for the mapping process, whereby it reaches its maximum 
colour saturation at a value that is scaled down relative to the largest CSP value in the dataset. 
In this case, the CSPs from the mutant data sets were globally scaled against each other and 
CSP data sets from titration of the catalytic domain with PARP inhibitors (as described in 
Section 5.2), which contained larger CSPs than those found in the mutant data sets in this 
Figure 4.5 Chemical shift perturbations observed in PARP-1 catalytic domain as a result of 
mutations L713F, L765F and L765A. (D), (E) and (F). Enlarged plots of chemical shift perturbations below 
0.249 from (A), (B) and (C) respectively. Subdomain and secondary structure boundaries are shown below 
each plot.  Scaling of CSP mapping by colour to the catalytic domain structure in Figure 4.6 is shown next to 
each plot.   
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chapter. In this case the threshold was set to 0.2, meaning that the colour ramp reaches its 
maximum of bright yellow at a CSP value that is 0.2 times the largest individual CSP value 
among all datasets. Among all CSP data collected for PARP-1 catalytic domain, the largest 
CSP value is 1.247 (residue G888 in the talazoparib data set from Section 5.2), meaning that 
a threshold of 0.2 scales all CSPs between 0.0 and 0.249 in size, and all CSPs greater in size 
than this are mapped with maximum colour saturation. 
 All three mutants displayed strong CSPs in the same regions of the HD and ART 
subdomains. In all cases, the largest chemical shift perturbations were observed in the aD, 
aE and aF helices in the HD subdomain (corresponding approximately to residues 700-720, 
726-740 and 755-780 respectively) and region 880-900 of the ART subdomain (Figure 4.5), 
a loop region which is part of the PARP signature fold and the active site location of PARP-
1. Although there was no significant difference in the size of the largest CSPs in these regions 
between each mutant, a greater number of CSPs were observed near the mutation sites for 
L713F and L765F compared to L765A. Although we knew that all three mutants possessed 
similar catalytic activity (John Pascal, personal communication) and had established that all 
three possessed similar thermal stability, in L765A one residue with an aliphatic side chain 
(leucine) is replaced with another (alanine), whereas in L713F and L765F leucine is replaced 
with phenylalanine, containing an aromatic benzyl ring. The introduction of an aromatic 
moiety in this manner may lead to large changes in chemical shifts of nearby chemical groups 
as a result of aromatic ring currents, as in the case of L713F and L765F. However, the fact 
that the locations of the largest CSPs observed were consistent between all three mutants, 
including L765A, despite the differences in location and nature of the mutations shows that 
the effects seen in the HD and ART subdomains are the result in a change in the behaviour 
of the HD subdomain. The observation of CSPs in the ART subdomain following the 
introduction of an activating mutation in the HD subdomain is consistent with previous 
studies showing that in wild-type inactive PARP-1, the HD is autoinhibitory in nature and 
blocks productive substrate access to the active site (Dawicki-McKenna et al., 2015). In this 
instance, disruption of the HD’s autoregulatory function would increase the accessibility of 
the active site to the substrate. Even in the absence of the substrate, CSPs at this location 
could occur due to an increase in solvent exposure or due to disruption of contacts between 
the active site loop and the aF helix, the region of the HD subdomain in closest proximity to 
the active site loop. Mapping of the CSPs from each mutation onto the structure of the wild-
type catalytic domain (Figure 4.6) reveals that introduction of a mutation into any one of the 
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a-helices aD, aE and aF in the HD subdomain causes wide-ranging CSPs in the other 
helices of this group, even if they are not immediate neighbours. For example, even in the 
L765F and L765A mutants (mutated in the mid-point of the aF helix), CSPs are observed in 
both the neighbouring aD helix, which immediately borders aF in the structure, but also the 
more distant aE helix, particularly in the case of L765F, where CSPs are observed among 
residues L735-745, the C-terminal section of the aE helix and beginning of the long aE-aF 
linker. Similar CSPs are also observed in the L713F mutant, despite the fact that the side 
chain of residue 713 faces towards the aF helix and not aE. However, the fact that all peaks 
in 15N-1H TROSY spectra of the mutants are well-dispersed and no random coil shifts are 
observed suggests that CSPs are not caused by partial melting of the helices. Instead, the 
largest CSPs observed in the HD subdomain suggest that mutations of residues in these a-
helical regions disrupt hydrophobic interactions between side chains which face towards the 
neighbouring a-helices.  For example, a CSP of 0.4, among the largest in the HD subdomain 
and catalytic domain as a whole, is observed for the residue Y710 in all three mutants (Figure 
4.5 and Figure 4.7). The bulky hydrophobic, aromatic side chain of Y710 protrudes from the 
aE helix in the direction of the aF helix, in close proximity to the entire hydrophobic side 
chain of L765 which extends from the aF helix in the opposite direction. Substitution of 
L765 in the L765F and L765A mutants and consequent disruption of this contact presumably 
explains why Y710 exhibits large CSPs. In the case of L765F, the leucine side chain has 
been substituted for the bulky benzyl ring of the phenylalanine side chain, whereas in L765A 
the longer leucine side chain has been substituted for a single methyl group that comprises 
the side chain of alanine, removing two methyl groups from close proximity to the phenyl 
group in the Y710 side chain. The CSPs observed for Y710 of the same size are the same in 
L765A and L765F, despite the greater number of smaller chemical shift perturbations 
observed in the aD helix in L765F overall, showing that this effect is likely to be independent 
of the CSPs caused by ring currents from insertion of an aromatic side chain group. Y710 
also lies in close proximity to L713 on the same helix and a CSP of the same magnitude is 
observed in the L713F mutant, in which a leucine side chain is also substituted for a 
phenylalanine. Overall, the presence of these CSPs in response to the introduction of 
mutations in regions of the HD subdomain proximal to the active site loop is consistent with 
the HD subdomain’s regulatory function and its autoinhibitory nature in wild-type PARP-1 
in the absence of DNA damage, and suggests that maintenance of this autoinhibitory function 
depends on the stability of interactions between key a-helices. 
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Figure 4.6 Mapping of chemical shift perturbations from PARP-1 catalytic domain mutants L713F, 
L765F and L765A. (A), (B) and (C). Chemical shift perturbations from Figure 4.5 globally scaled and mapped 
onto the structure of residues 662-1011 of wild-type PARP-1 catalytic domain (pdb 4DQY), as described in Chapter 
2. CSPs are shown on a gradient from grey (no CSP) to yellow (all CSPs > 0.249). Residues that are incomparable 
due to missing assignments (including proline residues) are shown in cyan. The position of L713 or L765 side 













4.4 15N relaxation analysis of backbone amides in PARP-1 catalytic domain 
mutants 
 
Analysis of chemical shift perturbations in the catalytic domain mutants showed that 
substitution of key leucine side chains in the a-helices of the HD subdomain disrupts 
interactions between the helices which are important for maintenance of autoinhibitory 
function. However, previous studies of activation following DNA binding in full-length 
PARP-1 reported that activation of the PARP-1 catalytic domain was mediated by changes 
in the secondary structure of HD helical regions and hypothesised that changes in the rate of 
solvent exchange in these regions were consistent with partial or even near-complete 
unfolding, leading to the loss of a-helical secondary structure (Dawicki-McKenna et al., 
2015). From examination of the two-dimensional TROSY spectra recorded from the 
catalytic domain mutants, in which the distribution of the peaks was consistent with well-
Figure 4.7 CSPs of Y710 in catalytic domain mutants. A) Chemical shifts of Y710 in catalytic 
domain mutants in comparison to wild-type. B) Location of Y710 side chain (orange) in wild-type PARP-1 
catalytic domain. Side chains of residues L713 (aD helix, left) and L765 (aF, right) are shown in red. The HD 
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folded protein samples, we concluded that complete unfolding of these regions did not occur 
in the mutants. Nonetheless, we sought to investigate whether any less substantial 
perturbation of a-helical secondary structure had occurred in these regions in the catalytic 
domain mutants by measuring the effect of the HD subdomain mutations on the dynamics 
of backbone amides in the catalytic domain using NMR spectroscopy. In NMR, the term 
relaxation describes how long it takes for a population of nuclei to return to equilibrium from 
an excited state. Relaxation times are generally longer for nuclei in disordered or linker 
regions in comparison to nuclei from regions with ordered secondary structure, in particular 
for a-helices, as the time taken for the NMR signal to decay in nuclei of interest is shortened 
by dipolar interactions and scalar coupling with neighbouring magnetically active nuclei, 
particularly protons, and this effect is greater for slowly moving regions in a molecule than 
for regions where internal flexibility causes motions to be faster. Chemical shift anisotropy 
(CSA), which arises when the electronic environment that surrounds a nucleus and shields 
it from the external magnetic field is non-spherical, also contributes to relaxation as it causes 
variation in the strength of local fields as the molecule tumbles. This effect is more 
pronounced at the high-strength magnetic fields used for biomolecular NMR as the rate of 
relaxation from this mechanism depends on the square of the externally applied field. 
Therefore, we hypothesised that if mutation of L713 or L765 disrupted the formation of a-
helices at those sites, or any sites in close proximity, we would observe corresponding 
changes in the relaxation behaviour of the backbone amides of those nuclei. 
 For PARP-1 catalytic domain and the catalytic domain mutants, we measured 
backbone 15N spin-locked relaxation times (T1ρ, Figure 4.7), 15N{1H} steady state NOEs 
(Figure 4.8) and T1 (longitudinal) relaxation times (data not shown). Each of these types of 
data have their own characteristic dependence on the rotational correlation time of the 
molecule (tc, defined as the average time that it takes for a particle to rotate by one radian), 
as well as on any faster internal motions or slow exchange processes that may be present for 
particular residues. T1ρ (which is quite similar in its behaviour to T2, but measurement of 
which was preferred for technical reasons) includes a dependence on slow motions and 
exchange processes (millisecond to microsecond timescale) while the heteronuclear NOE 
and T1 depend only on faster rates (nanosecond timescale) associated with longitudinal 
transitions. In the T1ρ experiment, the rate constant for decay of spin-locked 15N 
magnetisation is measured, while the T1 experiment measures the decay constant for 
longitudinal 15N magnetisation. In the 15N{1H} heteronuclear experiment, two spectra are 
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recorded from the sample with and without 1H saturation, and values for the 15N{1H} 
heteronuclear NOE are determined by the ratio of peak intensity in the two spectra for each 
amide group. Amide groups from relatively flexible or unstructured regions undergo faster 
motion and have lower 15N{1H} NOE values than amide groups of residues in more rigid or 
highly structured regions, where motion of amide groups is slower. By comparing the T1ρ 
and 15N{1H} NOE data, we aimed to assess the contributions of differing processes to the 
relaxation of backbone amides in the HD subdomain mutants. In addition, by also using the 
T1 data, we could derive tc values for the samples, using the method described in Section 
2.3.4. Values of tc are generally considered to be dependent on the molecular weight of the 
protein, assuming that it is approximately globular in shape. Although tc is theoretically 
defined as a single value for the molecule as a whole, one can calculate individual values for 
each residue of the protein and use these to estimate an average tc across ordered regions. 
Furthermore, if one estimates such an average across individual domains and then compares 
the results between domains, this can sometimes give an indication of whether the domains 
tumble as a single entity (if the domains have the same tc consistent with the overall size of 
the protein), or as flexibly linked semi-independent entities (if the domains have the 
appreciably different tc values roughly consistent with the sizes of the individual domains). 
 Both T1ρ (Figure 4.8) and heteronuclear NOE (Figure 4.9) data displayed clear 
variations in the dynamics of different residues across the HD subdomain in wild-type 
PARP-1 catalytic domain, which corresponded to regions of the catalytic domain structure 
with slower relaxation times and local motions in solution. For example, residues 780-785 
could be clearly identified as the linker region between the HD and ART subdomains from 
the sharp increase in T1ρ and decrease in intensity ratios of the heteronuclear NOE. T1ρ values 
for the three residues G723, S724 and S725, which form part of a short linker region between 
the aD and aE helices, were 39 ms, 48 ms and 49 ms respectively, compared to an average 
T1ρ value of 25 ms for the majority of residues in the HD and ART subdomains. In data from 
the heteronuclear NOE experiment, the intensity ratios of these three residues were 0.47, 
0.37 and 0.36, whereas intensity ratios for residues in nearby a-helices were typically 
between 0.7 and 0.8. This linker demonstrates significantly faster motion than any other 
inter-helical linkers in the HD subdomain, such as region 690-702, which in pdb 4DQY links 
the aB helix and the region which contains the short aC helix and the aD helix, or residues 
from 740-750, which link the aE and aF helices (although data was missing for some 
residues in this sequence). In the ART subdomain, which contains a far lower proportion of 
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the sequence with a-helical properties and more beta sheet and loop regions, no regions 
(with the exception of the disordered and highly mobile C-terminus)  exhibited noticeable 
differences from the average T1ρ value (Figure 4.10) but hNOE intensity ratios (Figure 4.11) 
were significantly lower for residues S939, K940, L941 and G944 (values of 0.46, 0.35, 0.44 
and 0.27 respectively) which appear to have no secondary structure in pdb 4DQY. However, 
Figure 4.8 15N T1ρ measurements of HD subdomain residues from wild-type and mutant PARP-1 
catalytic domain. (A), (B), (C) and (D). 15N T1ρ measurements of HD subdomain residues (657-785) from 
wild-type catalytic domain and L713F, L765F and L765A mutants respectively. All data was recorded at 25°C 
from 400 µM samples of 15N labelled samples in NMR buffer. Data was collected using a Bruker Avance III 
HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). Error bars were plotted 
according to the data fitting error in Sparky as described in Section 2.3.4. Subdomain and secondary structure 
boundaries are shown below each plot.   
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in general the residues of the active site loop exhibit no difference from the average intensity 
ratio of the hNOE. Furthermore, the results of both the T1ρ and hNOE measurements showed 
that there were no significant large differences in 15N dynamics between wild-type PARP-1 
catalytic domain and any of the constitutively partially active catalytic domain mutants. 
There was also no significant difference in tc between wild-type and mutant catalytic 
domains, indicating that there was no difference in tumbling speed of the domain in solution 
as a result of the HD subdomain mutations, or any difference in tc between the HD and ART 
Figure 4.9 15N{1H} NOE data from HD subdomain residues in wild-type and mutant PARP-1 
catalytic domain. (A), (B), (C) and (D). 15N{1H} steady-state NOE data measurements of HD subdomain 
residues (656-785) in wild-type catalytic domain and L713F, L765F and L765A mutants respectively. All 
data was recorded at 25°C from 400 µM samples of 15N labelled samples in NMR buffer. Data was collected 
using a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). 
Error bars were plotted according to standard deviation determined on the basis of background noise levels 
as described in Section 2.3.4. Secondary structure boundaries are shown below each plot.   
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subdomains (Figure 4.12). This reveals that despite their separation by a highly flexible 
linker, both subdomains tumble as a single unit in solution and do not tumble independently. 
Overall, tc for the majority of backbone amide groups across the wild-type and mutant 
catalytic domains was approximately 25 ns, as would be expected for a single folded globular 
domain approximately 40 kDa in size (Rossi et al., 2010). In conjunction with the chemical 
Figure 4.10  15N T1ρ measurements of ART subdomain residues from wild-type and mutant PARP-
1 catalytic domain. (A), (B), (C) and (D). 15N T1ρ measurements of ART subdomain residues (786-1014) 
from wild-type catalytic domain and L713F, L765F and L765A mutants respectively. All data was recorded 
at 25°C from 400 µM samples of 15N labelled samples in NMR buffer. Data was collected using a Bruker 
Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). Error bars were 
plotted according to the data fitting error in Sparky as described in Section 2.3.4. Secondary structure 
boundaries are shown below each plot.   
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shift perturbations observed for the HD subdomain mutations, this comparison of 15N 
relaxation parameters between wild-type catalytic domain suggests that the difference in 
catalytic activity between the wild-type and mutant catalytic domains is the result of 
disruption of the packing between the a-helices and the active site, as well as between the 
a-helices themselves.  
  
Figure 4.11 15N{1H} NOE data from ART subdomain residues in wild-type and mutant PARP-1 
catalytic domain. (A), (B), (C) and (D). 15N{1H} steady-state NOE data measurements of ART subdomain 
residues (786-1014) from wild-type catalytic domain and L713F, L765F and L765A mutants respectively. All 
data was recorded at 25°C from 400 µM samples of 15N labelled samples in NMR buffer. Data was collected 
using a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). 
Error bars were plotted according to standard deviation determined on the basis of background noise levels as 
described in Section 2.3.4. Secondary structure boundaries are shown below each plot.   
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Figure 4.12 tc values of wild-type and mutant PARP-1 catalytic domains. (A), (B), (C) and (D). tc 
values calculated from T1 and T1ρ measurements for wild-type catalytic domain and L713F, L765F and L765A 
mutants respectively. All T1 and T1ρ measurements were recorded at 25°C from 400 µM samples of 15N labelled 
samples in NMR buffer. Data was collected using a Bruker Avance III HD 800 spectrometer equipped with a 
triple-resonance cryoprobe (1H/15N/13C). tc values were calculated as described in Section 2.3.4. Subdomain and 
secondary structure boundaries are shown below each plot.   
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In PARP-1 catalytic domain, an increased rate of DNA-independent catalytic activity caused 
by disruption of a-helical packing by the HD subdomain mutations would be consistent with 
the autoinhibitory role of the HD subdomain identified by the Pascal group (Dawicki-
McKenna et al., 2015), and explains why the basal catalytic activity of the mutants is greater 
than unactivated wild-type catalytic domain, but lower than full-length PARP-1 activated by 
DNA damage binding. The most active form of PARP-1 identified by the Pascal group in 
their previous studies is PARP-1 ∆HD, which exhibits constitutive, DNA-independent 
hyperactivation of PARP-1 in the complete absence of the HD subdomain (Dawicki-
McKenna et al., 2015), and their subsequent kinetic studies of PARP-1 binding to the non-
hydrolysable NAD+ analogue benzamide adenine dinucleotide (BAD) confirmed that in the 
absence of activation by DNA damage, the PARP-1 HD subdomain sterically blocks NAD+ 
from binding to the catalytic domain, rather than allowing binding but in a non-productive 
manner, as had previously been hypothesised might be possible (Langelier et al., 2018).  
 The location of the chemical shift changes observed in the catalytic domain mutants 
partially correspond to the areas of greatest deprotection following DNA binding by full-
length wild-type PARP-1 in the Pascal group’s previously described HXMS experiments. In 
the ART subdomain, CSPs were observed for the active site loop between residues 880 and 
900 for all three mutants. In the HD subdomain, the areas of greatest deprotection after 100 
seconds in the HXMS study were located in the aB helix between residues 680 and 700 (in 
close proximity to the aF helix in the catalytic domain structure), for which no large CSPs 
were observed in the mutants, and the C-terminal half of the aF helix (residues 765 to 780), 
for which CSPs were observed for all three mutants. In contrast, the location of the CSPs in 
all three mutations had greater similarities with the location of the differences in solvent 
exchange between full length wild-type and PARP-1 L713F following activation (Figure 
4.13), with deprotection observed in the aD, aE and aF helices, and differences in 
deprotection in the aB helix only observed at later time points (104 and 105 seconds). In 
Section 5.4 of this thesis, slow solvent exchange of backbone amides in free PARP-1 
catalytic domains and PARP inhibitor complexes was investigated over long time scales (3 
hours to 48 hours) by re-suspending lyophilised PARP-1 catalytic domain in D2O-based 
NMR buffer and measuring peak heights from TROSY spectra over time. This data revealed 
changes in secondary structure in key a-helices that were not detected by relaxation 
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experiments and could be compared with the Pascal group’s HXMS data from later time 
points such as 105 seconds (27.78 hours) at the level of individual residues. Consequently, 
further characterisation of key a-helical regions in the HD subdomains of the catalytic 
domain mutants and comparison to wild type catalytic domain could potentially be 
performed using an experiment of this nature, and could possibly either provide new 
evidence of destabilisation or partial unfolding, or confirm its absence. If spectra could be 
acquired from full-length PARP-1 containing segmentally labelled wild-type PARP-1 
catalytic domain in the presence of DNA damage, a speculative and highly challenging 
experiment discussed further in Chapter 6, NMR data from the HD subdomain mutants could 
be directly compared with data from fully-activated PARP-1 catalytic domain in order to 
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Figure 4.13 Differences in HX following DNA binding between full-length PARP-1 and PARP-1 
L713F. (A) Percentage difference in catalytic domain deuteration following subtraction of L713F 
deuteration from wild-type full length PARP-1 at 101, 102, 103, 104 and 105 seconds. (B) HXMS data from 
the 105 s time point in (A) mapped onto the structure of PARP-1 catalytic domain (pdb 4DQY). Reproduced 
from Dawicki-McKenna et al, 2015. 
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In energetic terms, it could be suggested that mutation of key residues of the HD 
subdomain may lower the Gibbs free energy of activation required for the formation of ADP-
ribose from NAD+ in comparison to that required by the wild-type catalytic domain. PARP-
1 activity in vivo is tightly regulated, as PARP-1 activation depletes vital cellular reserves of 
NAD+. In the context of wild-type full-length PARP-1, the high energetic barrier to 
activation resulting from the presence of the wild-type HD subdomain could act to maintain 
the low basal rate of PARP-1 catalytic activity in the absence of DNA damage. The 
activation process of PARP-1 and propagation of the activation signal to the catalytic domain 
at the active site following detection of DNA damage by the N-terminal zinc-finger domains 
via the stepwise formation of interdomain contacts could then provide a sufficiently high 
quantity of energy to overcome this barrier, by altering the conformational state of the HD 
subdomain. However, activation of wild-type full-length PARP-1 in the presence of DNA 
damage does not represent the greatest possible modification of the rate of catalysis by the 
HD subdomain for the reaction, given that not only does the complete removal of the HD 
subdomain lead to constitutive hyperactivation in PARP1, but HXMS studies of the L713F 
mutation in the context of full-length PARP-1 showed that it displayed still greater 
deprotection in helical regions of the HD than that of wild-type even in the presence of DNA 
damage (Dawicki-McKenna et al., 2015), suggesting that even in the presence of DNA 
damage, key helical regions of the HD subdomain may restrain production of ADP-ribose 
to some extent in a full-length, post-activation context. In terms of Gibbs free energy 
required for activation of ADP-ribose synthesis from the NAD+ substrate, mutation of 
residues in a-helices of the HD subdomain could therefore represent an intermediate level 
between unactivated and fully activated catalytic domain in full-length PARP-1. In that case, 
the state of the HD subdomain in the catalytic domain mutants, in which changes in helical 
packing or another process lower the energetic requirement of the reaction, may represent a 
partial step towards the more extensive changes observed in full-length wild-type PARP-1 
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In addition to its role in the DNA damage response, PARP-1 is also of biomedical interest 
due to the role of PARP inhibitors in anti-cancer therapies. Inhibition of PARP-1 catalytic 
activity by small molecules is selectively cytotoxic to tumour cells with deficient 
homologous repair machinery arising from mutations in the tumour-suppressing BRCA1 or 
BRCA2 genes, as these cells are dependent on repair mediated by PARP-1 and ADP-
ribosylation. Numerous compounds that inhibit catalytic domain activity have been 
discovered, the majority of which bind with high affinity to the PARP signature region of 
the ART subdomain containing the active site loop.  However, the cytotoxicity of these 
compounds in vivo has been shown to vary considerably, and even through orders of 
magnitude according to some estimates. The basis of this variation, and the mechanism of 
clinically availability PARP inhibitors in vivo, remains to be definitively established.  
Furthermore, no published structural data is available for many PARP inhibitors in complex 
with PARP-1 catalytic domain. In this chapter, complexes of wild-type PARP-1 catalytic 
domain with three clinically available PARP inhibitors with differential inhibitory efficacy 
in vivo were investigated using NMR spectroscopy and interpreted with the help of crystal 
structures. Additional comparisons of data from NMR experiments were carried out with a 
fourth PARP inhibitor, EB-47, for which no crystallographic data was available.  
 
5.1 PARP inhibitors  
The majority of all PARP inhibitors discovered so far, including those investigated during 
this study, mimic the binding of NAD+’s nicotinamide moiety to the conserved PARP 
signature in the ART subdomain of PARP-1 catalytic domain, forming hydrogen bonds with 
residues from the conserved NAD+ binding site (Steffen et al., 2013). Of the four PARP 
inhibitors used in this work, the compounds veliparib, olaparib and talazoparib were chosen 
because they are either clinically available or undergoing clinical trials for treatment of 
tumours with BRCA mutations, the kinetics of their binding to PARP-1 have been studied, 
and they exhibit well-characterised differences in cytotoxicity in vivo, whether as a result of 
differential ability to form trapped PARP-1 lesions or via inhibition of the ADP-ribosylation 
signal in response to DNA damage. Of these three compounds, veliparib (developed by 
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AbbVie) has the lowest binding affinity and cytotoxicity, with olaparib (developed by 
AstraZeneca, and the first PARP inhibitor to be clinically approved and reach the market) 
the next highest in both properties and talazoparib (Pfizer) having the highest binding affinity 
and cytotoxicity of all clinically investigated compounds to date (Table 5.1).  
 
 Veliparib Olaparib Talazoparib EB-47 
Molecular weight  244.29 435.08 380.35 610.45 
Relative cytotoxicity in 
vivo (trapping) 
Lowest (10-fold 
less potent than 
olaparib*) 
Middle (10-fold 
more potent than 
veliparib*) 
Highest (100-
fold more potent 
than olaparib**) 
Unknown 
KD (no DNA, TR-FRET, 
nM) 
2.0 ± 0.2† 0.86 ± 0.26† 0.47 ± 0.11† Unknown 
KD (+SSB DNA, TR-
FRET, nM) 
3.3 ± 2.3† 1.3 ± 0.7† 0.5 ± 0.26† Unknown 
KD (Biacore, nM) 4.4† 1.3† 0.17† Unknown 
kd (Biacore, s-1) 7.0 x 10-3† 3.2 x 10-4† 6.3 x 10-5† Unknown 
Ki (Biacore, nM) 3.7 ± 0.2† 1.3 ± 0.5† 0.5 ± 0.1† Unknown 
IC50 (nM) 39 ± 12† 7.9 ± 2.2† 4.1 ± 0.9† 45‡ 
Figure 5.1 Chemical structures of PARP inhibitors used in this chapter, NAD+ and the non-
hydrolysable NAD+ analogue benzamide adenine dinucleotide (BAD). In BAD, carbon replaces the 





Table 5.1 Clinical efficacy, biochemical data and kinetic data for PARP inhibitors studied in this 
chapter. Molecular weight and reported relative cytotoxicity (“trapping” as defined by potentiation of DNA 
damage from alkylating agents in vivo), equilibrium dissociation constants (KD), off-rates (kd) inhibition 
constants (Ki) and IC50 (half maximal inhibitory concentration) values of PARP inhibitors used in this chapter. 
*Murai et al, 2012. **Murai et al, 2014. †Hopkins et al, 2015. ‡Jagtap et al, 2004.TR-FRET: Time-resolved 
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However, with the exception of talazoparib (pdb 4PJT, Aoyagi-Scharber et al., 
2014), no crystal structures of these compounds in complex with the whole wild-type PARP-
1 catalytic domain have been published, with crystal structures including veliparib and 
olaparib either limited to complexes with PARP-2 catalytic domain or other members of the 
PARP family (Karlberg et al., 2010; Qiu et al., 2014), or solved in complex with PARP-1 
catalytic domain ∆HD (Dawicki-McKenna et al., 2015), revealing the structural basis for 
binding of these compounds to the catalytic domain’s active site but providing no insight 
into the behaviour of the HD subdomain following binding of the compounds. One 
mechanism that has been proposed by which binding of inhibitors at the active site location 
can cause in vivo toxicity involves “trapping” of PARP-1 proteins at sites of DNA damage, 
but competing hypotheses exist as to how this may occur in vivo for these three compounds. 
It has been suggested that trapping of these compounds is mediated through an allosteric 
pathway that in effect resembles the DNA damage activation pathway in reverse (Murai et 
al., 2012) and in which the HD subdomain would consequently play a pivotal role; if the 
structural changes in the HD subdomain that are responsible for the relief of autoinhibition 
following DNA damage recognition were partially or completely prevented by the presence 
of an inhibitor, then this would presumably increase the overall free energy change 
associated with DNA binding.  
However, in vitro biochemical assays have suggested that these compounds are not 
able to increase the affinity of PARP-1 to DNA damage models in the absence of NAD+ and 
that even in the presence of inhibitors and NAD+, the slower off-rates of PARP-1 are directly 
correlated to binding affinity and the ability of compounds to inhibit ADP-ribosylation in a 
linear fashion, suggesting that trapping is caused by disrupted formation of the long 
negatively charged ADP-ribose chains required to discharge PARP-1 from sites of DNA 
damage (Hopkins et al., 2015). The importance of contact formation with the HD subdomain 
in this process in these three compounds has yet to be determined, as the structure of the 
whole catalytic domain has only been solved in complex with talazoparib, and not for other 
the other compounds used in this study that have lower binding affinities (Table 5.1). 
Therefore, investigation of the HD subdomain’s role in PARP inhibition is a critical part of 
the evaluation of both the structural basis of differences in effectiveness between compounds 
and clarification of the mechanistic basis of trapping. In addition to the absence of published 
structural data for the HD subdomain in complexes of PARP-1 catalytic domain with PARP 
inhibitors, to our knowledge no attempts to compare dynamic differences between 
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complexes across different residues of the catalytic domain or the HD subdomain in solution 
have previously been made.  
A fourth PARP inhibitor, EB-47, was also included following discussion with our 
collaborator John Pascal, who had found he was unable to obtain a crystal structure of a 
complex of EB-47 with the PARP-1 catalytic domain. We jointly speculated that this could 
be because binding of EB-47 might de-stabilise the HD subdomain (unpublished personal 
communication). The chemical structure of EB-47 (Figure 5.1) is significantly more similar 
to the structure of NAD+ than other PARP inhibitors, with a far greater molecular weight 
(610.45 g/mol) that is closer to the molecular weight of NAD+ (663.43 g/mol). 
Consequently, it could be the case that when bound, parts of the EB-47 structure occupy 
spatial regions that clash with the HD subdomain in a way that other, smaller, PARP 
inhibitors do not. To date, only the structure of PARP-2 CAT ∆HD has been solved by the 
Pascal group in complex with EB-47 (Dawicki-McKenna et al., 2015). The effectiveness in 
vivo of EB-47 in tumour cells, whether on the basis of cytotoxicity or hypothetical trapping 
ability, has not been evaluated, but with an IC50 of 45 nM for PARP-1 (Jagtap et al., 2004; 
Table 5.1), EB-47 exhibits high affinity for the PARP signature region and displays potent 
PARP inhibition in vitro in a similar manner to the other compounds investigated in this 
chapter. The chemical structures of all four inhibitors and NAD+ are shown in Figure 5.1 
and published biological, biochemical and kinetic data is summarised in Table 5.1. 
 
5.2 Mapping of chemical shift perturbations in PARP inhibitor complexes 
The chemical shifts of nuclei in a protein, particularly amide group protons, are highly 
sensitive to non-covalent interactions with binding partners. Furthermore, changes in 
chemical shifts can result not only from the primary effects of binding at the interaction site, 
but also from the secondary effects of conformational change at locations far away from the 
binding site. As with the HD subdomain mutants described in Chapter 4, measurements of 
perturbations in chemical shifts of backbone amides following binding of PARP inhibitors 
would allow us to probe changes in the catalytic domain at the level of individual residues. 
Furthermore, NMR experiments could be carried out in solution in the intact wild-type 
catalytic domain fragment, including the HD subdomain. In order to characterise, compare 
and contrast the binding of veliparib, olaparib, talazoparib and EB-47 to the catalytic domain, 
15N-labelled wild-type catalytic domain was titrated with stocks of these compounds re-
suspended in DMSO-d6 as described in Section 2.3.3. 15N1H TROSY spectra were recorded 
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(Figure 5.2), peaks were assigned using 15N NOESY-HSQC experiments described in 
Section 2.3.2 and compared to the reference TROSY spectrum of free wild-type catalytic 
domain (Figure 5.3); chemical shift perturbations were then calculated as described in 
Section 2.3.3 and plotted by residue (Figure 5.4). During the titrations, the catalytic domain 
became saturated at a 1:1 ratio for all four compounds and no further chemical shift 
perturbations were observed beyond this point. Nonetheless, all CSPs were calculated 
following titration of compounds at a 1:1.5 ratio to ensure that all titrations had reached their 
endpoints. Chemical shift perturbations from each complex were then mapped onto crystal 
structures of that complex as described in Section 2.3.3, with the exception of the EB-47 
complex, which was mapped onto the structure of free wild-type catalytic domain because 
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Figure 5.2 [15N 1H] TROSY spectra of PARP-1 catalytic domain in complex with veliparib, olaparib, 
talazoparib and EB-47. All spectra were acquired at 25°C from samples of 15N labelled catalytic domain 
mutants in NMR buffer at concentrations of 300 µM (veliparib complex), 400 µM (olaparib and EB-47 
complexes) or 500 µM (talazoparib complex). Data was collected using a Bruker Avance III HD 800 
spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C) 
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Figure 5.3 Comparison of [15N 1H] TROSY spectra of free PARP-1 catalytic domain and 
catalytic domain in complex with PARP inhibitors. (A) Spectra of inhibitor complexes shown in Figure 
5.2 (red) are superimposed on the spectrum of free wild-type catalytic domain (black). The free catalytic 
domain spectrum had a concentration of 400 µM and data was collected under the same conditions described 
for the inhibitor complexes in Figure 5.2. (B) Superposition of expanded spectra from free catalytic domain 
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mapped onto the co-ordinates of pdb 4PJT (Aoyagi-Scharber et al., 2014) and CSPs from 
complexes of the catalytic domain with veliparib and olaparib were mapped onto previously 
unpublished crystal structures of these complexes solved by Marianne Schimpl of 
AstraZeneca; we gratefully acknowledge her making these co-ordinates available to us. As 
with mapping of CSPs from catalytic domain mutants described in Chapter 4, the upper 
threshold was set to 0.2, and among all CSP data collected for PARP-1 catalytic domain, the 
largest CSP value is 1.247 (residue G888 in the talazoparib data set), meaning that a 
threshold of 0.2 scales all CSPs between 0.0 to 0.249 in size, and all CSPs greater in size 
than this are mapped with maximum colour saturation.  
 Visual comparison of the spectra from the four complexes (Figure 5.3), plotting of 
CSPs (Figure 5.4) and mapping of CSPs onto structures of the complexes (Figure 5.5) 
revealed both similarities and differences between complexes in the size and location of 
CSPs within the catalytic domain. All complexes displayed pronounced CSPs in the active 
site loop (corresponding approximately to residues 880-900) and the 10 residues 
immediately following it. The largest CSP from this region (and the complex as a whole) 
from the veliparib complex is found for residue F897 (0.772) and the largest CSPs from the 
complexes with olaparib and talazoparib are 1.21 (I879) and 1.24 (G888) respectively. In 
the 20 residues preceding the active site loop (residues 860-880, containing the ART 
subdomain helix aJ), the majority of which were under 0.2 in size, CSPs are also observed 
in all inhibitor complexes (Figures 5.4 and 5.5). The differences in CSP sizes between 
complexes is illustrated by the size of the CSP for the binding site residue T910 in each 
complex (Figure 5.3B). Of the three compounds, talazoparib has the largest chemical shift 
perturbation, followed by olaparib and then veliparib. In the case of EB-47, many 
assignments from the active site loop and neighbouring regions were missing in comparison 
to the other compounds, but the size of the largest CSP in the dataset (0.924, residue F897) 
and the size of the CSPs in the region 860-880 were intermediate between those of veliparib 
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and olaparib, although it is possible that residues that remain unassigned could have CSPs 
that are greater in size than this, as these are typically the most difficult assignments to make 
in protein-drug complexes. Unlike for other compounds investigated, two peaks were 
Figure 5.4 Chemical shift perturbations observed in complexes of PARP inhibitors with PARP-1 
catalytic domain. (A), (B), (C) and (D). All chemical shift perturbations observed in spectra of 1:1.5 
complexes of the catalytic domain with veliparib, olaparib, talazoparib and EB-47 (from Figure 5.3) 
respectively. Scaling of CSP mapping by colour to the catalytic domain structure in Figure 5.6 is shown next 
to each plot. Subdomain and secondary structure boundaries are shown below each plot. Chemical shift 
perturbations below 0.249, the upper limit of CSP scaling by colour, are enlarged in (E), (F), (G) and (H).    
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observed at position T910 following titration of a 1:1.5 ratio of EB-47, with a single sharp 
peak observed that overlapped with the signal from the olaparib titration, and a broad weaker 
peak that overlapped with the single peak observed following titration with veliparib. This 
was the only peak in the spectrum of the EB-47 complex to exhibit this behaviour, although 
Figure 5.4 Chemical shift perturbations observed in complexes of PARP inhibitors with PARP-1 
catalytic domain. (E), (F), (G) and (H). Enlarged plots of chemical shift perturbations below 0.249 from (A), 
(B), (C) and (D) respectively. Subdomain and secondary structure boundaries are shown below each plot. 
Scaling of CSP mapping by colour to the catalytic domain structure in Figure 4.6 is shown next to each plot.   
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it was clear that many signals in the TROSY spectrum of the EB-47 complex were either 
missing entirely or noticeably broader than their counterparts in the spectra of free catalytic 
domain and the other inhibitor complexes (Figure 5.2). The interpretation of these 
observations remains unclear. In the ART subdomain, chemical shift perturbations of 
differing sizes between complexes were also observed between residues 980 and 1000, a 
Figure 5.5 Mapping of chemical shift perturbations from PARP-1 catalytic domain in complex 
with veliparib, olaparib, talazoparib and EB-47. (A) and (B). Chemical shift perturbations from Figure 5.4 
globally scaled and mapped onto the structure of PARP-1 catalytic domain in complex with veliparib (A) or 
olaparib (B) inhibitor complexes as described in Chapter 2. CSPs are shown on a gradient from grey (no CSP) 
to yellow (all CSPs > 0.249). Residues that are incomparable due to missing assignments (including proline 
residues) are shown in cyan  Carbon atoms of PARP inhibitor molecules are shown in green, nitrogen atoms in 
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region which contains the key catalytic residue E988. These CSPs were greatest in size in 
the talazoparib complex, followed by EB-47 and then roughly equivalent in size for veliparib 
and olaparib. 
 Although the largest CSPs observed in the HD subdomains of the complexes were 






Figure 5.5 Mapping of chemical shift perturbations from PARP-1 catalytic domain in complex 
with veliparib, olaparib, talazoparib and EB-47. (C) and (D). Chemical shift perturbations from Figure 5.4 
globally scaled and mapped onto the structure of PARP-1 catalytic domain in complex with talazoparib (C) or 
in the case of EB-47, free catalytic domain (D), as described in Chapter 2. CSPs are shown on a gradient from 
grey (no CSP) to yellow (all CSPs > 0.249). Residues that are incomparable due to missing assignments 
(including proline residues) are shown in cyan. Carbon atoms of PARP inhibitor molecules are shown in green, 
nitrogen atoms in blue and oxygen atoms in red.   
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in the HD subdomains between complexes were significantly larger. In the case of veliparib, 
no CSPs in these helices and across the HD subdomain as a whole were greater than 0.11 in 
size. However, in the case of olaparib, larger CSPs were observed between residues 760 and 
780, corresponding to the C-terminal half of the aF helix, which borders the ART 
subdomain and the active site loop. In the case of talazoparib, even though (as for the other 
inhibitors) binding of the compound is to the PARP signature region of the ART subdomain, 
this causes wide-ranging CSPs across the a-helices of the HD subdomain. Talazoparib 
binding results in the largest and most widely-distributed CSPs in the aF helix, but also 
leads to CSPs in the neighbouring aD and aE helices, which do not occur for the complexes 
with olaparib or veliparib. Plotting of CSPs from the EB-47 complex and mapping onto the 
structure of free catalytic domain reveals that EB-47 binding also leads to large CSPs in the 
aF helix, comparable to those associated with talazoparib binding, and CSPs in residues 
700-720 of the aD helix that are slightly larger than those observed for talazoparib. In the 
case of talazoparib and EB-47, small CSPs were also found in the aB helix (residues 680-
690), which lies in close proximity to the C-terminus of the aF helix in the catalytic domain 
structure.  
In the veliparib, olaparib and talazoparib complexes, larger chemical shift 
perturbations in the aF helix appear to be correlated to the size of CSPs in the ART 
subdomain’s aJ helix, which lies in very close proximity to the C-terminus of the aF helix 
where the largest CSPs in the HD subdomain are observed. In the case of EB-47, many 
assignments between residues 860 and 880 could not be assigned due to line broadening in 
the spectra. The presence of these wide-ranging CSPs in talazoparib and EB-47 complexes, 
and the contrasting absence of these changes in veliparib and olaparib complexes, 
demonstrates that binding of small molecules to the PARP signature region in the ART 
subdomain can, in some cases but not others, lead to changes in areas of the HD subdomain 
that are distant from the active site, and suggests that as in the case of the HD subdomain 
mutants investigated in Chapter 4, effects can be propagated  to more distant a-helices 
through the aF helix, the helix closest to the active site. 
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5.3 15N relaxation analysis of backbone amides in PARP-1-inhibitor 
complexes 
In the case of veliparib, olaparib and talazoparib, CSPs in the aF and other helices of the HD 
subdomain appeared to be linked to the formation of contacts from the inhibitor to regions 
on the periphery of the NAD+ binding pocket such as the aF helix, which could also be 
consistent with the hypothesised role of the HD subdomain in allosteric trapping of PARP-
1 during PARP-1 inhibition. However, no large-scale structural rearrangements of the HD 
subdomain were observed in the crystal structures of these complexes, and in the case of the 
EB-47 complex, large CSPs in the HD subdomain were also observed and no 
crystallographic data was available to aid their interpretation.  
Therefore, in order to help establish how the behaviour of key a-helices in the HD 
subdomain were affected by the binding of these inhibitors, we sought to further characterise 
the changes observed across the HD and ART subdomains following the binding of these 
four compounds by measuring relaxation parameters and rates of solvent exchange in these 
complexes using NMR spectroscopy. We hypothesised that if binding of the compounds 
affected the secondary structure of any regions of the catalytic domain, led to changes in the 
motion of linkers, or any significant change in the interdependence of the ART and HD 
subdomains, corresponding changes in relaxation parameters would be detected for 
backbone amides. We also hypothesised that binding of the compounds, perturbation of 
secondary structure or changes in motion of dynamic regions in the HD or ART subdomains 
resulting from inhibitor binding, including those over very long timescales of hours to days, 
should be reflected in differences in rates of solvent exchange. Therefore, as described in 
Section 4.4, we measured backbone 15N spin-locked transverse relaxation times (T1r) and 
15N{1H} steady state NOEs for the HD and ART subdomains for the free catalytic domain 
and all four complexes (Figure 5.6-5.9), and also measured longitudinal relaxation times (T1) 
in order to calculate the overall rotational correlation time (tc) of each complex (Figure 5.10).  
In order to measure the rates of solvent exchange over very long timescales, 15N-
labelled, fully protonated wild-type PARP-1 catalytic domain was lyophilised overnight, re-
suspended in a D2O-based NMR buffer, and the heights of backbone amide peaks were 
measured by recording successive 15N1H TROSY spectra every three hours over a period of 
48 hours as described in Section 2.3.6. We also measured the rate of proton exchange 
between the solvent and backbone amides over much faster timescales for free wild-type 
catalytic domain and all four complexes using a CLEANEX-based experiment as described 
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in Section 2.3.5. All solvent exchange data over these timescales is plotted by colour in 
Figure 5.11. Where signals were observed in the CLEANEX experiment or at varying time 
points in the D2O exchange experiment, they were mapped onto the structure of the catalytic 
domain in Figures 5.12 and 5.13 using the same colour from Figure 5.11. Signals measured 
for the free catalytic domain were mapped onto pdb 4DQY, signals measured for veliparib, 
olaparib and talazoparib complexes were mapped onto the crystal structures of those 
complexes (described above), and in the absence of crystallographic data for the EB-47 
complex, signals measured for that case were mapped onto pdb 4DQY. Unfortunately, we 
were unable use this approach to measure solvent exchange rates for residues in what might 
be called the “intermediate” timescale of solvent exchange, that was too slow to be detected 
by CLEANEX and too fast to be detected in the first TROSY timepoint, because there is no 
NMR experiment conveniently available to measure such rates. However, although this 
meant that coverage was incomplete, these experiments did allow us to evaluate solvent 
exchange both in particularly fast-exchanging flexible regions and also in relatively slow-
exchanging regions, obtaining data at the level of individual residues. 
 In both T1ρ and heteronuclear NOE data, the particularly mobile regions of the 
catalytic domain that were identifiable from their relaxation times and motions in solution 
for the free catalytic domain, such as residues 723-725 and 780-785, were also clearly 
identifiable in the inhibitor complexes. In the ART subdomain, T1ρ data (Figure 5.8) and 
hNOE data (Figure 5.9) show no significant difference in relaxation between the free 
catalytic domain and the inhibitor complexes, although many assignments between residues 
860 and 900 are missing in the EB-47 complex. 
However, both T1ρ and heteronuclear NOE data revealed differences in 15N relaxation 
in different regions of the HD subdomain.  T1ρ data (Figure 5.6) shows that the relaxation 
times of residues 780-785, which form the highly flexible linker between the HD and ART 
subdomains, are noticeably lower for all drug complexes than they are for the free catalytic 
domain, and they are substantially lower in the talazoparib and EB-47 complexes. In the free 
protein, T1ρ values for these six residues were 56 ms, 96 ms, 76 ms, 65 ms, 64 ms and 31 ms 
respectively (all values rounded to the nearest millisecond). In the talazoparib complex, the 
values for these residues were 42 ms, 63 ms, 48 ms, 46 ms, 45 ms and 27 ms respectively, 
and for the EB-47 complex the respective values were 39 ms, 72 ms, 52 ms, 57 ms, 47 ms, 
and 29 ms. This suggests that the binding of these compounds to the active site reduces the 
motion of this highly flexible linker, perhaps through formation of contacts between the 
inhibitor and the aF helix. Interestingly, no corresponding effect on this linker is observed 
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in the heteronuclear NOE data in Figure 5.7, suggesting that this effect may occur due to 
slower chemical exchange between bound and unbound states in these complexes. However, 
it is important to note that in the crystal structure of the talazoparib complex no substantial 
structural rearrangement of either subdomains in relation to one another is observed (no data 
is available for EB-47) and that no overall difference in tc values was observed between the 
free catalytic domain and any complex in Figure 5.10, suggesting that binding of the 
compounds probably does not greatly affect the overall tumbling motion of the catalytic 
domain or the inter-dependence of the two subdomains. 
In the heteronuclear NOE data (Figure 5.7), the overall intensity ratios of residues in 
the aE and aF helices (residues 725-740 and 760-775) were reduced with respect to free 
catalytic domain to varying extents across the four complexes, indicating that the rate of 
motion in these residues had probably increased. In the veliparib, olaparib and talazoparib 
complexes, these changes correlate with binding affinity and in vivo cytotoxicity, as of the 
three complexes the increases in motion are most pronounced in the talazoparib complex, 
followed by olaparib, with only very minor decreases in intensity ratio relative to free 
catalytic domain in the veliparib complex. In EB-47, the increase in flexibility of residues 
750-760 (the C-terminus of the aE-aF linker and N-terminus of aF) 772-775 at the C-
terminus of the aF helix was greater relative to all other complexes and free catalytic 
domain, but motion in the aE helix, while faster than in the free catalytic domain, did not 
increase to the same extent as in the talazoparib complex.  Nonetheless, these heteronuclear 
NOE results suggest that binding of each of these four compounds to the active site in the 
ART subdomain may affect the conformation and dynamics of a-helices in the HD 
subdomain. 
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Figure 5.6 15N T1ρ measurements of HD subdomain residues in free PARP-1 catalytic domain and 
PARP-1 catalytic domain in complex with PARP inhibitors.  (A), (B), (C), (D) and (E). 15N T1ρ 
measurements of HD subdomain residues (656-785) from free catalytic domain (400 µM) and catalytic domain 
in complex with veliparib (300 µM), olaparib (400 µM), talazoparib (500 µM) and EB-47 (400 µM) 
respectively. All data was recorded at 25°C from 15N labelled samples in NMR buffer. Data was collected using 
a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). Error bars 
were plotted according to the data fitting error in Sparky as described in Section 2.3.4. Subdomain and 
secondary structure boundaries are shown below each plot.   
  




Figure 5.7 15N{1H} NOE data from HD subdomain residues in free PARP-1 catalytic domain and 
PARP-1 catalytic domain in complex with PARP inhibitors. (A), (B), (C), (D) and (E). 15N{1H} steady-
state NOE data measurements of HD subdomain residues (656-785) from free catalytic domain (400 µM) and 
catalytic domain in complex with veliparib (300 µM), olaparib (400 µM), talazoparib (500 µM) and EB-47 
(400 µM) respectively. All data was recorded at 25°C from 15N labelled samples in NMR buffer. Data was 
collected using a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe 
(1H/15N/13C). Error bars were plotted according to standard deviation determined on the basis of background 
noise levels as described in Section 2.3.4. Subdomain and secondary structure boundaries are shown below 
each plot.   
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Figure 5.8 15N T1ρ measurements of ART subdomain residues in free PARP-1 catalytic domain 
and PARP-1 catalytic domain in complex with PARP inhibitors. (A), (B), (C), (D) and (E). 15N T1ρ 
measurements of ART subdomain residues (786-1014) from free catalytic domain (400 µM) and catalytic 
domain in complex with veliparib (300 µM), olaparib (400 µM), talazoparib (500 µM) and EB-47 (400 µM) 
respectively. All data was recorded at 25°C from 15N labelled samples in NMR buffer. Data was collected 
using a Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). 
Error bars were plotted according to the data fitting error in Sparky as described in Section 2.3.4. Subdomain 
and secondary structure boundaries are shown below each plot.   
  
















































































































































Figure 5.9 15N{1H} NOE data from ART subdomain residues in free PARP-1 catalytic domain and 
PARP-1 catalytic domain in complex with PARP inhibitors. (A), (B), (C), (D) and (E). 15N{1H} steady-state 
NOE data measurements of ART subdomain residues (786-1014) from free catalytic domain (400 µM) and catalytic 
domain in complex with veliparib (300 µM), olaparib (400 µM), talazoparib (500 µM) and EB-47 (400 µM) 
respectively. All data was recorded at 25°C from 15N labelled samples in NMR buffer. Data was collected using a 
Bruker Avance III HD 800 spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). Error bars were 
plotted according to standard deviation determined on the basis of background noise levels as described in Section 
2.3.4. Secondary structure boundaries are shown below each plot.   
 






































































































































Figure 5.10 tc values of free PARP-1 catalytic domain and PARP-1 catalytic domain in complex 
with PARP inhibitors. (A), (B), (C), (D) and (E). tc values calculated from T1 and T1r measurements for 
free catalytic domain (400 µM) and catalytic domain in complex with veliparib (300 µM), olaparib (400 µM), 
talazoparib (500 µM) and EB-47 (400 µM) respectively. All T1 and T1r measurements were recorded at 25°C 
from 15N labelled samples in NMR buffer. Data was collected using a Bruker Avance III HD 800 
spectrometer equipped with a triple-resonance cryoprobe (1H/15N/13C). tc values were calculated as described 
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5.4 EB-47 destabilises a-helical regions of the HD subdomain 
Analysis of the solvent exchange data (Figure 5.11) and mapping of the data onto structures 
of the catalytic domain and inhibitor complexes (Figures 5.12 and 5.13) revealed pronounced 
differences between the EB-47 complex and all other samples. In the free catalytic domain 
and the veliparib, olaparib and talazoparib complexes, peaks were observed at later time 
points in the same regions of the ART subdomain (residues 810-820, 830-840, 860-880 
including the aJ helix, 915-925, 945-955, and 985-1005 including the catalytic residue 
E988) and in aA (670-680), aB (680-690), aD (700-720), aE (725-740) and aF (760-775) 
helices. This indicated that these residues were protected from D2O exchange, even over the 
48-hour duration of the experiment, by the folds of the ART or HD subdomains. The aF 
helix was particularly well protected, with the exception of residues 755-760 at the N-
terminus of the helix, for which no signals were observed in free catalytic domain or any 
inhibitor complex. Intense CLEANEX signals were observed at the N and C termini, and at 
previously identified loop regions such as the inter-subdomain linker at residues 780-785 
and 935-945. CLEANEX signals of lower intensity were also observed for the aD-aE linker 
at residues 723-725 and although the intensity of these signals was lowest in the talazoparib 
complex, given the small number of residues in the linker and overall similarity of these 
signals in all five samples it is unclear whether this represents a significant change in the rate 
of exchange at faster timescales in this linker for the talazoparib complex. 
However, despite the similarities observed in the CSP and relaxation data between 
EB-47 and other compounds (in particular talazoparib), the long-timescale solvent exchange 
properties of the HD subdomain in the EB-47 complex were completely different from those 
observed for the free catalytic domain and talazoparib, olaparib and veliparib complexes. As 
shown in Figure 5.13, many of the signals from backbone amides in the previously highly 
protected aB, aD and aF helices of the HD subdomain were not observed, indicating that a 
significant degree of deprotection consistent with a conformational change in these helices 
had taken place in this complex. This deprotection effect was also observed for the active 
site residues 860-870 that include the aJ helix, but was less apparent in the aE helix which 
is the furthest of the HD a-helices from the active site. Changes in solvent exchange of this 
magnitude suggested that EB-47 binding had significantly destabilised these a-helical 
regions, and that a corresponding destabilisation did not occur upon binding of the other 
compounds.  
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In the absence of a solved crystal structure of EB-47 in complex with the entire wild-
type PARP-1 catalytic domain to confirm this hypothesis, we re-examined data from the 15N 
NOESY-HSQC experiments that were used to complete the resonance assignment of 
backbone amides in these complexes described in Chapter 3. The backbone amides of 
residues in ordered a-helical regions would typically be expected to display strong NOE 
cross-peaks with the amides of sequentially neighbouring residues as a result of their strong 
dipolar interactions, and we had observed during the assignment process that many of these 
cross-peaks in the EB-47 complex appeared to be missing in comparison to their counterparts 
in the other inhibitor complexes. Therefore, we hypothesised that if EB-47 binding caused 
destabilisation of these a-helical regions, there would be a corresponding loss of cross peaks 
observed in the HD subdomain in comparison to free catalytic domain and complexes with 
other inhibitors. Plotting of intensity of all backbone amide cross-peaks in the HD 
subdomain in free catalytic domain and all inhibitor complexes (Figure 5.14) reveals that 
almost all backbone amide cross peaks in the main a-helical regions of interest (residues 
700-720, including aD, and 755-780, including aF) identified in Figures 5.11, 5.12 and 5.13 
are absent in the case of the EB-47 complex. In contrast, there is no significant difference in 
the number or intensity of cross-peaks (relative to neighbouring peaks) in the regions more 
distant from the active site containing aA (residues 660-680), aB (680-700) and aE helices 
(720-740), or linker regions such as residues 740-750, which did not exhibit significant 
differences in solvent exchange from the other samples. This suggests that, in contrast to the 
other PARP inhibitors studied as part of this investigation, EB-47 binding significantly 
destabilises the ordered helical regions of the HD subdomain closest to the active site 
location. 
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Figure 5.11 D2O exchange and CLEANEX data for PARP-1 catalytic domain and PARP-1 
catalytic domain in complex with PARP inhibitors. 15N1H TROSY experiments were performed on 15N 
labelled samples (500 µL volume, 100 µM concentration), every 3 hours for 48 hours following 
lyophilisation and re-suspension in D2O-based buffer and peak heights were measured and normalised 
between samples as described in Chapter 2 to obtain relative residual intensity. Relative residual intensity of 
peaks after 6 hours (light blue), 15 hours (blue), and 42 hours (dark blue) was calculated as described in 
Section 2.3.6 and superimposed for free catalytic domain (A) and catalytic domain in complex with veliparib 
(B), olaparib (C), talazoparib (D) and EB-47 (E). CLEANEX data was collected from 15N labelled samples 
at concentrations described in Figures 5.2 and 5.3 and CLEANEX relative intensity (red) calculated for each 
sample as described in Section 2.3.5 was plotted alongside relative residual intensity from the D2O exchange 
experiment. Subdomain and secondary structure boundaries are shown below each plot.     
  
 















Figure 5.12 (previous page) Mapping of solvent exchange rates to the structures of free PARP-1 
catalytic domain and PARP-1 catalytic domain in complex with veliparib and olaparib. Residues in the 
structures of free catalytic domain (A) or catalytic domain in complex with veliparib (B) or olaparib (C) were 
coloured according to the relative residual exchange data from D2O exchange experiments and CLEANEX 
data shown in Figure 5.11. Where data for the fastest-exchanging residues was acquired in CLEANEX 
experiments, residues were coloured red. Where data was acquired for slowly-exchanging residues in the D2O 
exchange experiment, residues were coloured according to the latest time point for which signals were 
observed. Signals from the 6-hour (light blue), 15-hour (blue) and 42-hour (dark blue) time points shown in 
Figure 5.11 were mapped. Residues with solvent exchange rates intermediate between CLEANEX and D2O 
exchanged time points, for which no signals were observed, were coloured white. Carbon atoms of PARP 
inhibitor molecules are shown in green, nitrogen atoms in blue and oxygen atoms in red. Mapping was 
performed as described in Section 2.3.6 using a script written by David Neuhaus. 
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  Figure 5.13 (previous page) Mapping of solvent exchange rates to the structures of free PARP-1 
catalytic domain and PARP-1 catalytic domain in complex with talazoparib and EB-47. Residues in the 
structures of free catalytic domain (A) or catalytic domain in complex with talazoparib (B) or EB-47 (C) 
were coloured according to the relative residual exchange data from D2O exchange experiments and 
CLEANEX data shown in Figure 5.11. Where data for the fastest-exchanging residues was acquired in 
CLEANEX experiments, residues were coloured red. Where data was acquired for slowly-exchanging 
residues in the D2O exchange experiment, residues were coloured according to the latest time point for which 
signals were observed. Signals from the 6-hour (light blue), 15-hour (blue) and 42-hour (dark blue) time 
points shown in Figure 5.11 were mapped. Residues with solvent exchange rates intermediate between 
CLEANEX and D2O exchanged time points, for which no signals were observed, were coloured white. 
Carbon atoms of the talazoparib molecule are shown in green, nitrogen atoms in blue and oxygen atoms in 
red. Mapping was performed as described in Section 2.3.6 using a script written by David Neuhaus.      
 




Figure 5.14 Backbone amide-amide cross-peaks from 15N NOESY-HSQC experiments in the HD 
subdomain of free PARP-1 catalytic domain and PARP-1 catalytic domain in complex with PARP 
inhibitors. (A), (B), (C), (D), (E). Intensity of backbone amide-amide cross-peaks plotted by residue number 
for HD subdomain residues (656-800) for free catalytic domain (400 µM), veliparib (300 µM), olaparib (400 
µM), talazoparib (500 µM) and EB-47 (400 µM). Bars representing sequential cross-peaks are positioned to 
span the pair of residues connected by the cross-peak and the average intensity of each pair of sequential 
cross-peaks is shown in blue, with the intensity of the largest cross-peak in each pair shown in grey. 15N 
NOESY-HSQC data was collected at 25°C using a Bruker Avance III HD 800 spectrometer equipped with a 
triple-resonance cryoprobe (1H/15N/13C) as described in Chapters 2 and 3. Subdomain and secondary structure 
boundaries are shown below each plot.   
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In this chapter, differences were found in the size of chemical shift perturbations in key 
regions of both the HD and ART subdomains in complexes of PARP-1 catalytic domain 
fragment in complex with the PARP inhibitors veliparib, olaparib and talazoparib. Given 
the very high binding affinities of all these inhibitors (see Table 5.1), these differences are 
clearly not related to the degree of saturation, which was complete in all cases. Despite the 
similarity of the size and locations of HD subdomain CSPs between the talazoparib and EB-
47 catalytic domain complexes, measurement of solvent exchange at long timescales 
revealed that binding of EB-47 is unique among the four compounds investigated in this 
chapter, as only EB-47 led to significant and clearly detectable destabilisation of the aF and 
aD helices in closest proximity to the active site. 
 For veliparib, olaparib and talazoparib, the similarity of solvent exchange data for 
these complexes to free wild-type catalytic domain, at least for all regions of the HD 
subdomain for which signals were observed at longer timescales (which includes the 
majority of residues from the aA, aB, aD and aF helices, and the five C-terminal residues 
of the aE helix), indicates that no significant destabilisation of the secondary structure of 
these a-helices occurred following binding of these compounds. However, differences in 
the size of CSPs in the aF and other helices of the HD subdomain appear to be linked to the 
presence or absence of contacts between the compounds and regions on the periphery of the 
NAD+ binding pocket. For example, in the case of talazoparib, contacts with the side chains 
of residues Q759 and E763 from the aF helix have been described, as well as the disruption 
of hydrogen bonding between Y889 in the active site loop and D766 by talazoparib binding 
(Aoyagi-Scharber et al., 2014). In the previously unpublished crystal structure of the 
catalytic domain in complex with olaparib, an oxygen atom also protrudes towards the 
vicinity of the D766 side chain, but no such potential contacts are observed in the structure 
of the veliparib complex, which appears to form contacts only with residues from the active 
site of the ART subdomain. From the results of similar experiments performed on HD 
subdomain mutants in Chapter 4, it appears that packing of HD subdomain helices in relation 
to both one another and the active site location is important for autoinhibitory function (and 
the relief of this function upon binding to DNA damage), and that any perturbation of this 
packing between helices in the HD subdomain leads to corresponding changes in chemical 
shifts not only within the helices but also for residues of the active site. As talazoparib forms 
contacts with two residues from the aF helix and also disrupts a contact between the aF 
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helix and the loop at the periphery of the active site, these more disruptive changes could 
explain why talazoparib binding causes CSPs in the other HD subdomain helices bordering 
aF, whereas olaparib binding causes CSPs in aF only and veliparib binding leads to minimal 
changes in any chemical shifts of HD backbone amides.  
Most importantly, the results of the CSP and solvent exchange data are in agreement 
with the results of previous biochemical and kinetic studies performed on these compounds 
in vitro (Hopkins et al., 2015; Rudolph et al., 2018), which have suggested that trapping of 
PARP-1 (or rather, slowed dissociation of inhibitor-bound PARP-1 from DNA) by these 
compounds in vitro occurs only in the presence of NAD+ and appears to be correlated to 
binding affinity of the compounds in a linear fashion, as opposed to the non-linear 
differences (particularly for talazoparib) reported in vivo (Murai et al., 2012; Murai et al., 
2014). As formation of long, branched, negatively charged poly ADP-ribose chains appears 
to be important for discharge of PARP-1 from DNA strand breaks, trapping of PARP-1 in 
the presence of NAD+ in a manner that correlates closely with binding affinity indicates that 
inhibition of formation of these chains by PARP inhibitor binding is the mechanism that 
drives any decrease in off-rate of the DNA.  If trapping of these compounds occurred via 
promotion of an allosteric pathway that mirrors the activation pathway in response to DNA 
damage, not only would decreased off-rates for PARP inhibitors be observed in in vitro 
assays in the presence of DNA, but pronounced conformational changes in key HD a-
helices, with parallels to the partial unfolding observed following activation (Dawicki-
McKenna et al., 2015) would also be expected. 
However, this means that the results of our in vitro studies do not provide a direct 
mechanistic explanation of the reported highly elevated cytotoxicity of talazoparib in vivo 
with respect to the other two compounds (Murai et al., 2014), which is one order of 
magnitude higher than would be expected from comparison of PARP-1 binding affinity 
alone (Table 5.1). These larger than expected differences in potentiation of DNA damage 
by alkylating agents reported in vivo could perhaps occur as a result of off target effects in 
these compounds. The PARP inhibitors veliparib, olaparib, niraparib, rucaparib and 
talazoparib have been shown to exhibit varying off-target effects on protein kinases (Antolin 
and Mestres, 2014; Antolin et al., 2019), with some impacts observed at clinically relevant 
submicromolar concentrations. Although talazoparib (the compound with the biggest 
difference between the relative cytotoxicity predicted from the Ki and the effects observed 
in vivo) did not affect the kinases which were inhibited by rucaparib or niraparib, it is not 
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improbable that off-target effects occur for other classes of proteins and that these may also 
vary in in vivo assays in a cell-line dependent manner.   
 In the case of EB-47, deprotection in our D2O exchange experiment was observed at 
the same locations as in the previously published HXMS data for WT full-length PARP-1 
upon DNA binding. 100 seconds after DNA binding, deprotection was observed in the aB 
helix (between residues 680 and 700) and the C-terminal half of the aF helix (residues 760-
775), where the fastest HX was observed after 100 seconds, as well as in the aD helix 
(residues 700-720) where moderately fast HX was also observed (Dawicki-McKenna et al., 
2015). Therefore, there appear to be parallels between EB-47 binding and the changes that 
occur in the HD subdomain in full length PARP-1 following DNA binding at the N-
terminus, which could suggest that EB-47 binding can promote allosteric trapping in full-
length PARP-1 by mimicking the changes that occur in the HD subdomain during activation 
following DNA damage.  
The chemical structure of EB-47 also resembles the structure of NAD+ far more 
closely than it does the structures of veliparib, olaparib and talazoparib (Figure 5.1). 
Analysis by the Pascal group of binding by the non-hydrolysable NAD+ analogue benzamide 
adenine dinucleotide (BAD) to PARP-1 in the presence of DNA damage reveals that BAD 
binding to the catalytic domain promoted stronger binding of N-terminal zinc finger 
domains to DNA (Langelier et al., 2018). In BAD (Figure 5.1), carbon replaces the nitrogen 
atom of NAD+’s nicotinamide ring, instead forming a benzamide moiety. Tightening of 
inter-domain and DNA binding interfaces in response to NAD+ binding (and a 
corresponding increase in the time spent bound to the site of DNA damage by activated 
PARP-1) may promote more effective signalling following detection of single-strand breaks 
in vivo. However, the structural basis of this effect has yet to be fully elucidated, as although 
the structure of BAD in complex with catalytic domain ∆HD was also solved by the Pascal 
group, revealing for the first time how the PARP- catalytic domain substrate interacts with 
the active site, no structure of any NAD+ analogue has been solved in complex with a PARP-
1 construct containing the HD subdomain. Langelier and co-workers also showed that BAD 
(and presumably NAD+) does not bind to the unactivated catalytic domain due to the 
autoinhibitory presence of the HD subdomain. It was also shown recently that NADP+ can 
function as an endogenous PARP inhibitor that suppresses ADP-ribosylation both in vitro 
and in vivo (Bian et al., 2019), confirming that molecules with strong structural similarity to 
NAD+ can function as PARP-1 inhibitors, although the ability of NADP+ binding to promote 
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an allosteric response in the same manner as BAD was not evaluated. Consequently, it would 
be of interest to evaluate the kinetics of EB-47 binding to PARP-1 bound to a model of DNA 
damage via a biophysical method such as surface plasmon resonance (SPR). If a decrease in 
the off-rate of DNA and inhibitor from PARP-1 was observed in the presence of EB-47 but 
not for veliparib, olaparib and talazoparib, this could provide insights into the relationship 
between PARP inhibitor structure and the different mechanisms of PARP inhibition.  
Given the similarity of EB-47 in both chemical structure and size to BAD and NAD+ 
(Figure 5.15) and the fact that BAD binding to unactivated PARP-1 catalytic domain is 
sterically blocked, there may also be differences in binding of EB-47 to activated catalytic 
domain in full-length PARP-1 bound to DNA.  These differences could potentially be further 
investigated by NMR spectroscopy using a model of segmentally labelled catalytic domain 
in full-length PARP-1 discussed further in Chapter 6, although both sample preparation and 
acquisition of spectra from segmentally labelled domains in full-length PARP-1 is 






Chapter Six  
 
Conclusions and outlook 
 
Detection of single-strand breaks by PARP-1 and its subsequent activation and 
automodification by ADP-ribosylation are critical processes in the DNA damage response 
in higher eukaryotic cells. Recently, the underlying structural basis of SSB and DSB 
recognition by the N-terminal zinc finger domains of PARP-1 has been discovered 
(Eustermann et al., 2011; Eustermann et al., 2015; Langelier et al, 2012), and much of the 
mechanistic basis of the subsequent interdomain interactions which lead to activation in the 
C-terminal catalytic domain has been characterised using NMR spectroscopy (Eustermann 
et al., 2015). It has also been shown by HXMS that the increase in catalytic domain activity 
following activation is unexpectedly due to partial loss of structure of a-helical regions in 
the HD subdomain of the catalytic domain (Dawicki-McKenna et al., 2015) and that in the 
absence of DNA damage, the HD subdomain sterically blocks NAD+ substrate binding to 
the active site in the ART subdomain (Langelier et al., 2018), therefore indicating that 
conformational change in the HD subdomain improves substrate access to the active site. 
However, the resolution of HXMS means that so far this process has only been characterised 
at the level of individual peptides and HXMS timescales (between 10 seconds and 105 
seconds) and the changes in the HD subdomain that lead to unfolding after binding of the 
catalytic domain to the binding site formed by the F3 and WGR domains of activated PARP-
1 (Figure 1.6) remain to be characterised at higher resolution.  
 Additionally, PARP-1 activity is an important drug target for treatment of tumours 
with mutations in BRCA1 and BRCA2 genes, and potentially for other genes such as RAD51 
and FANCA that are also involved in homologous recombination (McCabe et al., 2006). 
Cells that are deficient in homologous recombination are reliant on PARP-dependent DNA 
repair pathways, and inhibition of PARP-1 catalytic domain activity by small molecules is 
the first anti-tumour treatment to be based on a synthetically lethal approach, in which the 
combined loss of function of two genes, proteins or pathways results in cell death, but the 
loss of one of them does not. This effect is not simply the result of abolition of ADP-
ribosylation signalling, but rather arises because binding of PARP-1 inhibitors to the C-
terminal active site prevents the release of PARP-1 from sites of DNA damage, thereby 
forming bulky, toxic lesions (Murai et al., 2012). However, it remains unclear whether this 
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trapping of PARP-1, and the differences in potency between known PARP inhibitors, is the 
direct result of differences in their binding affinities (and thus their abilities to inhibit 
formation of the PAR chains needed to discharge PARP-1 from sites of DNA damage) or is 
due to enhancement of DNA binding via a reverse allosteric mechanism that mirrors the 
allosteric pathway involved in PARP-1 activation.  
By studying the differences between the wild-type catalytic domain fragment and 
constitutively partially active catalytic domain mutants that are hypothesised to partially 
mimic the effect of DNA binding, and by comparing the binding of different PARP 
inhibitors to the catalytic domain fragment using NMR spectroscopy, we aimed both to 
further characterise the changes that occur in the HD subdomain following PARP-1 
activation and determine whether there were any differences between the complexes which 
could explain the mechanism of PARP inhibition for these compounds. 
 The discovery that partially activating mutations in key a-helices of the HD 
subdomain lead to chemical shift perturbations in neighbouring a-helical regions, as well as 
the active site in the ART subdomain, suggests that the packing of the a-helices is critical 
to the autoinhibitory function of the HD subdomain and that these HD subdomain mutants 
may represent an intermediate level between the unactivated and fully activated states of the 
catalytic domain in wild-type PARP-1. 
In the case of all four PARP inhibitors investigated during the course of this work, 
chemical shift perturbations directly caused by binding were observed at the active site 
location in the ART subdomain. In the HD subdomain, comparison of the size and location 
of the observed chemical shift perturbations with crystal structures of the catalytic domain 
in complex with veliparib, olaparib and talazoparib showed that CSPs can occur as a result 
of formation of contacts on the boundary of the active site. In our experiments no systematic 
differences in solvent exchange rates from free catalytic domain were detected for these 
three complexes, but in contrast the EB-47 complex showed pronounced deprotection from 
solvent exchange in the key a-helical regions closest to the active site, indicating that EB-
47 binding significantly destabilises these regions. This was subsequently confirmed by 
analysis of cross-peaks from 15N NOESY HSQC experiments, which revealed that in 
contrast to the other complexes, cross-peaks between backbone amides of sequential 
residues in these regions were missing for the EB-47 complex alone. On the basis of these 
results and other in vitro studies that have been published (Hopkins et al., 2015; Rudolph et 
al., 2018), it appears likely that in the case of veliparib, olaparib and talazoparib, trapping is 
Conclusions and outlook 
 115 
due to the inhibition of ADP-ribosylation by active site binding alone. However, the case of 
EB-47 is more intriguing and the similarities between destabilisation of the HD subdomain 
and unfolding of the HD subdomain during activation suggest the unconfirmed possibility 
that EB-47 may promote trapping via a reverse allosteric pathway. 
Although by employing CLEANEX and real-time D2O exchange experiments, it was 
possible to examine the effects of inhibitor binding on solvent exchange at both fast and 
very slow timescales, these experiments could not provide data on exchange at intermediate 
rates, i.e. those residues whose amide NHs exchanged too slowly to be detected by 
CLEANEX but which exchange before the first TROSY timepoint (6 hours). Therefore, 
transient conformations of these complexes that exchange more quickly than the very slow 
timescale of the real-time experiment, or existed as a relatively low proportion of the 
dominant ground state, would be undetectable using this approach. NMR-based approaches 
to detect and study transient protein or protein-ligand conformations that exchange with 
highly populated ground state conformations at varying timescales of chemical exchange 
have been developed.  Techniques such as CEST (chemical exchange saturation transfer) 
can be applied to spectra of biomolecules by applying a weak radiofrequency field at 
different frequencies within the chemical shift range of the chosen nucleus (e.g. 15N) with 
the aim of detecting a loss in intensity of ground state peaks when the irradiation frequency 
is in close proximity to corresponding peaks of the excited state (Sekhar and Kay, 2013). 
CEST experiments have been successfully applied to systems with excited state lifetimes of 
5 to 50 ms, where the excited conformation represented at least 1% of the population in 
solution (Vallurupalli et al., 2012). However, in the case of the protein-inhibitor complexes 
investigated during the course of this project, T1ρ relaxation data covering a similar timescale 
revealed no significant differences in T1ρ values between samples.  
Where the conformational change in a system takes place in a slow exchange regime 
such that separate peaks are seen for the individual exchanging states (as can occur for slow 
ligand binding events or changes in secondary structure), a technique such as EXSY 
(Exchange SpectroscopY, also known as the ZZ-exchange experiment) may be used to 
quantify the precise timescales and kinetics of these changes. The peak of interest is defined 
or assigned by its chemical shift at each state and during the evolution period of this 
experiment, magnetisation is stored longitudinally for a variable length of time (T) while 
interconversion between the differing states A and B continues to occur, yielding a 
combination of self-peaks and cross-peaks that vary in strength in a time-dependent manner. 
By repeating experiments with differing values of T, curves can be generated according to 
Conclusions and outlook 
 
 116 
the intensities of the different species and rates of interconversion between the two states 
can be calculated.  However, the length of the z magnetisation step is limited by the duration 
of T1 for a given nucleus and so the exchange between the two states must occur at a rate 
comparable to or faster than the rate of longitudinal relaxation to be detectable, limiting the 
useful timescale of this technique (Kleckner and Foster, 2011).  
If it could be shown that EB-47 binding promotes delayed release of PARP-1 from 
DNA damage sites in vitro using a biophysical technique such as SPR (discussed in Section 
5.5), the changes promoted by EB-47 binding, as well as the changes in HD secondary 
structure that occur during activation, could be further investigated by NMR spectroscopy 
by acquiring spectra from segmentally labelled catalytic domain in the context of full-length 
PARP-1 bound to a DNA damage model. Segmental labelling of individual domains or 
continuous multi-domain fragments can be carried out using the transpeptidase Sortase A, 
which can be used to ligate two differentially labelled recombinant proteins to make an 
NMR sample. This approach has been successfully used in the Neuhaus lab in the past in 
order to reduce overlap and complexity of spectra (for instance in the PARP-1 F1-F2-F3 
fragment; Eustermann et al., 2015). Using this approach, we have so far ligated isotopically 
labelled catalytic domain to an unlabelled PARP-1 ∆CAT construct to make full-length 
PARP-1, which presumably has the same DNA binding and catalytic domain activity as 
non-recombinant PARP-1. During the course of previous work to characterise the structural 
and mechanistic basis of SSB binding to PARP-1 F1 and F2 domains, DNA dumbbells 
which act as models of different forms of SSBs were already designed by Sebastian 
Eustermann of the Neuhaus group, which means that full-length sortase-ligated PARP-1 
could be titrated with the DNA dumbbell inside the NMR tube and spectra acquired from 
fully activated catalytic domain in PARP-1. 
This experiment is highly challenging in comparison to the study of the isolated 
catalytic domain fragment in isolation, as the sample would have a molecular weight of 
approx. 113 kDa in isolation and approx. 128 kDa in complex with the DNA dumbbell 
ligand. Additionally, preparation of the ligated sample at the molar concentration required 
for acquisition of high-quality NMR spectra has been severely limited by the poor yield of 
the multi-domain N-terminal fragment in E. coli., as well as quite low yield of ligated 
product from the sortase ligation reaction. Nonetheless, to date we have acquired spectra 
from a single 40 µM sample of sortase-ligated full-length PARP-1 containing 15N-labelled 
catalytic domain ligated to unlabelled N-terminal domains (Figure 6.1; sample prepared by 
Laura Easton), in the absence of a DNA dumbbell ligand. Although some backbone amide 
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signals are missing in full-length PARP-1 catalytic domain in comparison with the isolated 
catalytic domain fragment, a fairly high proportion overall are still observed and in almost 
all cases overlap precisely with the isolated catalytic domain fragment, with no chemical 
shift perturbations. Because the assignment of the full-length spectrum has not been 
completed, at present it remains unknown which signals are missing, and it also remains 
unclear whether their disappearance is due to signal loss from slower tumbling, and 
consequently faster relaxation caused by more efficient dipole-dipole interactions that would 
be expected from high molecular weight proteins, or by transient interactions with other 
PARP-1 domains under an intermediate exchange regime, or by a combination of these 
factors, or by another explanation.  Other sharp peaks have appeared, which are likely (but 
yet to be confirmed) to be from additional residues in the sortase ligation sequence; these 
are in the linker that is expected to be relatively mobile. Finding solution conditions under 
which the complex of full-length PARP-1 with our DNA dumbbell ligand is soluble in 
















Figure 6.1 Segmental labelling of PARP-1 catalytic domain in full-length PARP-1. (A) Schematic of 
full-length PARP-1 containing segmentally labelled catalytic domain. Unlabelled domains are shown in grey, 
the WGR-CAT linker containing the sortase ligation site is represented by a dotted line. (B) [15N 1H] TROSY 
spectra of 15N segmentally labelled PARP-1 catalytic domain (40 µM, red), alone and superimposed on the 
spectrum of the isolated catalytic domain fragment (400 µM, black).    All spectra were acquired at 25°C in 
NMR buffer. Data was collected using a Bruker Avance III HD 800 spectrometer equipped with a triple-
resonance cryoprobe (1H/15N/13C). 
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than working with the protein fragments studied in the group until now, but work by Laura 
Easton has found that a sodium phosphate buffer previously used in DNA binding studies 
of full-length PARP-1 (Langelier et al., 2018) appears to avoid precipitation at 
concentrations where NMR becomes feasible, paving the way for attempts to acquire spectra 
of the separately labelled catalytic domain in the context of activated, DNA-bound full-
length PARP-1.  
Any change in NMR buffer is likely to lead to changes in chemical shifts in the 
spectra and necessitate transfer of assignments to the new spectra, and it also remains unclear 
whether signals from backbone amides can be observed in the catalytic domain following 
activation, as both the extent of the independence of the catalytic domain from the other 
domains involved in activation and the strength of the interaction between the catalytic 
domain and its binding site interface (formed from surfaces on F3 and WGR) are unknown. 
However, acquisition of spectra from activated catalytic domain could shed light on these 
questions, as well as potentially allowing us to probe the changes observed in the HD 
subdomain in previously published HXMS experiments, and from the EB-47 complex in 
our solvent exchange experiments, with a view to establishing whether EB-47 binding 
promotes allosteric strengthening of CAT-WGR binding in full-length PARP-1. As 
assignments for PARP-1’s 11 kDa WGR domain (which precedes the catalytic domain in 
the PARP-1 sequence and forms both contacts with DNA and part of the catalytic domain 
binding site during activation) have previously been completed by other members of the 
Neuhaus group, samples of full-length PARP-1 could also be prepared containing an 
isotope-labelled WGR-CAT fragment ligated to an unlabelled N-terminal F1-F2-F3-BRCT 
fragment. In the absence of DNA, we could expect to detect a high proportion of the 
backbone amide signals from the WGR domain in the absence of DNA (as already observed 
for the catalytic domain), as prior to activation all PARP-1 domains are known to tumble 
independently in a manner consistent with “beads on a string”. However, as the WGR 
domain is known to form interdomain contacts with DNA, F1, F3 and the catalytic domain 
(Eustermann et al., 2015; see Section 1.1.6) in the DNA complex, we hypothesise that it 
does not tumble independently from DNA and other PARP-1 domains upon activation and 
that regardless of the results observed for the catalytic domain, this would be reflected in 
lower intensity, or complete absence, of signals from the WGR domain in the spectra 
following titration with a DNA dumbbell ligand. Therefore, repeating any experiments 
carried out on segmentally labelled catalytic domain in segmentally labelled WGR-CAT 
may function as an important control experiment, as if catalytic domain signals are observed 
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post-titration and WGR signals are not, this will confirm that PARP-1 activation is 
associated with loosening of the interdomain contacts between CAT and the rest of the 
complex. 
Additionally, for high molecular weight systems, isotope labelling of methyl groups 
from amino acid side chains has often provided insights into the dynamics and function of 
molecular assemblies up to 1 MDa in size (Sprangers and Kay, 2007), as methyl groups very 
often have relatively sharp signals due to their rapid internal motions. In the case of the 
sortase-ligated catalytic domain, methyl groups of methionine, isoleucine, leucine and 
valine side chains could be labelled in a perdeuterated background (MILV labelling) and 2D 
[13C-1H] spectra acquired. Given that in this thesis we have identified the importance of 
inter-helical side chain contacts in leucine residues such as L713F and L765F in the 
autoinhibitory function of the HD subdomain, signals from methyl groups of side chains 
could be informative in characterising the changes that occur in these residues upon 
activation of full-length PARP-1. 
The differences in catalytic domain binding observed between the PARP inhibitors 
investigated in this study have implications for our understanding of PARP-1 inhibition by 
small molecules.  The fact that chemical shift perturbations are observed across multiple 
helical regions of the HD subdomain upon binding of talazoparib, a compound that makes 
relatively extensive contacts with side chain residues of the aF helix, and the active site loop 
that bridges the HD and ART subdomain (Aoyagi-Scharber et al., 2014), but not for olaparib 
and veliparib that make lesser contacts with the HD, confirms that HD subdomain contacts 
can also play a role in binding of compounds to PARP-1 catalytic domain.  
Exploiting HD subdomain contacts may also present opportunities to improve the 
selectivity of PARP inhibitors. Given the highly conserved nature of the PARP signature 
(and therefore the active sites) across the 17 members of the PARP family, compounds that 
are designed to bind to the PARP-1 active site or ART subdomain alone are highly likely to 
bind to other members of the PARP family. Due to the diversity of functions across the 
PARP family, there is significant interest in generating highly selective PARP inhibitors for 
improved functional in vivo studies of individual PARPs, or multiple PARPs that are 
grouped by function (Steffen et al., 2013). One such study was recently reported for PARP-
11, revealing that PARP-11 catalytic domain activity is required for localisation of PARP-
11 to the nuclear envelope (Kirby et al., 2018). Of the 17 PARP family members, only 
PARP-1, PARP-2 and PARP-3 appear to have functions relevant to detection of DNA 
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damage and only PARP-1, PARP-2, PARP-3 and PARP-16 appear to contain autoregulatory 
HD subdomains (see Chapter 1, Figure 1.2). Differences also exist between the sequences 
of these HD subdomains that can have relevance to the binding mechanism of small 
molecules, as already shown in the case of talazoparib binding to PARP-1 and PARP-2 
(Aoyagi-Scharber et al., 2014).  
In the case of EB-47, it still remains to be confirmed in follow-up experiments 
whether the mechanism of inhibition differs in full-length PARP-1 from the other 
compounds investigated during this work. However, the relative similarity of EB-47 to 
NAD+ and recent findings showing that binding of the NAD+ analogue BAD to PARP-1 
catalytic domain promotes reverse allosteric tightening of PARP-DNA binding, and that the 
NAD+ derivative NADP+ functions as an endogenous PARP inhibitor in vivo, suggest 
intriguing possibilities for the design of future PARP inhibitors.  
In addition to PARP-1, PARP-2 and PARP-3 also show DNA-dependent activation, 
although to a lesser extent than does PARP-1, and one aim of future work in the Neuhaus 
group is to attempt to characterise the mechanism of activation in these cases also. In contrast 
to PARP-1, PARP-2 and PARP-3 each have only a short, disordered DNA binding domain 
and a WGR domain N-terminal to the catalytic domain, but the catalytic domain of both 
proteins contains an autoregulatory HD subdomain and an ART subdomain that contains the 
PARP signature fold (Chapter 1, Figure 1.2) and despite the differences in their domain 
structure and that of PARP-1, PARP-2 and PARP-3 share PARP-1’s allosteric  activation 
mechanism. Unlike for PARP-1, activation of PARP-2 or PARP-3 appears to require that 
there is a 5' phosphoryl group at a DNA strand break (Langelier et al., 2014), although 
PARP-3 possesses only mono-ADP-ribosyl transferase (MART) activity (Vyas et al., 2014), 
whereas PARP-2 (like PARP-1) has poly-ADP-ribosylation activity. However, the ADP-
ribosylation activity of wild-type PARP-2 following activation is not as high as for PARP-
1, with estimates varying between a two and four-fold greater level of stimulation above 
basal activity for PARP-1 than for PARP-2 (Langelier et al., 2014). Furthermore, it has been 
reported that in conjunction with WGR, the catalytic domain of PARP-2 plays a role in 
localisation of PARP-2 to DNA damage sites (Riccio et al., 2016)  Consequently, it would 
also be of interest to replicate any studies of catalytic domain activation in full-length PARP-
1 in PARP-2, in order to compare and contrast the changes that occur during activation of 
the domains and determine whether this difference in activated catalytic domain activity is 
the result of differences in HD subdomain behaviour. As PARP-2 has fewer N-terminal 
domains, it can form fewer interdomain and DNA contacts upon activation, and this may 
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reduce the amount of Gibbs free energy available for activation upon DNA binding, for 
example leading to less extensive changes in HD helical regions. Equally, this deficit could 
be compensated if PARP-2’s catalytic domain interacts with DNA, in which case 
comparison with the events leading to PARP-1 activation would be of interest.  Due to its 
smaller number of domains, the molecular weight of full-length PARP-2 is 62 kDa in size, 
substantially lower than PARP-1, although this is still considered to be a challenging, high 
molecular weight protein in NMR terms. If high-quality spectra can be acquired from full-
length PARP-2, segmental labelling of WGR and catalytic domains using Sortase A could 
be employed to reduce spectral congestion in order to aid interpretation of PARP-2 spectra. 
In conclusion, the work described in this thesis represents the first study of activation 
and inhibition in the PARP-1 catalytic domain at the level of individual residues in solution. 
The ability of solution NMR spectroscopy to both detect and characterise highly flexible 
regions and its sensitivity to environmental changes of backbone amides has provided new 
insights into the dynamic changes occurring in regions of the HD subdomain in these 
processes that could not have been determined using other structural methods. In particular, 
our findings demonstrate the importance of the relationship between the helical regions of 
the catalytic domain in PARP-1 autoinhibition, and our detection of differences in HD 
subdomain behaviour following binding of different PARP inhibitors, including 
destabilisation of HD helical regions by EB-47, may reflect the different mechanisms by 
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Appendix: Binding of 58-bp dsDNA to the Dictyostelium 
discoideum mating-type protein MatA 
 
The work described in this appendix concerns a publication arising from the project of a 
previous student in the group (Dr. Katy Hedgethorne), for which further experiments were 
required to respond to a referee’s comments on a previously submitted paper after the 
original student had left.  This work resulted in my becoming an author of the following 
publication:  
 
Hedgethorne, K., Eustermann, S., Yang, J.-C., Ogden, T.E.H., Neuhaus, D., and Bloomfield, 
G. (2017). Homeodomain-like DNA binding proteins control the haploid-to-diploid 
transition in Dictyostelium. Science Advances 3, e1602937. 
 
The slime mould Dictyostelium discoideum is a species of social amoeba found in the soil 
of temperate climates in regions such as North America, Japan and eastern China (Swanson 
et al., 2019). D. discoideum is eukaryotic and unicellular, but as part of its lifecycle, cells 
aggregate to form a multi-cellular “slug” in which cells differentiate into distinct pre-stalk 
and pre-spore cells (Raper et al., 1940). The slug is capable of migration to the surface of 
the soil based on environmental cues and further differentiates upon reaching this point to 
form a fruiting body, in which the 20% of cells that form the stalk will die in an altruistic 
bid to ensure the survival of the remaining 80% (Flowers et al., 2010).   As a unicellular 
eukaryotic organism that nonetheless undergoes differentiation, is easy to manipulate 
genetically and easily grown in the laboratory (Howard et al., 1988), D. discoideum has been 
used as a model organism for many decades and has contributed to our understanding of 
cellular processes such as cell differentiation and chemotaxis (Willard and Devreotes, 2006). 
Its susceptibility to infection by human pathogens including Pseudomonas aeruginosa and 
Legionella pneumophilia has also been useful for studies of host-pathogen interactions 
(Pukatzki, et al., 2002; Solomon et al., 2002).  
However, D. discoideum is also of interest in its own right, due to its ability to 
undergo differential developmental pathways and multiple asexual and sexual lifecycles 
with different ploidy levels in response to differing environmental conditions. The social 
cycle of development described above culminates in the formation of a fruiting body to 
spread spores necessary for asexual reproduction, and all D. discoideum cells remain haploid 
throughout. However, if cells respond to starvation cues in dark humid conditions that are 
not favourable for fruiting body formation, D. discoideum cells can enter another 
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developmental pathway, in which zygotic diploid cells form by mating and (without cell 
division) cannibalise haploid cells to grow into large dormant cells called macrocysts (Filosa 
and Dengler, 1972). During dormancy, macrocysts have been reported to undergo meiosis 
before subsequently releasing haploid progeny, thereby completing the lifecycle (Macinnes 
and Francis, 1974).  Furthermore, D. discoideum has three different mating types (type I, 
type II, and type III) (Bloomfield et al., 2010), with each mating type able to fuse with either 
of the other mating types in a pairwise manner to form a diploid zygote, but not its own type 
(Okamoto et al., 2016). Mating type for individual D. discoideum cells is determined by a 
single genetic locus, containing different genes that specify sexual compatibility of the 
different mating types. Type I cells encode only the gene matA at this locus, type III cells 
encode only the gene matS and type II cells encode the genes matB and matC that are 
homologues of matA and matC respectively (Bloomfield et al., 2010). matA and matB 
encode the 107-amino acid proteins MatA and MatB respectively, and matS encodes the 209 
amino acid protein MatS. None of the genes found at this locus displayed any recognisable 
sequence homology to other known protein families or domains, and homologues of these 
genes have only been detected in the genomes of other closely related dictyostelid species 
(Bloomfield, 2011).  
 Therefore, the work described by Hedgethorne et al. (2017) prior to my involvement 
initially focused on determining the solution structures of the MatA and MatB proteins using 
NMR spectroscopy. In both cases, the small size and hydrophilic natures of these proteins 
made them good candidates for structural study via this method. In both cases, 15N-1H 
HSQC, 13C-1H HSQC, 3D data sets for the purposes of resonance assignment and 15N 
NOESY-HSQC and 13C NOESY HSQC experiments (both with mixing time of 150 ms) 
were collected and following resonance assignment, structure calculations were performed 
using restraints from NOESY spectra as described in the published article. In both cases, 
solution structures revealed that the proteins consisted of a folded core domain composed of 
approximately 50 amino acids flanked by long flexible tail regions, and that this folded core 
was arranged in the form of three a-helices to form a homeodomain-like fold. This suggested 
that MatA controls mating-type function by acting as a transcription factor, binding to DNA 
in order to regulate gene expression at loci that determine type I mating type identity.  
 Therefore, the authors next attempted to establish whether MatA had DNA-binding 
activity in vitro, as would be expected for a transcription factor. In order to do this, they 




MatA protein were added to double-stranded DNA (dsDNA) (Appendix Figure 1A). As the 
specific sequences that MatA binds in vivo are yet to be determined, the authors used a 57bp 
dsDNA oligonucleotide that was previously used in a crystal structure of the S. cerevisiae 
protein Mata2 bound to DNA (Wolberger et al., 1991; pdb 1APL). As the concentration of 
MatA increased, the DNA band observed in the EMSA became more smeared (Appendix 
Figure 1A). This indicated that MatA bound to this oligonucleotide, but most likely in a 
weak, non-specific manner, which could likely be because the oligonucleotide did not 
correspond to the unknown specific MatA recognition sequence found in vivo. After 
overlaying the MatA structural ensemble with the DNA-bound crystal structure of S. 
cerevisiae Mata2, the authors also hypothesised that MatA lysine residues K72 and K76 
could form contacts with DNA. Mutation of these residues was shown to abolish MatA’s 
DNA binding activity (Appendix Figure 1B). This also indicated that, as for other known 
homeodomain proteins, DNA binding activity appeared to be mediated via residues in the 
third a-helix of the homeodomain fold.  
 Work then proceeded to further characterise MatA DNA binding using NMR 
spectroscopy, via mapping of chemical shift perturbations in backbone amides of 15N-
labelled MatA following addition of a 4:1 excess of dsDNA oligonucleotides of varying 
lengths (Appendix Figure 1C). In this case, sequences of DNA from the E. coli expression 
vector pET30a were used as the specific MatA recognition sequence remained unknown. In 
this experiment, several peaks exhibited noticeable chemical shift perturbations upon 
addition of the DNA oligonucleotides, and the CSPs became progressively larger as the 
length of the dsDNA was increased, suggesting that MatA exhibits higher (non-specific) 
affinity for DNA as the sequence length increases. Many of the largest CSP values, such as 
those for residues E69, I75, K76 and N77, were observed for residues that formed part of 
the C-terminal helix of the MatA structure, further supporting the hypothesis of the authors 
that it is this helix that mainly interacts with the DNA. However, the observation of large 
CSPs for residues L32 and L35, located between the N-terminal tail and folded core region, 
also suggested the unconfirmed possibility that DNA-induced conformational changes may 
take place in MatA (Appendix Figure 1D). Later in this project, following initial submission 
of the manuscript, a referee requested follow-up experiments to confirm using NMR 
spectroscopy that MatA weakly interacted with the dsDNA in a manner consistent with fast 
exchange on the NMR timescale. Therefore, I prepared fresh 15N-labelled MatA protein and 
performed and optimised titration experiments with Ji-Chun Yang, in which the protein was 
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titrated with an increasing ratio of the longest 58bp nucleotide and 15N1H HSQC spectra 
were recorded (Appendix Figure 1E). This experiment showed that the system was indeed 
in fast exchange, as increasing the concentration of the DNA increased the size of the CSPs 
smoothly and continuously as more DNA ligand was added; this increase of the size of the 
CSPs with increasing DNA concentration paralleled that seen as a function of increasing 
DNA oligo length in the earlier experiments (Appendix Figure 1C). Under conditions of fast 
exchange, the location of each peak represents an average chemical shift weighted by 
population. Therefore, as the concentration of the ligand increases, the weighting of the 
populations also increases in favour of the complex and the chemical shift perturbation 
increases in size. As the interaction between MatA and the DNA was so weak in this 
experiment, the protein remained unsaturated even at the highest ratio of DNA to protein 
Appendix Figure 1. Studies of MatA binding to DNA using NMR spectroscopy. (A) EMSA experiment 
showing that wild-type MatA binds weakly to a 57bp dsDNA oligonucleotide. (B) Mutation of residues K72 
and K76 to alanine abolishes DNA binding in MatA. (C) Addition of dsDNA (80 µM) to 15N labelled MatA 
(20 µM) causes chemical shift perturbations. (D) Chemical shift perturbations from MatA complex with 29bp 
dsDNA mapped onto the lowest energy structure of the core MatA folded region, showing that the largest 
chemical shift perturbations occur in helix 3 of the homeodomain fold. (E) Titration of MatA (20 µM) with 
increasing amounts of a 58bp dsDNA oligo reveals that MatA DNA binding is in fast exchange on the NMR 
timescale. NMR experiments were performed in 25 mM sodium phosphate (pH 6.0), 50 mM NaCl and 50 
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Fig. 3. Assessing the DNA binding activity of MatA and MatB. (A) EMSA experiments show that adding an increasing concentration of MatA to a dsDNA oligonucleotide
causes the free DNA band to be progressively replaced by a broad smear, indicating (nonspecific) binding (see text). (B) Mutating residues Lys72 and Lys76 to Ala abolishes this
interaction, implicating these residues in themechanismof DNA binding. (C) Addition ofMatB causes a similar pattern to that seen for the addition ofMatA. (D and E) Electrostatic
potential surface of MatA, omitting the tail regions for clarity. The orientation shown in (D) (same as in Fig. 1A) shows the pronounced basic patch resulting from the conserved basic
residues on the surface of helix 3. (F) Adding various lengths of dsDNA to samples of 15N-labeled MatA causes peaks to shift in the 15N-1H HSQC (heteronuclear single-quantum
coherence) NMR spectrum; these CSPs can beplotted as a histogram (G) andmapped as a color ramponto the lowest energy structure ofMatA (H), shown in the sameorientation
as (D). This shows that many of th shifts map t the third h lix, again implicating this r gion in direct interactions with the DNA; Leu32, which is N-terminal to the core folded
domain, is also strongly affected. The NMR experiments used MatA (20 mM) and DNA (80 mM) in 25 mM phosphate (pH 6), 50 mMNaCl, and 50 mM EDTA. ppm, parts per million.
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Fig. 3. Assessing the DNA binding activity of MatA and MatB. (A) EMSA experiments show that adding an increasing concentration of MatA to a dsDNA oligonucleotide
causes the free DNA band to be progressively replac d by a broad smear, indicating (nonspecific) binding (see text). (B) Mut ting residues Lys72 and Lys76 to Ala abolishes this
interaction, implicating these residues in themechanismof DNA binding. (C) Addition ofMatB causes a similar pattern to that seen for the addition ofMatA. (D and E) Electrostatic
potential surface of MatA, omitting the tail regions for clarity. The orientation shown in (D) (same as in Fig. 1A) shows the pronounced basic patch resulting from the conserved basic
residues on the surface of helix 3. (F) Adding various lengths of dsDNA to samples of 15N-labeled MatA causes peaks to shift in the 15N-1H HSQC (heteronuclear single-quantum
coherence) NMR spectrum; these CSPs can beplotted as a histogram (G) andmapped as a color ramponto the lowest energy structure ofMatA (H), shown in the sameorientation
as (D). This shows that many of the shifts map to the third helix, again implicating this region in direct interactions with the DNA; Leu32, which is N-terminal to the core folded
domain, is also strongly affected. The NMR experiments used MatA (20 mM) and DNA (80 mM) in 25 mM phosphate (pH 6), 50 mMNaCl, and 50 mM EDTA. ppm, parts per million.
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fig. S11. CSPs for MatA as a function of added 58-bp DNA concentration. Adding increasing 
amounts of the 58 bp DNA to MatA results in very similar chemical shift perturbations in the [15N-
1H]-HSQC NMR spectrum as those seen as a function of increasing dsDNA length; because the 
binding to this non-cognate DNA is very weak, the protein remains unsaturated even at the highest 
DNA:protein ratio. These experiments employed MatA at 20 μM and 58 bp DNA at 40 μM, 80 μM 
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Fig. 3. Assessing the DNA binding activity of MatA and MatB. (A) EMSA experiments show that adding an increasing concentration of MatA to a dsDNA oligonucleotide
causes the free DNA band to be progressively replaced by a broad smear, indicating (nonspecific) binding (see text). (B) Mutating residu s Lys72 and Lys76 o Ala abolishes this
interaction, implicating these residues in themechanismof DNA binding. (C) Addition ofMatB causes a similar pattern to that seen for the addition ofMatA. (D and E) Electrostatic
potential surface of MatA, omitting the tail regions for clarity. The orientation shown in (D) (same as in Fig. 1A) shows the pronounced basic patch resulting from the conserved basic
residues on the surface of helix 3. (F) Adding various lengths of dsDNA to samples of 15N-labeled MatA causes peaks to shift in the 15N-1H HSQC (heteronuclear single-qua tum
coherence) NMR spectrum; these CSPs can beplotted as a histogram (G) andmapped as a color ramponto the lowest energy structure ofMatA (H), shown in the sameorientation
as (D). This shows that many of the shifts map to the third helix, again implicating this region in direct interactions with the DNA; Leu32, which is N-terminal to the core folded
domain, is also strongly affected. The NMR experime ts used MatA (20 mM) and DNA (80 mM) in 25 mM phosphate (pH 6), 50 mMNaCl, and 50 mM EDTA. ppm, parts per million.
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Fig. 3. Assessing the DNA binding activity of MatA and MatB. (A) EMSA experiments show that adding an increasing concentration of MatA to a dsDNA oligonucleotide
causes the free DNA band to be progressively replaced by a broad smear, indicating (nonspecific) binding (see text). (B) Mutating residues Lys72 and Lys76 to Ala abolishes this
interaction, implicating these residues in themechanismof DNA binding. (C) Addition ofMatB causes a similar pattern to that seen for the addition ofMatA. (D and E) Electrostatic
potential surface of MatA, omitting the tail regions for clarity. The orientation shown in (D) (same as in Fig. 1A) shows the pr nounced basic patch resulting from the conserved basic
residues on the surface of helix 3. (F) Adding various lengths of dsDNA to samples of 15N-labeled MatA causes peaks to shift in the 15N-1H HSQC (heteronuclear single-quantum
coherence) NMR spectrum; these CSPs can beplotted as a histogram (G) andmapped as a color ram onto the lowest ene gy structure ofMatA (H), shown in the sameorientation
as (D). This shows that many of the shifts map to the third helix, again implicating this region in direct interactions with the DNA; Leu32, which is N-terminal to the core folded
domain, is also strongly affected. The NMR experiments used MatA (20 mM) and DNA (80 mM) in 25 mM phosphate (pH 6), 50 mMNaCl, and 50 mM EDTA. ppm, parts per million.
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Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
G655 - - - - - - - - - - - - - - - - - - - - 
T656 - - 61.68 69.41 - - - - - - - - - - - - - - - - 
V657 8.16 123.57 61.58 31.93 8.16 123.61 8.16 123.74 8.17 123.76 8.17 123.75 8.16 123.66 8.16 123.69 8.15 123.54 8.15 123.59 
N658 8.51 125.01 54.73 - 8.51 124.95 8.52 125.22 8.52 125.13 8.53 125.27 8.51 125.07 8.52 125.20 8.51 125.1 8.5 125.06 
P659 - - - 32.5 - - - - - - - - - - - - - - - - 
G660 8.83 111.11 45.02 - 8.79 110.97 8.8 111.09 8.82 111.17 8.81 111.13 8.86 111.26 8.83 111.21 8.86 111.25 8.85 111.27 
T661 7.85 114.01 61.7 69.66 7.82 113.89 7.83 113.97 7.83 113.92 7.83 113.95 7.82 113.85 7.83 113.89 7.82 113.82 7.81 113.84 
K662 8.34 122.71 55.11 33.09 8.30 122.83 8.3 122.96 8.31 122.98 8.31 122.94 8.29 122.92 8.31 123.04 8.28 122.89 8.31 122.94 
S663 8.43 117.59 57.82 62.96 8.46 117.35 8.5 117.76 8.52 117.77 8.51 117.76 8.50 117.71 8.49 117.75 8.45 117.7 8.53 117.77 
K664 9.43 128.53 55.22 31.37 9.40 128.39 9.43 128.65 9.41 128.57 9.42 128.59 9.41 128.53 9.40 128.64 9.47 128.79 9.43 128.57 
L665 8.33 123.65 54.15 40.72 8.32 123.58 8.32 123.57 8.31 123.65 8.32 123.59 8.31 123.64 8.32 123.68 8.3 123.57 8.3 123.45 
P666 - - - - - - - - - - - - - - - - - - - - 
K667 9.29 127.56  - 8.03 118.40 8.05 118.71 9.28 127.5 - - 9.29 127.58 9.29 127.60 - - - - 
P668 - - 65.82 30.49 - - - - - - - - - - - - - - - - 
V669 7.02 115.35 65.23 30.41 7.77 122.42 6.98 115.3 6.99 115.35 6.98 115.33 7.78 122.59 7.78 122.67 7.88 123.66 6.98 115.3 
Q670 7.91 120.07 59.94 27.19 7.87 119.94 7.89 120.18 7.88 120.2 7.88 120.19 7.88 120.22 7.88 120.19 7.88 120.29 7.87 120.2 
D671 8.31,7 117.25 - 39.23 8.31 117.17 8.32 117.4 8.33 117.42 8.32 117.42 8.33 117.40 8.32 117.42 8.36 117.12 8.33 117.4 
L672 7.34 123.32 57.61 40.43 7.31 123.33 7.34 123.7 7.33 123.56 7.33 123.6 7.32 123.53 7.32 123.42 7.37 123.82 7.35 123.71 
I673 8.08 119.7 62.43 - 8.04 119.39 8.05 119.86 8.05 119.69 8.07 119.71 8.06 119.67 8.04 119.58 8.09 119.7 8.01 119.79 
K674 8.1 118.77 59.3 31.38 8.07 118.77 8.05 118.78 8.08 118.83 8.08 118.8 8.06 118.91 8.04 118.71 8.09 118.65 8.03 118.49 
M675 7.45 116.68 58.35 32.97 7.41 116.75 7.37 116.95 7.4 116.82 7.4 116.83 7.41 116.79 7.43 116.70 7.38 116.83 7.37 116.84 
I676 7.94 114.93 63.8 36.44 7.90 114.98 7.95 116.53 7.93 114.92 7.92 115.64 7.93 115.37 7.92 114.26 7.98 115.53 - - 
F677 7.35 118.13 57.85 37.22 7.30 118.10 7.35 117.47 7.35 118.32 7.31 117.82 7.32 117.85 7.31 118.53 7.35 117.76 7.36 117.76 
D678 6.74 119.34 54.46 40.88 6.70 119.19 6.69 119.33 6.71 119.27 6.71 119.31 6.71 119.25 6.69 119.21 6.69 119.17 6.71 119.2 
V679 8.56 129.76 64.79 31.19 8.56 129.84 8.57 129.64 8.57 130.06 8.56 129.79 - - - - - - 8.55 129.91 
E680 8.28 121.59 58.76 27.2 8.26 121.42 8.29 121.56 8.27 121.77 8.28 121.54 8.28 121.46 8.27 121.63 8.28 121.56 8.35 121.5 
S681 7.88 117.22 61.34 62.02 7.85 117.21 7.79 117.47 7.82 117.31 7.81 117.44 7.82 117.37 7.85 117.30 7.77 117.61 7.79 117.55 
M682 7.41 122.81 59.88 32.14 7.36 122.75 7.36 122.91 7.36 122.98 7.37 122.99 7.36 122.90 7.35 123.03 7.37 123.03 7.35 122.82 
K683 7.83 118.46 55.79 28.35 7.84 118.56 7.82 118.47 7.85 118.44 7.82 118.35 7.81 118.44 7.79 118.53 7.85 118.36 7.82 118.17 
K684 8.05 118.89 59.3 31.44 8.01 118.69 8.05 118.78 8.05 118.84 8.04 118.84 8.04 118.79 8.00 118.97 8.13 119.05 8.1 119.02 
A685 7.53 121.42 54.43 16.85 7.49 121.33 7.45 121.4 7.41 121.41 7.47 121.47 7.48 121.37 7.51 121.66 7.43 121.47 7.36 121.15 
M686 7.33 115.01 59.64 32.28 7.29 114.94 7.28 115.24 7.23 114.99 7.29 115.1 7.29 115.10 7.30 115.13 7.26 115.25 7.28 115.05 
V687 8.21 120.47 65.71 30.67 8.19 120.38 8.2 120.45 8.13 120.21 8.2 120.53 8.21 120.53 8.19 120.51 8.28 120.66 8.24 120.72 
E688 8.02 124.22 58.88 28.09 7.99 124.12 8 124.28 8.06 124.43 8 124.26 8.02 124.21 7.99 124.41 8.06 123.79 8.02 123.85 
Y689 7.31 118.04 58.06 37.74 7.30 118.08 7.29 118.19 7.3 118.32 7.29 118.29 7.29 118.05 7.27 118.15 7.31 118.36 7.28 118.2 
E690 7.87 111.12 57.14 25.43 7.83 110.95 7.82 110.84 7.81 111.05 7.81 110.63 7.85 111.10 7.83 110.87 7.8 110.67 7.87 111.25 
I691 7.35 119.09 60.3 36.09 7.32 118.93 7.32 119.08 7.31 118.99 7.3 119.13 7.33 119.01 7.32 119.22 7.31 118.82 7.25 118.64 
D692 7.89 124.74 51.88 39.77 7.86 124.60 7.9 124.86 7.9 124.72 7.86 124.85 7.86 124.80 7.87 124.89 7.88 124.6 7.87 124.72 
L693 8.04 127.97 55.61 40.94 8.03 127.84 8.04 128.08 8.04 128.28 8.05 128.14 8.05 128.16 8.04 128.01 8.05 128.3 8.06 128.24 
Q694 8.08 116.87 57.37 27.36 8.04 116.75 8.05 116.82 8.05 116.66 8.03 116.85 8.05 116.86 8.05 116.88 8.05 116.73 8.06 116.76 
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1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
K695 6.99 118.22 56.75 33.59 6.94 118.10 6.94 118.2 6.92 117.99 6.94 118.15 6.95 118.20 6.92 118.26 6.95 118.19 6.93 118.1 
M696 8.31 121.91 51.98 32.36 8.30 121.79 8.27 121.99 8.33 122.46 8.29 121.97 8.30 121.80 8.28 121.87 8.29 121.98 8.31 121.76 
P697 - - 61.88 31.42 - - - - - - - - - - - - - - - - 
L698 8.15 121.2 57.62 40.24 8.14 121.10 8.13 121.45 8.17 121.28 8.16 121.31 8.14 121.26 8.17 121.39 8.07 121.1 8.13 121.26 
G699 - - 45.44 - - - - - - - - - - - - - - - - - 
K700 7.8 119.41 54.72 32.26 7.76 119.26 7.72 119.22 7.79 119.67 7.76 119.36 7.76 119.29 7.76 119.41 7.75 119.25 7.77 119.35    
L701 7.07 122.73 55.49 41.7 7.03 122.62 7.18 123.21 - - 7.03 122.59 7.04 122.70 7.02 122.69 7.16 122.56 7.19 122.97 
S702 8.02 119.14 55.52 65.85 7.97 119.11 7.97 119.32 - - 7.99 119.07 7.97 119.14 7.98 119.13 8.02 118.4 7.9 118.64 
K703 8.86 125.22 59.99 31.19 8.83 125.12 8.79 125.79 8.67 125.02 8.82 125.13 8.84 125.30 8.85 125.06 8.91 126.45 8.95 126.94 
R704 8.21 118.27 58.58 28.65 8.20 118.14 8.19 117.89 8.2 118.38 8.25 118.29 8.23 118.27 8.23 118.42 8.19 118.16 8.24 118.34 
Q705 7.47 121.34 58.45 27.84 7.44 121.31 7.48 121.3 7.54 121.21 7.47 121.5 7.46 121.52 7.46 121.62 7.44 121.14 7.46 121.56 
I706 7.55 120.04 65.17 37.35 7.53 119.97 7.6 119.59 7.58 119.96 7.55 119.92 7.55 120.15 7.56 120.15 7.59 119.83 7.65 119.58 
Q707 8.48 118.71 59.79 28.16 8.43 118.59 8.48 118.32 8.26 118.55 8.41 118.96 8.45 118.92 8.44 118.72 8.41 118.72 - - 
A708 7.86 121.43 54.3 17.21 7.83 121.34 7.87 122.72 7.74 121.72 7.8 121.81 7.86 121.63 7.85 121.45 7.75 121.7 7.87 121.57 
A709 8.09 124.23 55.01 17.34 8.08 124.23 7.93 123.27 7.98 124.12 8.03 124.19 8.10 124.27 8.09 124.53 8.04 123.69 7.98 123.86 
Y710 8.58 121.07 61.8 37.33 8.55 121.13 8.32 123.03 8.36 119.24 8.41 118.92 8.60 121.53 8.60 121.26 8.5 121.33 8.59 122.71 
S711 7.83 113.78 62.1 - 7.80 113.62 7.83 113.98 7.83 114.33 7.89 113.93 7.84 113.78 7.80 113.54 7.68 113.5 7.92 114.88 
I712 7.76 122.84 63.85 35.94 7.72 122.73 7.53 122.45 7.73 123.11 7.87 123.08 7.72 122.76 7.77 122.83 7.57 122.47 7.46 122.72 
L713/F713 8.06 119.73 57.36 40.35 8.03 119.60 8.01 119.95 8.27 119.97 8.16 120.09 8.04 119.74 8.02 119.83 8.07 119.72 8.12 120.16 
S714 8.32 116.73 62.78 62 8.29 116.69 8.28 116.29 8.32 116.44 8.35 116.97 8.33 116.93 8.34 117.10 8.44 116.94 8.2 115.88 
E715 7.93 124.78 59.82 29.18 7.89 124.65 7.59 123.19 7.84 124.7 7.86 124.85 7.90 124.82 7.93 125.11 7.89 124.91 7.67 123.81 
V716 8.82 123.49 66.28 30.29 8.79 123.45 8.52 121.93 8.78 123.18 8.85 123.31 8.82 123.52 8.81 123.73 8.81 123.32 8.76 123.09 
Q717 8.16 119.57 58.38 27.59 8.14 119.42 7.83 118.47 8.21 119.72 8.18 119.93 8.20 119.63 8.22 119.63 8.31 119.8 8.33 119.73 
Q718 7.59 119.63 58.28 27.63 7.56 119.51 7.7 119.68 8.02 119.49 7.59 119.57 7.57 119.70 7.57 119.80 7.65 119.53 7.56 119.57 
A719 8 123.76 54.54 17.21 7.96 123.65 7.91 123.52 7.96 123.8 7.97 123.88 7.96 123.87 7.97 123.94 7.96 123.74 7.96 123.85 
V720 8.67 118.76 64.97 30.81 8.64 118.73 8.38 118.95 8.64 118.57 8.67 118.88 8.67 118.86 8.68 118.84 8.7 119.29 8.66 118.98 
S721 7.92 116.31 60.89 62.65 7.89 116.25 7.87 116.64 7.93 116.52 7.92 116.5 7.93 116.50 7.91 116.44 8.11 116.77 7.93 116.51 
Q722 7.82 118.34 55.66 28.33 7.80 118.16 7.78 118.56 7.82 118.41 7.82 118.35 7.81 118.27 7.81 118.23 7.85 118.31 7.83 118.18 
G723 7.62 109.38 45.69 - 7.58 109.34 7.64 109.23 7.59 109.34 7.59 109.43 7.60 109.42 7.60 109.44 7.6 109.37 7.6 109.5 
S724 8.14 116.1 58.42 63.15 8.12 116.04 8.11 116 8.14 116.15 8.13 116.13 8.12 116.11 8.12 116.11 8.12 116.08 8.11 116.21 
S725 8.45 117.34 57.23 64.1 8.45 117.42 8.44 117.47 8.46 117.42 8.46 117.45 8.45 117.40 8.46 117.48 8.45 117.36 8.44 117.37 
D726 8.68 123.02 57.17 39.4 8.67 119.97 8.63 123.1 8.68 122.99 8.68 123.04 8.69 122.87 8.66 122.95 8.69 122.99 8.69 123 
S727 8.37 115.73 61.04 61.74 8.35 115.76 8.34 115.63 8.35 115.75 8.35 115.7 8.35 115.77 8.36 115.85 8.37 115.62 8.38 115.53 
Q728 7.62 123.73 58.26 27.78 7.59 123.70 7.63 123.67 7.6 123.87 7.59 123.88 7.60 123.86 7.59 123.84 7.58 123.83 7.59 123.84 
I729 7.8 120.03 62.99 35.74 7.78 119.99 7.81 119.89 7.79 120.26 7.79 120.08 7.79 120.12 7.80 120.13 7.77 120.14 7.76 119.99 
L730 8.34 125.86 58.33 40.45 8.30 125.68 8.29 126.11 8.27 125.5 8.32 125.86 8.31 125.72 8.32 125.88 8.33 125.66 8.3 125.46 
D731 7.65 119.35 57.44 40.72 7.58 119.60 7.69 119.69 7.64 119.19 7.63 119.29 7.63 119.22 7.63 119.30 7.62 119.18 7.61 119.15 
L732 8.03 119.1 57.93 41.75 8.00 118.98 7.98 119.46 8.01 119.38 8 119.01 8.01 118.97 8.00 118.82 7.94 119.08 7.92 119.09 
S733 8.15 115.26 62.46 - 8.12 115.13 8.13 115.55 8.12 115.64 8.15 115.49 8.15 115.47 8.14 115.45 8.21 115.54 8.21 115.37 
N734 8.53 119.14 55.7 36.98 8.51 118.99 8.58 119.52 8.56 119.84 8.52 119.28 8.53 119.17 8.52 119.20 8.52 119.05 8.52 119.06 
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1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
R735 8.3 122.14 59.69 29.29 8.27 122.09 8.15 122.28 8.3 122.29 8.27 122.14 8.35 122.47 8.35 122.52 8.22 122.37 8.33 122.47 
F736 8.24 122.87 63.04 38.13 8.21 122.79 8.05 122.77 8.31 122.61 8.22 122.98 8.22 122.93 8.21 123.01 8.24 123.13 8.24 122.79 
Y737 8.05 115.86 58.46 36.5 8.02 115.79 7.94 115.91 8.13 116.13 8.06 116.13 8.02 115.94 8.02 115.91 8.06 116.26 8.02 116.08 
T738 7.7 115.91 65.23 68.46 7.66 115.91 7.6 115.81 7.68 116 7.66 115.95 7.67 116.04 7.67 116.07 7.66 115.94 7.65 115.94 
L739 7.14 123.1 56.72 42.06 7.10 122.94 7.19 123.38 7.21 123.47 7.12 123.44 7.11 123.03 7.11 123.13 7.07 122.96 7.09 122.75 
I740 7.67 117.3 54.99 34.62 7.64 117.13 7.57 117.09 7.74 117.44 7.64 116.73 7.62 117.33 7.66 117.15 7.65 117.07 7.53 117.21 
P741 - - 63.15 31.44 - - - - - - - - - - - - - - - - 
H742 8.88 123.59 54.04 32.3 8.86 123.55 8.88 123.5 9.22 124.27 8.85 123.66 8.93 123.73 8.88 123.68 8.98 123.72 - - 
D743 8.53 122.01 51.93 40.13 8.51 121.97 8.48 121.85 8.44 121.86 8.5 121.89 8.52 121.86 8.49 121.97 8.47 121.85 8.51 121.94 
F744 8.35 123.2 57.16 38.49 8.36 123.13 8.39 123.02 8.41 123.21 8.37 123.37 8.37 123.25 8.38 123.36 8.4 123.23 8.37 123.29 
G745 8.57 111.48 46.9 - 8.54 111.44 8.53 111.49 8.57 111.83 8.56 111.6 8.56 111.55 8.56 111.56 8.55 111.48 8.56 111.57 
M746 - - 55.04 31.37 8.85 125.50 - - 8.93 124.68 - - -       - - -   8.9 125.22 - - 
K747 7.71 121.27 55.52 32.29 7.68 121.17 7.69 121.33 7.67 121.44 7.68 121.29 7.68 121.17 7.68 121.29 7.66 121.15 7.67 121.14 
K748 8.02 122.52 53.57 30.76 8.02 122.46 8.04 122.68 8.03 122.7 8.04 122.66 8.04 122.58 8.03 122.80 8.03 122.54 8.03 122.47 
P749 - - - - - - - - - - - - - - - - - - - - 
P750 - - 61.88 31.06 - - - - - - - - - - - - - - - - 
L751 8.26 124.2 54.26 42.05 8.26 124.25 8.3 124.03 8.26 124.34 8.26 124.28 8.27 124.52 8.27 124.40 8.28 124.67 8.26 124.76 
L752 7.78 123.49 52.41 38.3 7.77 123.49 7.69 122.28 7.75 124.03 7.78 123.76 7.78 123.95 7.78 123.65 7.75 124.49 7.7 124.53 
N753 7.23 114.17 51.15 38.54 7.19 114.09 7.44 114.03 7.22 114.6 7.2 114.34 7.20 114.33 7.19 114.33 7.21 114.51 7.24 114.32 
N754 7.35 113.07 51.56 39.92 7.31 112.98 7.28 115.13 7.32 113.34 7.32 113.08 7.31 112.84 7.33 113.08 7.29 112.34 7.3 112.77 
A755 8.87 124.24 54.74 17.58 8.85 124.25 8.81 125.94 8.95 124.78 8.89 124.5 8.90 124.42 8.87 124.40 8.95 124.7 8.89 124.37 
D756 8.26 118.76 57.03 39.38 8.24 118.67 8.21 118.51 8.28 118.99 8.27 118.91 8.27 119.02 8.26 118.92 8.25 118.84 8.25 118.85 
S757 8.15 117.4 61.52 62.33 8.13 117.35 8.1 117.34 8.15 117.48 8.15 117.71 8.18 117.71 8.15 117.65 8.2 117.66 8.27 118.17 
V758 7.26 122.55 66.68 30.37 7.23 122.47 7.51 121.88 7.21 122.35 7.23 122.45 7.27 122.67 7.25 122.60 7.27 122.78 7.32 122.68 
Q759 7.94 118.81 58.59 27.06 7.92 118.73 7.98 119.45 7.97 119.36 7.99 119.01 7.90 118.76 7.96 118.94 8.04 119.06 7.96 118.84 
A760 7.98 121.21 54.6 17.48 7.94 121.01 7.7 120.87 7.98 121.01 7.94 121.13 7.95 121.08 7.97 121.05 7.9 120.58 7.82 120.9 
K761 7.9 116.29 56 30.39 7.87 116.23 7.81 117.53 7.75 116.77 7.84 116.54 7.84 116.61 7.82 116.13 7.77 116.99 7.84 117.62 
A762 8.43 125.33 55.54 15.73 8.39 125.31 8.11 124.31 8.39 124.05 8.48 126.19 8.43 125.21 8.37 125.42 8.49 125.66 8.36 125.35 
E763 7.64 117.22 58.93 28.44 7.67 117.34 7.63 118.23 7.95 118.98 7.77 118.35 7.70 117.47 7.65 117.14 7.65 119.18 7.65 116.98 
M764 7.28 119.15 58.79 31.27 7.24 119.01 7.35 119.36 7.39 119.71 7.33 119.14 7.30 119.63 7.20 119.45 7.28 119.46 7.29 120.11 
L765/F765/A765 8.05 120.94 57.93 39.84 8.01 120.70 7.91 120.16 7.96 118.98 8.09 123.78 8.01 120.92 7.94 121.18 8.03 120.78 8.07 121 
D766 8.53 119.94 56.97 39.6 8.48 119.83 8.06 119.52 8.22 121.46 8.44 118.03 8.50 119.98 8.56 120.48 8.46 120.01 8.45 120.06 
N767 7.51 117.82 55.5 38.27 7.46 117.84 7.69 118.3 7.33 117.29 7.59 118.43 7.45 117.96 7.30 117.21 7.63 118.37 7.62 117.32 
L768 8.71 121.45 57.66 40.06 8.70 121.19 8.87 121.84 8.78 120.85 8.8 120.95 8.74 121.39 8.60 120.55 8.93 120.7 8.75 121.74 
L769 8.61 120.21 58.22 41.03 8.60 120.12 8.61 120.44 8.49 119.97 8.61 120.29 8.65 120.33 8.63 120.18 8.54 120.63 8.44 120.07 
D770 7.03 118.96 57.69 39.97 6.99 119.14 7.14 119.91 6.99 119.78 7.05 119.4 6.94 119.17 7.11 117.94 7.15 120.11 6.85 118.93 
I771 8.37 127.83 65.92 37.1 8.39 127.94 8.46 128.2 8.33 128.24 8.45 128.16 8.36 128.21 8.56 128.46 8.7 129.21 - - 
E772 8.57 121.66 60.64 26.96 8.56 121.60 8.5 121.83 8.42 121.37 8.55 121.72 8.57 121.53 8.62 121.62 8.61 122.48 8.58 121.94 
V773 7.46 119.02 65.9 30.53 7.41 118.87 7.53 119.6 7.42 119.59 7.43 119.14 7.49 119.20 7.34 118.67 7.61 119.88 7.42 119.72 
A774 7.86 122.68 55.34 18.12 7.82 122.82 7.81 122.84 7.86 123.05 7.82 122.82 - - - - - - 7.65 123.7 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
Y775 9.09 118.42 62.33 37.35 9.06 118.34 9.13 118.6 9.03 118.32 9.1 118.57 9.12 118.72 9.04 118.48 9.25 118.74 9.32 119.4 
S776 8.63 115.68 61.5 62.22 8.61 115.53 8.7 115.68 8.5 115.61 8.67 115.72 8.64 115.67 8.59 115.69 8.68 115.72 8.81 115.64 
L777 8.02 123.29 56.91 41.31 7.91 122.90 7.99 123.49 8.02 123.27 8 123.49 7.94 123.16 7.85 122.98 7.98 123.1 7.85 123.7 
L778 7.8 120.36 56.72 41.33 7.78 120.27 7.77 120.48 7.8 120.19 7.79 120.47 7.81 120.44 7.76 120.33 7.78 120.24 7.74 120.49 
R779 7.66 117.56 56.32 28.98 7.64 117.42 7.69 117.47 7.62 117.56 7.66 117.58 7.66 117.49 7.65 117.76 7.62 117.44 7.69 117.64 
G780 7.63 108.56 45.1 - 7.60 108.48 7.61 108.67 7.62 108.72 7.61 108.63 7.60 108.54 7.62 108.58 7.6 108.51 7.58 108.61 
G781 7.88 108.35 44.74 - 7.86 108.21 7.86 108.32 7.89 108.3 7.87 108.28 7.88 108.22 7.87 108.23 7.83 108.09 7.85 108.2 
S782 8.15 115.79 57.3 63.45 8.14 115.66 8.13 115.64 8.14 115.66 8.15 115.72 8.15 115.71 8.17 115.76 8.13 115.6 8.13 115.61 
D783 8.33 123.45 54.14 40.61 8.31 123.46 8.29 123.52 8.32 123.65 8.32 123.57 8.32 123.64 8.33 123.54 8.31 123.56 8.31 123.51 
D784 8.05 121.15 53.21 40.58 8.03 121.03 8.03 121.08 8.04 121.18 8.04 121.13 8.04 121.16 8.04 121.12 8.02 121.01 8.03 121.11 
S785 8.47 119.99 59.16 63.07 8.46 120.01 8.47 120.16 8.45 120.11 - - 8.52 120.37 8.45 120.09 8.46 120.33 8.45 120.35 
S786 8.56 117.87 58.91 63.3 8.53 117.70 8.54 117.85 8.54 117.86 8.53 117.82 8.55 117.84 8.54 117.84 8.55 117.82 8.55 117.82 
K787 7.33 122.7 54.96 33.83 7.29 122.65 7.28 122.76 7.3 122.79 7.29 122.79 7.29 122.76 7.29 122.89 7.27 122.64 7.29 122.72 
N788 8.84 126.05 52.19 42.68 8.80 125.96 8.84 126.23 8.85 126.22 8.85 126.24 8.86 126.16 8.85 126.21 8.84 126.2 8.84 126.08 
P789 - - 64.89 31.72 - - - - - - - - - - - - - - - - 
I790 8.81 118.43 63.65 36.22 8.76 118.22 8.78 118.33 8.78 118.31 8.78 118.33 8.80 118.34 8.79 118.36 8.8 118.26 8.8 118.31 
D791 7.23 121.55 57.11 39.15 7.18 121.35 7.19 121.71 7.18 121.56 7.18 121.62 7.18 121.58 7.18 121.53 7.17 121.75 7.23 121.8 
V792 7.69 121.45 65.63 31.06 7.65 121.35 7.63 121.67 7.68 121.64 7.68 121.54 7.65 121.55 7.66 121.54 7.64 121.61 7.63 121.58 
N793 7.85 119.15 55.3 35.81 7.83 119.01 7.86 119.26 7.85 119.27 7.86 119.26 7.85 119.25 7.83 119.29 7.86 119.37 7.89 119.26 
Y794 8.39 119.59 61.19 38.18 8.36 119.51 8.37 119.59 8.37 119.65 8.38 119.69 8.38 119.78 8.37 119.64 8.35 119.46 8.43 120.4 
E795 8.18 121.26 59.03 28.45 8.15 121.11 8.1 121.22 8.14 121.28 8.16 121.32 8.15 121.27 8.18 121.40 8.1 121.25 8.04 120.58 
K796 7.45 117.59 57.95 32.22 7.39 117.47 7.42 117.59 7.44 117.71 7.42 117.67 7.42 117.71 7.42 117.83 7.46 117.65 7.45 117.69 
L797 7.3 114.09 55.19 40.76 7.25 113.92 7.24 114.14 7.26 114.18 7.25 114.12 7.26 114.07 7.28 114.23 7.23 114.51 7.31 114.18 
K798 7.39 114.79 56.54 29.08 7.36 114.71 7.39 114.86 7.39 114.88 7.39 114.89 7.38 114.87 7.37 114.99 7.41 114.86 7.38 114.91 
T799 8.23 114.82 61.79 72.36 8.20 114.69 8.23 114.98 8.23 114.88 8.23 114.92 8.24 114.96 8.22 114.84 8.23 114.95 8.23 115.02 
D800 8.17 128.37 53.91 42.22 8.12 128.25 8.15 128.58 8.14 128.52 8.14 128.52 8.15 128.45 8.13 128.46 8.18 128.73 8.1 128.38 
I801 7.95 126.4 61.2 38.31 7.92 126.31 7.96 126.37 7.93 126.41 7.94 126.44 7.91 126.41 7.92 126.39 7.98 126.35 7.91 126.55 
K802 8.67 126.29 53.45 35.48 8.59 125.92 8.64 126.35 8.64 126.32 8.63 126.33 8.64 126.29 8.62 126.41 8.65 126.29 8.63 126.25 
V803 9.04 123.93 62.82 31.5 9.04 123.80 9.05 123.95 9.06 124.02 9.05 123.99 9.05 124.02 9.06 124.10 9.05 123.99 9.04 123.95 
V804 8.53 131.43 61.7 31.05 8.53 131.51 8.49 131.57 8.53 131.66 8.52 131.64 8.53 131.62 8.55 131.66 8.47 131.51 8.48 131.52 
D805 8.65 128.58 54.6 41.38 8.65 128.50 8.65 128.83 8.66 128.8 8.66 128.81 8.66 128.76 8.66 128.72 8.64 128.9 8.65 128.79 
R806 8.65 127.24 58.66 29.14 8.65 127.26 8.66 127.38 8.67 127.45 8.66 127.48 8.67 127.47 8.67 127.53 8.66 127.28 8.66 127.42 
D807 8.37 117.91 53.32 39.98 8.34 117.80 8.34 117.89 8.34 117.93 8.34 117.95 8.35 118.00 8.36 117.99 8.35 117.84 8.35 117.96 
S808 7.52 115.71 - 65.72 7.49 115.67 7.5 115.82 7.5 115.82 7.5 115.82 7.50 115.75 7.50 115.77 7.52 115.74 7.5 115.75 
E809 8.86 124.11 57.75 28.58 8.84 123.85 8.85 124.05 8.86 124.08 8.86 124.06 8.87 124.06 8.87 124.09 8.86 124.03 8.86 124.05 
E810 8.51 118.28 59.23 28.87 8.51 118.23 8.48 118.4 8.51 118.44 8.51 118.44 8.52 118.45 8.54 118.42 8.47 118.56 8.5 118.49 
A811 7.28 119.97 54.6 17.95 7.25 119.93 7.25 119.96 7.25 120.03 7.25 120.03 7.25 120.05 7.26 120.09 7.26 119.89 7.25 120.02 
E812 7.64 118.71 58.97 28.19 7.59 118.58 7.6 118.78 7.61 118.77 7.61 118.75 7.61 118.78 7.63 118.76 7.61 118.85 7.6 118.76 
I813 7.89 120.73 64.69 37.13 7.85 120.72 7.89 120.94 7.88 120.92 7.89 120.95 7.89 120.90 7.88 120.86 7.91 120.9 7.89 120.86 
I814 7.59 120.27 65.36 36.68 7.56 120.16 7.57 120.33 7.58 120.36 7.57 120.31 7.58 120.38 7.59 120.43 7.57 120.27 7.57 120.34 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
R815 8.7 118.59 60.94 29.92 8.67 118.41 8.69 118.71 8.69 118.69 8.7 118.82 8.68 118.72 8.69 118.66 8.7 118.77 8.69 118.72 
K816 8.05 122.14 59.57 31.41 8.07 122.17 8.04 122.37 8.11 122.33 8.07 122.29 8.05 122.24 8.05 122.36 8.07 122.25 8.03 122.22 
Y817 8.31 122.76 56.92 37.31 8.27 122.59 8.29 122.91 8.28 122.64 8.28 122.59 8.29 122.71 8.32 122.97 8.29 122.73 8.27 122.8 
V818 8.28 119.92 65.79 31.03 8.24 119.86 8.22 119.92 8.25 120.01 8.24 120 8.26 120.08 8.27 120.07 8.25 120.04 8.23 119.97 
K819 8.02 117.72 58.48 31.91 7.98 117.59 7.96 117.7 7.98 117.73 7.98 117.74 7.96 117.57 8.00 117.83 7.95 117.68 7.99 117.71 
N820 9.1 115.92 54.36 37.41 9.06 115.70 9.05 115.81 9.07 115.87 9.07 115.87 9.08 115.90 9.11 116.02 9.03 115.83 9.08 115.84 
T821 7.33 106.22 61.47 69.44 7.28 106.15 7.27 106.56 7.28 106.29 7.28 106.32 7.28 106.31 7.30 106.02 7.26 106.73 7.28 106.33 
H822 7.01 120.65 55.26 30.24 6.96 120.57 6.88 120.69 6.92 120.75 6.92 120.65 6.88 120.58 6.98 120.46 6.81 120.82 6.9 120.65 
A823 - - - - - - - - - - - - - - - - - - - - 
T824 - - - - - - - - - - - - - - - - - - - - 
T825 - - - - - - - - - - - - - - - - - - - - 
T826 - - - - - - - - - - - - - - - - - - - - 
T827 - - - - - - - - - - - - - - - - - - - - 
A828 8.35 122.89 52.4 18.42 8.34 122.85 - - 8.34 122.7 8.34 122.7 8.32 122.93 8.36 122.92 8.31 121.97 8.37 122.85 
Y829 6.82 112.07 54.55 38.66 6.79 111.89 6.77 111.75 6.78 111.89 6.79 111.88 6.73 111.70 6.76 112.01 6.72 111.29 6.77 111.84 
D830 8.17 119.88 52.21 43.32 8.13 119.76 8.07 119.51 8.09 119.66 8.09 119.73 8.09 119.68 8.14 120.08 8.03 119.07 8.07 119.72 
L831 8.53 121.26 53.09 44.55 8.56 121.08 - - - - 8.59 121.08 8.56 121.47 8.55 120.28 8.8 120.88 8.62 121.5 
E832 8.5 122.56 53.7 32.37 8.47 122.49 8.49 122.54 8.48 122.67 8.49 122.64 8.47 122.62 8.49 122.76 8.5 122.41 8.5 122.61 
V833 9 126.16 63.03 30.44 9.00 126.13 9 126.34 9.01 126.39 9.01 126.39 9.00 126.41 9.02 126.47 8.97 126.34 9 126.44 
I834 8.86 129.85 62.17 36.87 8.84 129.79 8.83 129.93 8.86 129.97 8.85 129.95 8.84 129.86 8.85 129.92 8.8 129.81 8.81 129.82 
D835 7.14 114.84 53.52 47.63 7.10 114.72 7.09 114.96 7.11 114.98 7.11 115 7.10 114.99 7.12 114.94 7.07 114.83 7.09 114.97 
I836 8.49 119.87 60.49 39.82 8.48 120.11 8.48 120 8.47 120.2 8.48 120.1 8.47 120.22 8.47 120.16 8.45 120.33 8.46 120 
F837 9.29 124.18 54.97 39.68 9.26 123.84 9.24 124.07 9.28 123.84 9.27 123.97 9.26 123.76 9.30 123.79 9.23 124.13 9.25 123.6 
K838 9.53 126.91 55.09 33.31 9.49 126.80 9.47 126.97 9.49 127.01 9.49 126.97 9.49 126.97 9.51 127.11 9.48 126.98 9.48 126.96 
I839 7.72 120.59 57.77 40.57 7.67 120.60 7.73 120.46 7.71 120.59 7.7 120.6 7.70 120.56 7.71 120.66 7.74 120.49 7.71 120.63 
E840 8.01 120.46 54.67 30.91 7.97 120.22 7.96 120.06 7.97 120.29 7.97 120.29 7.97 120.26 7.97 120.35 7.96 119.94 7.97 120.13 
R841 9.55 131.61 56.84 29.8 9.53 131.83 9.58 132.03 9.56 131.97 9.56 131.98 9.56 131.94 9.57 131.95 9.58 132.07 9.62 131.89 
E842 8.72 128.43 58.37 28.64 8.68 128.27 8.71 128.55 8.73 128.6 8.71 128.55 8.72 128.52 8.70 128.48 8.78 128.73 8.69 128.36 
G843 9 115.1 45.66 - 8.99 115.04 9.01 115.22 9.02 115.21 9.02 115.21 9.02 115.22 9.01 115.24 9 115.18 9.02 115.27 
E844 7.67 125.06 60.08 31.41 7.62 124.85 7.63 125.02 7.64 125.08 7.63 125.04 7.63 125.03 7.63 125.03 7.66 125.15 7.61 124.96 
C845 8.99 118.58 62.54 25.58 8.94 118.64 8.99 118.65 8.98 118.68 8.98 118.72 8.99 118.68 8.99 118.77 8.99 118.51 8.97 118.68 
Q846 8.29 120.06 58.55 27.01 8.31 120.16 8.31 120.16 8.31 120.19 8.32 120.16 8.32 120.10 8.37 120.24 8.28 120.25 8.31 119.92 
R847 7.44 120.79 58.02 29.71 7.42 120.89 7.4 120.76 7.42 120.85 7.41 120.86 7.42 120.83 7.43 120.84 7.44 120.89 7.41 120.44 
Y848 8.03 118.61 57.7 39.16 7.98 118.41 8.04 118.79 8.03 118.78 8.04 118.79 8.05 118.63 7.97 118.70 8.05 118.75 8.04 118.95 
K849 7.11 118.42 61.04 29.81 7.09 118.23 7.08 118.63 7.08 118.55 7.09 118.56 7.08 118.46 7.08 118.35 7.08 118.72 7.08 118.47 
P850 - - - 29.86 - - - - - - - - - - - - - - - - 
F851 8.03 116.24 59.62 37.74 7.98 116.23 7.98 116.34 8 116.31 8 116.32 8.00 116.08 8.03 116.14 7.95 116.05 7.98 116.06 
K852 7.23 120.4 57.62 31.27 7.18 120.29 7.17 120.38 7.18 120.42 7.18 120.43 7.18 120.32 7.21 120.40 7.18 120.34 7.2 120.3 
Q853 6.86 111.22 54.32 28.25 6.84 111.00 6.87 111.23 6.86 111.18 6.86 111.19 6.85 111.19 6.84 111.30 6.85 111.16 6.84 111.17 
L854 7.45 124.45 54.9 41.61 7.41 124.47 7.42 124.36 7.42 124.53 7.43 124.51 7.42 124.43 7.42 124.53 7.42 123.99 7.45 124.55 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
H855 7.66 119.07 54.88 30.23 7.63 119.04 7.64 119.04 7.65 118.65 7.67 118.63 7.63 118.97 7.66 118.78 7.65 118.79 7.63 118.83 
N856 8.52 113.22 53.16 36.24 8.51 113.12 8.51 113.23 8.52 113.26 8.52 113.25 8.51 113.29 8.52 113.35 8.49 113.2 8.5 113.25 
R857 7.9 119.24 54.85 29.62 7.88 119.06 7.86 119.26 7.87 119.27 7.86 119.26 7.88 119.27 7.87 119.30 7.83 119.21 7.84 119.27 
R858 8.32 122.35 53.62 34.47 8.30 122.27 - - 8.27 122.28 8.27 122.21 8.27 122.29 8.28 122.31 8.2 122.73 8.27 122.93 
L859 7.99 125.5 53 41.86 7.96 125.41 7.98 125.76 7.97 125.66 7.97 125.67 7.96 125.74 7.96 125.50 8.01 125.96 7.95 125.75 
L860 8.67 126.45 53.01 45.71 8.63 126.46 8.64 126.53 8.64 126.56 8.63 126.63 8.63 126.91 8.65 126.63 8.63 126.99 8.64 126.97 
W861 8.51 119.89 55.85 32.2 8.49 119.95 8.48 120.01 8.51 119.99 8.49 119.97 8.52 119.96 8.5 119.94 8.47 120.01 - - 
H862 8.9 118.32 56.75 31.02 8.84 118.35 8.79 118.45 8.83 118.63 8.82 118.65 8.72 116.93 8.87 116.92 8.81 116.43 - - 
G863 8.12 115.47 43.52 - 8.31 111.88 8.41 110.26 - - 8.15 115.48 8.42 110.23 8.41 110.23 8.41 110.2 - - 
S864 7.25 111.72 57.68 64.01 7.23 111.63 7.24 111.62 7.2 111.59 7.21 111.56 7.25 111.51 7.34 113.52 7.15 112.36 - - 
R865 7.86 121.88 56.69 30.21 7.80 121.87 7.79 121.94 7.72 121.9 7.8 122.03 7.81 121.85 7.71 122.41 7.54 121.96 7.65 120.87 
T866 9.24 119.18 66.75 67.94 9.23 119.26 9.25 119.78 9.29 120.01 9.25 119.66 9.23 119.41 9.35 120.29 9.28 120.59 9.2 119.39 
T867 7.28 107.36 62.72 67.98 7.25 107.26 7.33 107.54 7.29 107.17 7.31 107.41 7.29 107.32 7.27 107.43 7.44 107.25 7.38 107.38 
N868 7.88 118.6 53.88 38.29 7.83 118.42 7.82 118.43 7.88 118.53 7.74 118.5 7.89 118.74 7.82 118.28 7.83 118.01 7.85 117.93 
F869 7.75 118.29 63.74 38.94 7.62 118.25 7.72 118.91 7.64 118.75 7.58 118.43 7.65 118.51 7.64 118.77 7.73 119.04 7.69 118.96 
A870 9.36 125.93 55.19 15.63 9.31 125.90 9.18 126 9.34 126 9.27 126.12 9.24 126.10 9.48 126.09 9.11 125.96 9.23 126.1 
G871 8.78 109.8 46.25 -   8.77 109.93 8.81 110.14 8.74 109.87 8.8 110.19 8.76 110.01 8.78 109.49 8.86 110.19 8.81 110.02 
I872 8.08 122.28 64.68 37.15 8.04 122.32 8.14 122.39 8.06 122.4 8.05 122.38 8.06 122.13 8.2 122.44 8.33 122.64 - - 
L873 8.5 116.69 57.62 39.36 8.48 116.93 8.5 116.91 8.52 117.05 8.52 116.91 8.50 116.89 8.51 116.86 8.54 117.67 - - 
S874 7.84 112.7 61.24 63.24 7.81 112.67 7.88 113.06 7.81 112.83 7.84 112.93 7.80 112.84 7.8 112.82 7.89 112.8 - - 
Q875 8.33 117.82 55.29 28.98 8.29 117.70 8.29 118.06 8.33 117.82 8.3 117.92 8.32 117.96 8.31 117.42 8.34 117.37 - - 
G876 7.73 114.27 44.03 - 7.69 114.28 7.79 114.39 7.81 114.46 7.75 114.44 7.76 114.50 7.66 114.63 7.91 114.44 7.73 114.07 
L877 8.55 117.86 54.88 39.63 8.54 117.68 8.45 117.53 8.55 117.71 8.54 117.85 8.55 118.03 8.47 118.62 8.42 117.88 8.56 118.21 
R878 8.54 124.98 54.55 32.92 8.53 125.16 8.52 125.25 8.49 125.17 8.5 125.23 - - 7.92 127.46 8.43 126.23 - - 
I879 7.47 119.65 59.86 38.09 7.46 119.62 7.64 120.47 7.59 120.08 7.55 120.11 7.53 120.11 6.89 114.56 7.63 120.42 - - 
A880 8.17 131.05 50.73 16.1 8.15 130.66 8.08 130.95 8.22 131.76 8.24 131.99 8.15 131.45 7.74 129.39 8.38 132 8.3 131.75 
P881 - - - - - - - - - - - - - - - - - - - - 
P882 - - 65.17 31.08 - - - - - - - - - - - - - - - - 
E883 9.22 114.18 58.45 28.81 9.17 114.04 8.96 113.76 9.17 114.05 9.25 114.1 9.18 114.26 9.24 114.37 9.25 114.13 9.22 114.37 
A884 7.3 120.1 49.61 17.8 7.27 120.04 7.23 121.03 7.03 120.48 7.18 120.44 7.17 119.94 7.3 120.40 7.03 120.61 7.01 119.93 
P885 - - 61.75 30.39 - - - - - - - - - - - - - - - - 
V886 8.93 124.72 64.64 30.58   8.93 124.60 9.09 125.21 8.9 125.46 8.88 124.78 8.82 123.05 9.05 125.90 - - 8.86 123.32 
T887 7.27 107.67 62.31 67.91 7.25 107.35 7.21 108.49 7.26 109.48 7.29 109.47 7.23 109.63 7.35 107.16 - - - - 
G888 7.9 108.5 44.79 - 7.89 108.50 7.88 108.81 8.08 108.9 8.02 109.2 8.03 109.26 7.9 108.08 8.53 113.97 8.01 108.78 
Y889 7.03 117.49 56.55 39.98 7.00 117.49 7.2 118.93 7.16 119.07 7.1 118.23 7.22 118.34 7.02 117.58 7.19 116.65 7.38 116.47 
M890 9.19 126.51 59.55 32.77 9.19 126.48 - - - - 9.23 126.1 9.69 126.73 9.29 127.60 9.36 128.31 - - 
F891 8.59 113.27 56.39 38.61 8.57 113.25 8.46 114.22 8.47 113.91 8.41 113.97 8.31 113.44 8.71 113.15 7.97 114.03 - - 
G892 7.82 105.25 43.64 - 7.78 105.19 7.7 105.42 7.73 105.36 7.76 105.39 7.74 104.83 7.83 104.98 7.38 104.77 7.68 105.05 
K893 8.99 121.88 56.98 28.8 8.96 120.74 8.98 121.97 8.94 121.97 8.93 121.79 8.83 121.60 8.98 121.76 8.7 121.15 8.81 121.65 
G894 6.97 111.17 43.5 - 6.93 111.27 6.87 111.32 6.89 111.38 6.9 111.45 6.76 110.90 6.72 112.68 6.78 111.05 6.79 111.55 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
I895 8.57 122.01 60.65 37.62 8.51 121.84 8.54 122.05 8.39 122.25 8.48 121.88 8.51 121.92 8.3 121.56 - - - - 
Y896 8.63 127.63 57.77 38.13 8.64 127.64 8.72 127.86 8.62 127.66 8.64 127.59 8.43 127.08 8.18 128.14 8.79 127.74 - - 
F897 9.85 121.37 56.69 45.03 9.81 121.23 9.82 121.24 9.81 121.2 9.79 121.22 10.34 118.44 10.22 118.26 9.98 117.79 10.47 118.02 
A898 9.1 124.65 51.13 22.31 9.02 124.61 9.07 117.24 8.96 124.35 8.99 124.49 - - 9.05 125.93 9.16 120.66 - - 
N899 9.07 117.46 52.8 42.75 9.02 117.31 9.08 117.51 9.11 117.43 9.03 117.2 9.02 116.71 9.03 117.12 8.96 116.63 8.95 116.65 
M900 7.07 113.34 53.86 33.72 7.05 113.20 7.06 113.33 7.08 113.54 7.09 113.25 7.10 113.45 7.17 113.59 - - - - 
V901 8.19 126.87 63.73 29.54 8.18 126.92 8.1 127.18 8.15 127.17 8.12 127.17 8.17 127.17 8.18 127.23 8.14 127.35 8.19 127.12 
S902 6.99 113.91 60.32 62.03 7.03 114.10 6.89 113.83 6.8 113.61 6.86 113.88 6.75 113.34 6.92 113.80 6.63 113.55 6.95 113.73 
K903 6.56 119.56 56.92 30.76 6.53 119.87 6.63 120.33 6.53 120.02 6.57 120 6.70 120.01 6.55 118.97 6.83 121.2 6.67 119.73 
S904 6.6 112.72 61.14 63.77 6.54 112.86 6.49 113.03 - - 6.52 112.91 6.32 113.67 6.41 113.44 6.45 113.52 6.48 114.64 
A905 8.74 122.7 53.67 16.53 8.71 122.91 8.71 123.65 8.71 122.98 8.72 123.25 8.85 124.05 8.86 124.09 8.87 124.97 8.96 124.35 
N906 7.19 116.67 54.88 37.45 7.16 116.74 7.2 117.08 7.17 116.9 7.18 116.99 7.05 116.87 6.94 116.30 7.11 117.31 7.08 117.1 
Y907 7.54 117.3 58.65 36.49 7.43 116.67 7.53 117.61 7.48 117.44 7.51 117.55 7.32 117.28 7.35 116.44 7.28 116.54 - - 
C908 7.32 117.12 60.63 27.6 7.29 117.06 7.34 117.32 7.25 117.33 7.31 117.27 7.22 117.26 7.23 117.79 7.23 117.7 7.22 117.5 
H909 7.43 113.56 56.42 26.3 7.37 113.39 7.42 113.94 7.34 113.25 7.38 113.55 7.35 113.93 7.47 113.29 7.22 112.81 7.43 114.57 
T910 7.21 108.91 60.43 70.18 7.20 108.92 7.14 108.49 7.19 108.83 7.19 108.82 7.16 108.55 7.09 108.31 7.06 107.96 7.1 108.32 
S911 7.92 113.96 57.03 65.12 7.89 113.96 7.85 113.86 7.89 113.98 7.89 113.92 7.84 113.58 7.89 113.84 7.82 113.38 7.83 113.57 
Q912 8.21 119.43 58.97 26.99 8.19 119.39 8.21 119.62 8.21 119.65 8.21 119.64 8.22 119.62 8.21 119.63 8.21 119.62 8.23 119.64 
G913 7.93 104.83 45.05 - 7.92 104.73 7.92 104.82 7.92 104.85 7.92 104.84 7.91 104.76 7.92 104.81 7.9 104.68 7.91 104.8 
N914 7.12 119.9 51.72 40.31 7.07 119.70 7.08 119.91 7.08 119.81 7.08 119.84 7.07 119.86 7.08 119.80 7.06 119.89 7.07 119.86 
P915 - - 64.73 30.91 - - - - - - - - - - - - - - - - 
I916 7.65 122.42 58.19 36.74 7.62 122.35 7.63 122.36 7.62 122.47 7.63 122.44 7.60 122.39 7.6 122.42 7.6 122.45 7.61 122.44 
G917 8.96 113.8 42.86 - 8.93 113.83 8.94 114.03 8.94 114.08 8.95 114.12 8.96 114.13 8.95 114.04 8.93 114.11 8.94 114 
L918 9.46 121.52 52.39 43.61 9.44 121.40 9.42 121.38 9.47 121.61 9.46 121.51 9.46 121.47 9.51 121.54 9.42 121.35 9.42 121.21 
I919 8.2 115.38 60.16 38.03 8.17 115.22 8.2 115.52 8.17 115.25 8.17 115.43 8.17 115.39 8.18 115.78 8.23 116.26 8.19 116.28 
L920 - - - - - - - - - - - - - - - - - - - - 
L921 8.73 118.96 53.14 45.02 8.68 118.78 8.62 118.55 8.7 118.9 8.7 118.84 8.71 118.82 8.68 118.74 8.72 118.76 - - 
G922 9.36 110.05 43.2 - 9.32 110.01 9.34 110.15 9.36 110.23 9.34 110.2 9.40 110.26 9.4 110.32 9.38 110.3 9.39 110.42 
E923 8.75 126.54 55.22 29.33 8.72 126.48 8.69 126.56 8.7 126.52 8.69 126.52 8.69 126.48 8.71 126.54 8.69 126.63 8.7 126.56 
V924 8.65 127.58 59.81 32.1 8.65 127.50 8.64 127.7 8.61 127.64 8.67 127.73 8.63 127.71 8.6 127.55 8.64 128.03 8.61 127.79 
A925 8.17 130.81 50.69 17.57 8.19 130.99 8.15 131.24 8.1 130.97 8.12 130.96 8.11 130.95 8.13 130.94 8.19 131.26 8.05 130.95 
L926 7.6 123.73 55.53 40.84 7.56 123.79 7.56 123.89 7.55 123.86 7.55 123.84 7.54 123.89 7.55 123.79 7.49 124.04 7.53 123.91 
G927 7.23 105.13 45.28 - 7.17 105.00 7.17 105.08 7.17 105.13 7.17 105.11 7.16 105.10 7.19 105.21 7.15 104.86 7.17 105.13 
N928 11.55 128.66 52.23 37.53 11.53 128.65 11.54 128.79 11.54 128.79 11.53 128.8 11.50 128.76 11.51 128.82 11.52 128.65 11.51 128.73 
M929 8.8 126.01 55.16 32.58 8.79 126.12 8.77 126.24 8.79 126.2 8.78 126.22 8.78 126.19 8.79 126.08 8.72 126.37 8.76 126.17 
Y930 9.62 128.87 53.61 36.44 9.60 128.83 9.57 128.97 9.59 129.02 9.59 129.03 9.61 129.09 9.62 129.08 9.58 129 9.59 129.07 
E931 8.59 128.94 55.77 29.57 8.59 128.78 8.59 128.95 8.6 129 8.6 128.98 8.61 128.98 8.6 129.02 8.58 128.91 8.59 128.95 
L932 8.65 125.08 53.06 46.66 8.61 125.06 8.59 125.38 8.61 125.36 8.61 124.98 8.58 125.29 8.66 125.30 8.74 125.58 8.52 125.22 
K933 8.45 118.31 55.65 33.44 8.43 118.24 8.46 118.31 8.45 118.32 8.44 118.44 8.44 117.97 8.44 118.24 8.61 118.38 8.44 118.09 
H934 7.1 113.14 53.4 32.32 7.07 113.17 7.07 113.43 7.06 113.3 7.09 113.25 7.12 113.48 7.11 113.07 7.08 113.4 7.08 113.5 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
A935 8.34 122.4 52.73 18.07 8.41 122.28 8.33 122.76 8.32 122.68 8.34 122.71 8.47 122.94 8.37 122.58 8.32 122.84 8.37 122.52 
S936 6.84 116.31 57.37 65.09 6.79 116.26 7.01 116.58 6.76 116.75 6.77 116.8 7.27 116.75 6.82 116.45 7.66 116.73 6.78 116.69 
H937 - - 54.9 27.01 - - - - - - - - - - - - - - - - 
I938 6.99 126.92 59.94 37.09 6.99 126.86 6.89 127.09 6.92 127.61 6.98 127.3 7.06 126.67 7.06 126.41 6.84 128.17 6.86 128.06 
S939 8.62 120.29 - - 8.41 120.04 - - 8.59 120.31 8.62 120.11 8.59 119.77 8.62 119.58 8.36 - 8.69 120.17 
K940 7.31 121.29 54.65 33.62 7.28 121.19 7.29 121.27 7.28 121.3 7.29 121.32 7.30 121.33 7.28 121.55 7.27 120.94 7.29 121.12 
L941 8.39 125.66 52.47 40.45 8.38 125.59 8.41 125.99 8.41 125.96 8.4 125.9 8.38 125.81 8.37 125.81 8.57 126.08 8.35 125.63 
P942 - - 61.75 30.98 - - - - - - - - - - - - - - - - 
K943 8.04 122.14 57.5 31.28 8.02 122.27 8.02 122.32 8.01 122.29 8.02 122.3 8.01 122.27 8.02 122.41 8.03 122.25 8.03 122.38 
G944 8.61 113.81 44.66 - 8.62 113.84 8.63 114.05 8.63 114.04 8.63 114.04 8.62 114.03 8.63 114.00 8.61 114.12 8.65 114.09 
K945 7.37 116.79 52.67 32.81 7.32 116.62 7.34 116.76 7.33 116.75 7.33 116.74 7.32 116.74 7.29 116.79 7.37 116.9 7.35 116.77 
H946 9.49 118.2 57.49 - 9.47 118.09 9.44 118.16 9.46 118.21 9.46 118.21 9.44 118.12 9.47 118.21 9.37 117.99 9.44 118.14 
S947 8.15 114.16 57.69 64.53 8.11 114.17 8.1 114.24 8.11 114.31 8.11 114.31 8.10 114.39 8.12 114.47 8.07 114.13 8.09 114.32 
V948 9.2 121.03 60.38 34.47 9.17 120.92 9.1 120.97 9.15 121.06 9.14 121.07 9.17 121.11 9.23 121.28 9.03 121.05 9.18 121.22 
K949 8.09 126.27 53.4 36.01 8.02 126.04 7.99 126.25 8.01 126.2 8 126.17 7.95 126.07 7.98 126.18 7.91 126.23 7.99 126.15 
G950 9.35 116.05 44.03 - 9.15 117.28 9.27 116.1 9.31 116.25 9.31 116.25 8.83 120.98 8.87 121.15 8.7 120.69 9.29 116.36 
L951 8.43 125.57 54.05 41.57 8.41 125.59 8.36 125.56 8.38 125.55 8.39 125.54 - - - - - - 8.37 125.49 
G952 8.86 109.92 43.19 - 8.83 109.79 8.82 110.06 8.85 109.92 8.85 109.92 8.93 109.71 8.9 109.89 8.9 109.85 8.9 109.82 
K953 7.75 121.44 58.65 33.11 7.69 121.39 7.71 121.59 7.65 121.57 7.65 121.59 7.58 121.44 7.65 121.30 7.66 121.48 7.63 121.59 
T954 7.59 117.06 61.2 69.74 7.54 116.95 7.55 117.1 7.56 117.12 7.56 117.13 7.63 117.16 7.53 117.15 7.47 116.71 7.59 117.17 
T955 9.09 121.43 56.83 72.46 9.06 121.31 9.09 121.39 9.09 121.51 9.09 121.48 9.12 121.64 9.07 121.70 9.15 121.34 9.11 121.56 
P956 - - 63.56 31.61 - - - - - - - - - - - - - - - - 
D957 8.49 126.63 52.06 40.7 8.45 126.53 8.44 126.86 8.45 126.76 8.45 126.74 8.43 126.58 8.47 126.53 8.41 126.81 8.43 126.65 
P958 - - 63.97 31.05 - - - - - - - - - - - - - - - - 
S959 8.4 115.69 60.05 62.64 8.35 115.59 8.35 115.65 8.36 115.73 8.35 115.7 8.37 115.78 8.35 115.80 8.35 115.6 8.37 115.78 
A960 7.47 123.99 50.56 19.7 7.44 123.86 7.46 124.05 7.45 124.06 7.45 124.05 7.44 124.07 7.42 124.04 7.52 123.98 7.43 124.04 
N961 7.02 117.15 54.27 37.92 6.98 117.02 6.97 117.13 6.98 117.15 6.98 117.15 6.98 117.15 7.01 117.19 6.94 117.11 6.97 117.12 
I962 7.76 117.56 58.64 41.01 7.72 117.30 7.7 117.4 7.71 117.3 7.7 117.52 7.70 117.22 7.69 117.20 7.68 117.39 7.68 117.3 
S963 8.11 116.15 55.97 63.83 8.05 116.16 8.11 116.14 8.1 116.19 8.13 116.13 8.11 116.18 8.1 116.12 8.12 116.46 8.11 116.24 
L964 9.12 129.33 53.02 42.64 9.10 129.23 9.1 129.36 9.09 129.32 9.1 129.32 9.09 129.26 9.08 129.17 9.08 129.33 9.08 129.24 
D965 9.2 128.38 54.78 39.43 9.17 128.18 9.16 128.4 9.22 128.64 9.18 128.41 9.17 128.39 9.21 128.33 9.11 128.33 9.21 128.53 
G966 7.93 102.91 44.94 - 7.92 102.84 7.93 102.93 7.94 102.94 7.94 102.94 7.94 102.94 7.95 102.98 7.94 102.91 7.94 102.98 
V967 7.39 122.18 60.5 31.93 7.36 122.10 7.36 122.18 7.37 122.18 7.37 122.2 7.37 122.19 7.37 122.18 7.36 122.16 7.36 122.21 
D968 8.22 127.04 55.01 41.95 8.19 126.94 8.19 127.09 8.19 127.17 8.19 127.16 8.18 127.17 8.22 127.18 8.18 127 8.21 127.12 
V969 8.99 124.04 58.67 31.36 8.96 123.91 8.97 123.98 8.97 124.03 8.97 124.05 8.98 124.15 8.97 124.13 8.99 124.03 8.96 124.09 
P970 - - 60.85 28.19 - - - - - - - - - - - - - - - - 
L971 6.74 112.34 53.11 39.97 6.68 111.93 6.7 111.82 6.72 111.88 6.72 111.85 6.73 111.92 6.74 112.19 6.7 111.93 6.72 111.9 
G972 8.52 106.78 45.54 - 8.52 106.68 8.56 106.84 8.55 106.82 8.55 106.83 8.55 106.87 8.52 106.82 8.59 106.93 8.54 106.88 
T973 7.55 108.73 61.16 69.5 7.53 108.56 7.54 108.75 7.53 108.65 7.53 108.65 7.53 108.61 7.52 108.50 7.56 108.73 - - 
G974 8.24 108.83 46.27 - 8.21 108.77 8.19 109.09 8.23 109 8.21 108.98 8.24 108.85 8.26 108.79 8.22 109.04 8.22 108.97 
 
Chemical shift assignments for wild-type PARP-1 catalytic domain, catalytic domain mutants and catalytic domain-inhibitor complexes 
  











1:1.5 25°C 15N 
EB-47 1:1.5 
25°C 15N 
 H N CA CB H N H N H N H N H N H N H N H N 
I975 9.22 123.34 59.1 42.48 9.19 123.18 9.17 123.28 9.19 123.23 9.19 123.23 9.20 123.12 9.21 123.06 9.18 123.14 9.19 123.13 
S976 8.33 115.42 58.11 62.44 8.33 115.31 8.35 115.58 8.35 115.5 8.35 115.64 8.37 115.52 8.35 115.55 8.35 115.39 8.36 115.66 
S977 8.68 122.72 58.19 64.73 8.67 122.81 8.69 122.97 8.67 123.14 8.68 123.04 8.69 123.07 8.69 123.11 - - 8.68 123 
G978 8.31 110.89 45.09 - 8.28 110.86 8.3 111.02 8.3 111.01 8.3 111.01 8.31 111.00 8.3 110.96 8.31 111.01 8.3 110.96 
V979 7.59 121.99 61.58 30.3 7.56 121.86 7.56 121.98 7.57 122 7.57 121.99 7.61 122.07 7.58 121.95 7.63 122.14 7.6 122.05 
N980 8.44 124.49 - - 8.43 124.42 8.42 124.39 8.43 124.51 8.44 124.55 8.43 124.14 8.45 124.52 8.41 123.94 - - 
D981 8.8 119.74 53 38.26 8.77 119.68 8.78 119.86 8.79 119.93 8.79 119.94 8.81 120.19 8.8 119.96 8.8 120.28 8.8 120.04 
T982 6.86 110.12 57.59 69.43 6.83 109.93 6.82 110 6.83 110.01 6.82 110.02 6.83 109.88 6.83 110.00 6.79 109.86 6.82 109.96 
S983 8.3 120.96 58.04 63.45 8.28 120.90 8.29 121.07 8.3 121.08 8.29 121.08 8.34 121.15 8.29 121.04 8.32 121.19 8.35 121.04 
L984 8.12 125.84 54.18 40.42 8.08 124.93 8.06 125.82 8.07 125.87 8.07 125.86 8.03 125.35 8.06 125.72 7.96 124.41 8.05 125.42 
L985 8.76 124.31 57.5 41.65 8.74 124.32 8.71 124.24 8.72 124.28 8.72 124.25 -       - 8.79 124.19 8.97 123.63 8.72 124.1 
Y986 7.1 114.25 55.47 41.39 7.06 114.19 7.08 114.33 7.13 114.44 7.08 114.37 7.13 114.25 7.05 114.49 6.99 114.18 7.13 114.75 
N987 10.32 119.75 52.61 38.5 10.31 119.70 10.34 119.8 10.34 119.83 10.33 119.8 10.34 119.35 10.33 120.10 10.29 119.01 10.32 119.69 
E988 8.36 119.91 55.16 33.5 8.33 119.78 8.34 120.01 - - 8.35 120.1 8.35 120.12 8.34 118.72 8.3 119.24 8.38 119.47 
Y989 8.64 121.08 55.8 39.78 8.57 121.03 8.5 120.99 - - 8.59 121.08 -       -       - -       - - - - 
I990 9.15 123.92 60.19 39.73 9.10 123.67 9.06 123.84 9.07 123.56 9.07 123.86 9.04 122.65 9.04 123.30 9.05 123.36 9.05 122.87 
V991 7.59 113.82 58.29 33.32 7.57 113.67 7.57 113.66 7.58 113.64 7.56 113.61 7.46 113.34 7.58 113.74 7.47 113.01 7.72 113.74 
Y992 8.91 118.65 57.75 37.11 8.88 118.49 8.89 118.79 8.87 118.64 8.89 118.68 8.86 118.79 - -       8.75 118.43 8.81 118.45 
D993 6.71 120.26 52.43 43.35 6.66 120.15 6.65 120.25 6.66 120.28 6.66 120.3 6.64 120.21 6.66 120.20 6.67 120.35 6.66 120.27 
I994 8.3 121.29 63.33 36.95 8.28 121.13 8.3 121.54 8.31 121.43 8.3 121.09 8.26 121.30 8.31 121.03 8.33 121.24 8.29 121.58 
A995 9.06 123.65 52.64 18.25 9.02 123.52 9 123.72 9.02 123.71 9.02 123.71 9.01 123.68 9.01 123.61 9 123.39 9.01 123.51 
Q996 6.98 113.32 56.53 29.92 6.94 113.20 6.95 113.67 6.95 113.59 6.94 113.56 6.94 113.58 6.96 113.37 6.98 114.18 6.97 114.02 
V997 6.62 116.39 59.49 34.28 6.56 116.32 6.6 116.26 6.58 116.33 6.58 116.33 6.56 116.39 6.57 116.51 6.6 116.31 6.56 116.02 
N998 8.6 125.45 49.08 39.54 8.57 125.46 8.57 125.69 8.58 125.65 8.57 125.64 8.59 125.63 8.52 125.23 8.59 125.69 8.57 125.8 
L999 10.11 129.34 56.45 40.84 10.08 129.20 10.07 129.48 10.09 129.53 10.09 129.5 10.09 129.51 10.1 129.53 10.07 129.4 10 129.23 
K1000 8 118.51 55.53 35.35 8.03 118.66 8.04 118.75 8.06 118.64 8.05 118.78 8.02 118.68 7.93 118.75 8.03 118.71 8 118.53 
Y1001 8.19 113.39 55.46 - 8.14 113.44 8.13 113.41 8.18 113.5 8.15 113.48 8.18 113.57 8.2 113.54 8.17 113.47 8.19 113.58 
L1002 9.29 124.08 54.95 39.67 9.28 124.05 9.26 123.99 9.27 124.16 9.26 124.11 9.28 124.16 9.28 124.15 9.25 123.84 9.26 124.15 
L1003 9.64 127.85 54.15 - 9.62 128.12 9.64 128.05 9.64 128.18 9.64 128.13 9.69 128.09 9.68 128.28 9.68 128.06 9.65 128.16 
K1004 8.54 122.12 54.8 - 8.49 122.12 8.48 122.41 8.51 122.28 8.49 122.28 8.50 122.22 8.5 122.34 8.47 122.35 8.42 122.19 
L1005 9.22 128.5 52.98 44.55 9.21 128.40 9.22 128.66 9.21 128.41 9.21 128.57 9.22 128.62 9.22 128.58 9.22 128.59 9.15 128.34 
K1006 9.01 122.62 54.34 34.06 8.99 122.56 8.99 122.76 9 122.67 9 122.77 9.01 122.76 9.01 122.89 8.97 122.8 9.03 122.89 
F1007 9.13 128.3 55.41 38.36 9.09 128.16 9.11 128.3 9.1 128.4 9.1 128.39 9.09 128.37 9.12 128.54 9.1 128.31 9.11 128.35 
N1008 8.57 122.71 51.31 38.05 8.54 122.65 8.55 122.91 8.55 122.94 8.55 122.95 8.55 122.97 8.51 122.82 8.57 122.97 8.55 122.99 
F1009 8.55 125.13 59.66 38.84 8.54 125.13 8.53 125.25 8.53 125.28 8.53 125.27 8.54 125.22 8.56 125.40 8.51 125.14 8.54 125.31 
K1010 8.32 123.33 55.85 32.01 8.28 123.19 8.3 123.43 8.3 123.37 8.3 123.41 8.30 123.26 8.27 123.38 8.29 123.26 8.29 123.3 
T1011 8.12 115.01 61.33 69.07 8.11 114.99 8.11 115.07 8.11 115.07 8.12 115.05 8.11 114.97 8.11 115.02 8.09 114.95 8.1 114.91 
S1012 8.09 118.15 57.52 63.19 8.09 118.15 8.09 118.29 8.09 118.31 8.1 118.31 8.08 118.24 8.08 118.22 8.08 118.22 8.08 118.22 
L1013 7.96 124.69 54.98 41.24 7.96 124.59 7.96 124.72 7.96 124.74 7.96 124.73 7.97 124.65 7.96 124.64 7.96 124.67 7.97 124.64 
W1014 7.36 125.83 57.9 29.37 7.34 125.69 7.34 125.85 7.34 125.85 7.35 125.84 7.34 125.75 7.34 125.82 7.33 125.69 7.33 125.69 
